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RESUMEN/ABSTRACT 
 
 
 
Las células reconocen y responden a estímulos extracelulares mediante la activación de 
diferentes procesos intracelulares como puden ser las cascadas de señalización que 
llevan a la activación de las proteinas quinasas activadas por mitógenos (MAPKs). Las 
células eucariotas tienen múltiples cascadas de señalización MAPKs involucradas en la 
regulación de diversos procesos celulares. En mamíferos se han descrito cinco 
subgrupos de MAPKs, ERK1/2, JNK, p38 and ERK5. Esta tesis se centra en las p38 
MAPKs, también conocidas como proteínas quinasas activadas por estrés (SAPKs) 
junto a las JNK puesto que son activadas por estímulos de estrés. Esta subfamilia 
comprende 4 isoformas de p38: p38α, p38β, p38γ	   y p38δ. Debido a la disponibilidad de 
inhibidores específicos y de modelos de ratón deficientes para p38α y p38β, la función 
de estas dos isoformas ha sido ampliamente estudiada. Sin embargo, se conoce mucho 
menos sobre las implicaciones fisiológicas de p38γ y p38δ. 
El objetivo principal de este trabajo es ampliar el conocimiento actual sobre las 
funciones de las proteínas quinasa p38γ y p38δ en homeostasis y en el desarrollo de 
enfermedades inflamatorias y cardiovasculares. Para ello se emplearon modelos de 
ratón deficientes en las quinasas en todo el organismo y modelos condicionales de 
tejido. En combinación, se emplearon técnicas básicas bioquímicas y estudios in vitro, 
para poder dilucidar los mecanismos moleculares mediante los cuales p38γ y p38δ 
ejercen su función biológica. Nuestros estudios muestran que las distintas isoformas de 
p38 se regulan de forma diferente por las quinasas activadoras MKK3 y MKK6. Esta 
regulación diferencial es específica de tejido. Además, p38γ y p38δ presentan un patrón 
de expresión muy característico, diferente entre sí y que difiere completamente de la 
expresión ubicua que muestran las quinasas p38α y p38β. Aquí demostramos que p38γ 
y p38δ son esenciales para la regulación de la respuesta inflamatoria. Además, juegan 
un papel clave en el desarrollo de enfermedades hepáticas con un fuerte componente 
inflamatorio como son la hepatitis aguda o la esteatosis. En este contexto, p38γ y p38δ 
tienen papeles parcialmente redundantes, por lo que es necesaria la inhibición de ambas 
quinasas para prevenir el daño hepático. Asimismo, mostramos que p38γ y p38δ son 
fundamentales en el control del crecimiento cardiaco hipertrófico tanto fisiológico como 
patológico. En este caso, ambas quinasas interaccionan y cooperan en la regulación del 
crecimiento del corazón. Nuestros resultados indican que p38γ y p38δ son potenciales 
dianas terapéuticas para el tratamiento de enfermedades hepáticas e hipertrofia cardiaca. 
 Cells recognize and respond to extracellular stimuli by engaging different intracellular 
programs, such as the signaling cascade that leads to the activation of the mitogen 
activated protein kinases (MAPKs). All eukaryotic cells posses multiple MAPK 
pathways, which regulate a diverse array of cellular processes. In mammals four distinct 
subgroups have been described (1) extracellular signal-regulated kinases 1/2 (ERKs), 
(2) c-jun N-terminal or stress-activated protein kinases (JNK/SAPK), (3) the p38 group 
of protein kinases and (4) ERK5. The focus of this thesis is the p38 kinases, also called 
stress-activated protein kinases (SAPKs) together with the JNKs, because are activated 
by environmental and genotoxic stresses. This subfamily comprises four different p38 
isoforms: p38α, p38β, p38γ and p38δ. Due to the availability of specific inhibitors and 
animal models for p38α and p38β, the role of these two kinases has been broadly 
studied. However, much less is known about the physiological implications of p38γ and 
p38δ. 	  
The main objective of this thesis is to broaden our knowledge about the functions of 
p38γ and p38δ, also called alternative p38s, in homeostasis and disease, taking 
advantage of full knockout or conditional knockout mice for these kinases. Besides, to 
better understand their biological implications at the molecular level we used in vitro 
models and basic biochemistry. Our data shows that the p38 MAPK isoforms are 
differentially regulated by their up-stream kinases, MKK3 and MKK6 in a tissue-
specific manner. Besides, the p38γ and p38δ isoforms have very distinctive expression 
patterns in comparison with the ubiquitous expression of p38α and p38β, which 
suggests highly specialized cellular functions for these p38 isoforms. We demonstrate 
that p38γ and p38δ are essential in the regulation of inflammatory responses and key 
players in the development of liver inflammatory-mediated diseases such as acute 
hepatitis and steatosis. In these contexts, they play partially redundant roles, and the 
inhibition of both kinases is necessary to protect against the disease progression. 
Moreover, p38γ and p38δ are also involved in the control of cardiac growth and in the 
development of cardiomyopathies. We have shown that their expression and activation 
in the heart are developmentally upregulated during early postnatal stages of cardiac 
development. Besides, we report for the first time that p38γ and p38δ interact and 
cooperate in the regulation of both physiological and pathological cardiac hypertrophic 
growth. Our findings indicate that p38γ and p38δ are potential targets for the treatment 
of liver inflammatory-mediated diseases and cardiac hypertrophy. 
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INTRODUCTION 
1. General aspects of cell communication 
Cells need to perceive and correctly respond to the continuous changes that occur in the 
physical and chemical properties of the surrounding environment to survive. Therefore, cells do 
not live in isolation and are continuously communicating with its environment and with itself. 
Besides, cells can also communicate directly with one another and change their own internal 
machinery in response by way of a variety of chemical and mechanical signals.  
Cell signaling is part of a complex system of communication that governs basic cellular 
activities and coordinates cell actions. [22]. A proper cellular communication is the basis of 
development, tissue repair, and immunity as well as normal tissue homeostasis. Errors in 
cellular information processing are responsible for diseases such as cancer, autoimmunity, and 
cardiovascular diseases [153, 167, 168]. Understanding of cell signaling will help to the 
treatment of diseases. 
1.1 Cell Signaling 
Cell signaling (or signal transduction) involves the detection of a stimulus that can be soluble 
factors generated locally (for example, synaptic transmission) or distantly (hormones or growth 
factors), ligands present on the surface of another cell, a molecule present in the surrounding 
environment or mechanical forces [118]. To achieve this, cells maintain a diversity of receptors 
on their surface that respond specifically to individual stimuli. These signals have been 
classically categorized based on the distance between signaling and responder cells. Signaling 
within, between, and among cells is subdivided into the following classifications [22]: 
·Intracrine signals are produced by the target cell and stay within the target cell.  
·Autocrine signals are produced by the target cell, are secreted, and affect the target cell itself 
via receptors.  
·Juxtacrine is a cell contact-dependent signaling and therefore occurs in short distance. These 
signals are transmitted along cell membranes via protein or lipid components integral to the 
membrane and are capable of affecting either the emitting cell or cells immediately adjacent.  
·Paracrine signaling molecules are released from paracrine cells and diffuse locally through the 
extracellular fluid, targeting cells that are nearby, thus acting as local mediators.  
·Endocrine signaling involves sending a signal throughout the whole body by secreting 
hormones into the bloodstream. The cells that produce hormones are called endocrine cells. 
Once the signaling molecule activates a specific receptor located on the cell surface or inside the 
cells, the signal transduction occurs, triggering a biochemical chain of events inside the cell to 
33
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create a cellular response. The signal can be amplified at any step. Thus, one single molecule 
can cause many responses.  
There are different mechanistic principles that are used to initiate and transmit receptor-
activated signals in the cytoplasm and down a signaling pathway. Every protein typically 
changes the conformation of the next down the path by post-translational modifications such as 
phosphorylation, ubiquitination, acetylation, SUMOylation, glycosylation, by calcium 
mobilization, lipid-derived second messengers, protein-protein interactions, Cyclic Nucleotides, 
and G proteins. The final effect is to trigger a cell response, such as the activation of gene 
transcription [48]. 
Protein phosphorylation and dephosphoylation by kinases or phosphatases, respectively, is the 
main regulatory mechanism through which protein activity is regulated in eukaryotic cells [29].  
2. Protein kinases 
Protein kinases are important players in almost every signaling pathway involved in normal 
development and disease. The transduction, amplification and integration of intracellular and 
intercellular processes need a specific regulation made, often, by protein phosphorylation [32]. 
 It is predicted that vertebrate genome might encode as many as 1001 protein kinases, and that 
more than 30% of intracellular proteins can be phosphorylated at one or more residues. Protein 
phosphorylation not only regulates enzymatic activity through inducing conformational changes 
or through direct steric effects, but also modulates the function of structural proteins through 
conformational changes or charge effects. The different classes of protein kinases are classified 
by nature of the amino acid that is phosphorylated. The two mayor classes of protein kinases are 
the Serine/Threonine kinases and the Tyrosine kinases, but the phosphorylation in other amino 
acids has been described in prokaryotes and eukaryotes [18]. 
2.1 Serine/Threonine and tyrosine kinases 
Most of the eukaryotic protein kinases belong to a superfamily of kinases. This superfamily 
comprises serine/threonine-, tyrosine-specific and dual specificity protein kinases that share a 
conserved catalytic domain. Ser/Thr kinases are found in all eukaryotes and function in a broad 
range of signaling pathways. Tyrosine kinases appear later in evolution and are predominately 
found in multicellular animals, were they play very important roles in intracellular signaling 
[76].  
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Figure 1. Conserved core of the eukaryotic protein kinases. Functional motifs in the N-lobe (a) and the C-
lobe (b) using PKA as a prototype for the ePK family. Helices are shown in red; β-strands in teal. (a) The 
N-lobe contains five β -strands and a large αC-helix. (b) The C-lobe is mostly helical with a large 
activation segment. A four-stranded β-sheet rests on the helical core and forms one surface of the active 
site cleft. ATP is bound in the cleft between the two lobes [163] 
Their catalytic domains consist of N-terminal and C-terminal lobes connected by a hinge. ATP 
binds the active site cleft between the lobes, forming critical contacts with residues and motifs 
that are conserved among kinases. The activation loop in the C-terminal lobe of the kinase 
forms contacts with the substrate. It is a flexible segment that can rearrange substantially and is 
often the location for regulatory phosphorylation [181]. The structure of Ser/Thr and Tyrosine 
kinases is very similar in the active state. In contrast, the mechanisms by which these kinases 
are inhibited are numerous, leading to different conformations in the inactive state [18]. 
Therefore, we could take advantage from these differences in inactivated kinase structure, to 
design specific small-molecule inhibitors of kinase function. 
2.2 Atypical kinases 
A much smaller number of protein kinases do not share this catalytic domain with other kinases, 
and are often collectively called atypical kinases [117]. In addition to Ser, Thr and Tyr, several 
other amino acids in proteins can be phosphorylated, including Lys, Arg and His, but in most 
cases remains unclear the provenance of the respective protein kinases. 
Histidine Kinases phosphorylate themselves (autophosphorylate) on Histidine, before 
transferring that phosphate to an Aspartate on a substrate protein (so they are more correctly 
called Histidine-Aspartate Kinases).  This type of protein kinases is common in prokaryotes and 
lower eukaryotes, but it was believed that regulatory histidine phosphorylation was of minor 
importance in vertebrates and that histidine kinases were not found in mammals [91, 157]. 
However, recent research provided evidence for a regulatory role of histidine phosphorylation in 
mammals with the identification of the ubiquitously expressed histidine kinase nucleoside 
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diphosphate kinase (NDPK) and its specific counteracting phosphatase (PHPT-1), what gives 
rise to the assumption that there is more to be detected [8].  
A wide variety of other kinases phosphorylate various small molecules, including those 
involved in metabolism, such as glycolysis or nucleotide metabolism. These come from a wide 
variety of different structures, distinct from that of protein kinases. One notable exception is the 
phosphatidyl inositol 3' kinases (PI3K). These are structurally related to protein kinases, and a 
subset of PI3K, known as PIKK, do phosphorylate proteins rather than small molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The Human Kinome. This phylogenetic tree depicts the relationships between members of the 
complete superfamily of human protein kinases. The inset diagram shows trees for seven atypical protein 
kinase families. (Courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)) 
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3. The MAP Kinase Family 
The Mitogen –activated protein kinases are Ser/Thr kinases that belong to the CMGC group 
(CDK, MAPK, GSK3, CLK group) within the Eukaryotic Protein Kinase Superfamily. The 
CMGC group also includes cyclin-dependent kinases (CDKs), glycogen synthase kinases 
(GSK) and CDK-like kinases [17]. 
MAPK cascades are evolutionarily conserved in all eukaryotes and play a key role in the 
regulation of a diverse array of cellular programs, participate extensively in the control of cell 
fate decisions such as proliferation, differentiation and death, as well as in the regulation of 
stress responses and inflammation in all eukaryotic phyla and in all tissues of metazoans [24, 
183]. 
MAPK activity is regulated through three-tiered cascades composed of a MAPK, MAPK kinase 
(MAPKK, MKK or MEK) and a MAPKK kinase or MEK kinase (MAPKKK or MEKK) [6, 26, 
36]. Transmission of signals is achieved by sequential phosphorylation and activation of the 
components specific to a respective cascade. The MAPKs are activated upon dual 
phosphorylation of tyrosine and threonine residues in a conserved Thr–Xaa–Tyr motif (where 
Xaa is any amino acid) in the activation loop of kinase subdomain VIII. Phosphorylation of 
MAPKs is catalyzed by the dual specificity kinases, MKKs, which are in turn activated upon 
phosphorylation of Ser/ Thr residues, and are highly selective in phosphorylating specific 
MAPKs. This specificity is in part conferred by the phosphorylation motif and by the interaction 
on the N-terminal region on the MKK with different docking sites on the MAPK. The activation 
of these kinases is tightly regulated by a group of MAPK phosphatases that return the MAPK 
into the inactive state by the phosphorylation [26, 144]. 
To date, four distinctly regulated groups of MAPKs have been described to be express in 
mammals, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases 
(JNK1/2/3), p38 proteins (p38α/β/γ/δ) and ERK5. Each of these groups is activated by dual 
phosphorylation on their conserved motif in which Xaa is Glu in ERKs, Pro in JNKs and Gly in 
p38s. Besides, the different MAPK subfamilies are activated by specific MAPKKs; MEK1/2 for 
ERK1/2, MKK3/6 for the p38s, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each 
MAPKK, however, can be activated by more than one MAPKKK, in a stimulus-dependent 
manner, increasing the complexity and diversity of MAPK signaling.  Having in mind that 
Saccharomyces Cerevisiae possesses six different MAPKs, and the relative complexity of the 
human genome, its plausible thinking that there are probably several additional vertebrate 
MAPK subfamilies [142].  
37
  
INTRODUCTION 
 
Figure 3. A simplified overview of MAPK pathways in mammals organized into three main signaling 
modules (ERK1/2, JNK/p38 and ERK5); (From Wikipedia). 
 
The most extensively studied groups of vertebrate MAPKs to date are the ERK1/2, JNKs, and 
p38 kinases. Although, these MAPK groups can be activated by a wide variety of different 
stimuli, in general, ERK1 and ERK2 are preferentially activated in response to growth factors 
and phorbol esters. While the JNK and p38 kinases are more responsive to stress stimuli ranging 
from osmotic shock and ionizing radiation to cytokine stimulation, and therefore are called 
Stress Protein Kinases (SAPKs) [24]. 
Once activated, MAPKs mediate a wide range of functions through phosphorylation of several 
substrates, including phospholipases, transcription factors, and cytoskeletal proteins as well as 
the phosphorylation and activation of other protein kinases, termed MAPK-activated protein 
kinases (MKs) such as RSKs, MSKs or MNKs, which mediate a wide range of biological 
functions in response to mitogens and stress stimuli [24, 26].  
 
4. The p38 MAP Kinases  
The p38 MAPKs were cloned for the first time in 1994 (Han et al, 1994), identified as a 38 kDa 
polypeptide that undergoes tyrosine phosphorylation in response to LPS treatment and 
hyperosmolarity shock, and that shares high sequence homology with HOG1 from 
Saccharomyces Cerevisae. p38α is the mammalian MAPK orthologue of HOG1. In parallel, 
two other groups independently identified p38α as a kinase activated by stress (also called 
Reactivating Kinase, RK) and IL-1 (named p40) that can directly phosphorylate and activate 
MAPKAP-K2 [41].  
A few years after the identification of p38α, three additional isoforms were described: p38β 
[83], p38γ (also called SAPK3 and ERK6) [110] and p38δ (also called SAPK4) [84]. Different 
38
  
 
INTRODUCTION 
genes encode the p38 isoforms, located tandemly in two chromosomes, with p38β (Mapk11) 
and p38γ (Mapk12) genes in one chromosome (15 in mice and 22 in humans), and p38δ 
(Mapk13) and p38α (Mapk14) genes in other chromosome (17 in mice and 6 in humans). It has 
been proposed that Mapk12 arise from a tandem duplication of Mapk11, and that the Mapk13-
Mapk14 unit comes from a segmental duplication of the Mapk11-Mapk12 gene unit [108]. 
Although p38 isoforms are widely expressed, p38α and p38β are considered ubiquitous, while 
p38γ is most significantly expressed in skeletal muscle [110], and p38δ is mainly found in testis, 
pancreas, kidney, lung, small intestine and neutrophils [81, 84]. According to the Human 
protein atlas, the expression at the protein level of the different p38 isoforms in human cells is 
very similar to the mouse pattern [166]. 
The p38 MAPK family can be further subdivided into two subsets, with p38α and p38β in one 
group and p38γ and p38δ in the other. This is first evident from their amino acid sequence 
identity; p38α and p38β are 75% identical, whereas p38γ and p38δ are 62% and 61% identical 
to p38α, respectively. Of note, p38γ and p38δ are more identical (70%) to each other. Moreover, 
they present differential susceptibility to inhibition by certain compounds; In vitro and in vivo 
assays demonstrated that only p38α and p38β are inhibited by pyridinyl imidazoles (SB202190 
and SB203580) inhibitors, whereas p38γ and p38δ were completely unaffected by the drugs. A 
third difference between these two subgroups of p38MAPKs is with regard to substrate 
selectivity of these kinases. For example, microtubule-associated protein Tau is a better in vitro 
substrate for p38γ and p38δ than p38α and p38β [58, 69], and this is also true for the scaffold 
proteins α1-syntrophin, SAP90/PSD95 and SAP97/hDlg [77, 143, 145]. Conversely, MAPKAP-
K2 and MAPKAPK3 are better phosphorylated by p38α and p38β than p38γ and p38δ [145]. 
4.1 Subcellular localization 
With the apparent complexity of p38 MAPK signaling pathway and the identification of 
multiple targets and effectors which include both nuclear and cytoplasmic proteins, there is 
increasing interest in the spatio-temporal organization of these signaling cascades. Despite the 
number of studies showing activation of p38 MAPK in response to different stimuli, their 
intracellular distribution remains unclear. Unlike other MAPKs, p38s have no nuclear 
localization signal, but they have been shown to be distributed throughout the cytosol and 
nucleus. Furthermore, not direct interaction has been reported between importins or exportins 
and p38 MAPKs. Thus, the translocation across the nuclear membrane most likely occurs 
through interactions with NES- and NLS-containing proteins. p38α is exported from the nucleus 
to the cytoplasm in response to hyper-osmotic stimuli in a complex with the NLS-containing 
protein, MAPKAP kinase-2 in a phosphorylation dependent manner of MAPKAP kinase-2 by 
p38α [14]. Other groups have reported a selective nuclear accumulation of p38α MAPK in 
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response to DNA damage [177]. Although several studies have been performed on p38α cellular 
localization, there are only a few reports about the other p38 isoforms. It has been shown in 
cardiomyocytes that p38α and p38β are localized in the nucleus and the cytoplasm while p38γ is 
only present in the cytoplasm, probably reflecting specialized functions for the different 
isoforms [34]. According to the Human Proteome Atlas, p38α and p38γ are localized to the 
nucleus but excluded from the nucleoli in both human and mouse cells; in contrast, p38δ is 
mainly localized to the nucleus and nucleoli, and in addition localized to the cytoplasm. 
However, p38β seems to be localized to the mitochondria in human cells. It is possible that the 
intracellular distribution of p38 MAPK is associated with its substrate specificity and 
determined by the nature of the stimuli. 
4.2 Structure 
p38 MAPKs contain little more than the kinase catalytic domain. The short N- and C-terminal 
extensions bear little homology to other known proteins except the related p38 family members 
and JNK isoforms. The structures of unphosphorylated and phosphorylated p38s have been 
solved by X-ray crystallography, providing insight into the mechanism controlling activation 
and substrate specificity [164, 173-176, 190].  
The fold and topology of p38 MAPKs is similar to that of ERK2, despite significant differences 
in the conformation of the activation loop. The phosphorylation lip sequence in p38 MAPKs is 
six residues shorter than in ERK2, placing the Thr and Tyr phosphorylation sites in distinct 
positions.  In p38 isoforms, as in JNK3, this sequence is folded up between the two domains. 
The Gly residue in the Thr-Gly-Tyr (TGY) dual-phosphorylation motif, as well as the length of 
the loop, contributes to p38 substrate specificity. The P+1 specificity pocket is blocked by the 
C-terminus of the lip in p38. The length of the activation loop also plays an important role in 
controlling autophosphorylation, yet modifications of the loop structure do not result in any 
change in the selection of p38 by MKKs [85]. p38 specificity is also influenced by docking sites 
within various substrates as described for ERK2 [82, 184]. 
A surprising observation is that, despite a high degree of sequence similarity in the p38 MAPK 
family, different residues are utilized to carry out the coordination of the phosphate groups in 
the different p38 MAPKs [190]. 
4.3 Regulation of the p38 MAPK signaling module 
 
4.3.1  Dual phosphorylation by MKKs 
The p38 MAPKs are strongly activated in response to various physical and chemical stresses, 
such as oxidative stress, UV irradiation, hypoxia, ischemia, and various cytokines, including 
interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) [28]. The canonical activation of 
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p38 MAPKs occurs via dual phosphorylation of their Thr–Gly–Tyr motif, in the activation loop, 
by MKK3 (MEK3) and MKK6 (MEK6). These two upstream kinases show a high degree of 
specificity for p38 MAPK isoforms, as they do not activate ERK1/2 or JNK. MKK4 (also 
known as MEK4 and Sek1) is a known JNK kinase that possesses some MAPKK activity 
toward p38α, suggesting that MKK4 represents a site of integration for the p38 and JNK 
pathways [19]. Upon activation, the dually phosphorylated p38 MAPK undergoes global 
conformational changes that alter the alignment of the kinase lobes (N-terminal and C-terminal 
domains) of the folded protein and enhances access to substrate, which together increases 
enzymatic activity. 
The physiological relevance of these two MKKs comes from knockout studies, where mice 
lacking both MKK3 and MKK6 are not viable, dying in mid-gestation due to placental defects 
and altered development of the embryonic vasculature [19]. This observation indicates that 
MKK3 and MKK6 have some redundant roles, because loss of either gene alone yields healthy 
mice [113, 160, 179]. 
Specificity of p38 MAPK signaling has been reported in studies of the MAPK kinases 
(MAPKKs) that activate the p38 MAPK isoforms [136]. However, the mechanism that accounts 
for signaling specificity by the p38 MAPK pathway is not well understood. Previously, it has 
been demonstrated in vitro that MKK6 is a common activator of p38α, p38β, p38γ and p38δ  
MAPK, while MKK3 activates only p38α, p38γ and p38δ MAPK [38, 54, 68, 83, 170]. This 
selectivity of p38 MAPK activation by MKK3 and MKK6 may contribute to the specificity of 
signal transduction by the p38 MAPK pathway. The specificity in p38 activation is thought to 
result from the formation of functional complexes between MKK3/6 and different p38 isoforms 
and the selective recognition of the activation loop (T-loop) of individual p38 MAPK isoforms 
by the MKKs. Furthermore, the tissue-specific expression of the MKKs and p38s, will add 
another layer of complexity to the signaling specificity. Although MKK6 is present in various 
forms in multiple tissues, tissue-specific splice forms of MKK6 have been described in skeletal 
muscle and heart [74]. Given the distinct expression patterns of MKKs and p38s, it is likely that 
these MKK act as a regulators of p38 activation depending on expression in a given tissue 
and/or cell type. For instance, MKK3 has been shown to be the major p38 activator in 
mesangial cells stimulated by transforming growth factor [169], while MKK6 appears to be the 
predominant isoform in thymocytes [160]. Other factor that could contribute to the specificity of 
the p38 MAPK activation is the presence of scaffold molecules that mediate the interaction 
between the MKKs and the different p38 isoforms and regulate the activation of the pathway. 
Although a number of scaffold proteins have been implicated in the regulation of different 
MAPK signaling modules, not many have been found to participate in the p38 MAPK cascade. 
Examples are JIP-2 and JIP-4 that mediate the interaction between MKK3 and different p38 
isoforms. These scaffold proteins could be express in a tissue-specific manner and promote the 
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interaction of a specific MKK with and particular p38 isoform, contributing to the specificity of 
p38 MAPK activation.[119, 147, 148]. 
4.3.2 Autophosphorylation 
Although the canonical p38 MAPK pathway regulation is by MKKK–MKK pathway in 
mammalian cells, two other possible mechanisms of activating p38α have been proposed. In a 
yeast two-hybrid screen TAB1 (Transforming growth factor-β-activated protein 1 (TAK1)- 
binding protein 1) was identified to bind to p38α MAPK, but not to interact with other p38 
family members. TAB1 binding to p38α induces its autophosphorylation and activation. This 
MKK-independent activation of p38α has been implicated in the ischemic heart and 
immunological processes [65, 161]. Furthermore, this mechanism appears to be involved in the 
AMPK activation of p38α in ischemic heart [107]. 
 Another MKK-independent mechanism of activation of p38α has been observed in T cells 
stimulated through the T cell antigen receptor (TCR). In this system, p38α is activated by an 
alternative mechanism in which TCR-mediated stimulation activates proximal tyrosine kinases 
that results in the phosphorylation of p38α on a non-canonical activating residue, Tyr323, and 
subsequently to its autophosphorylation on its Thr–Gly–Tyr motif (Thr180 and Tyr182) [146]. 
On the other hand, autophosphorylation activity has been detected in intrinsically active p38α, 
p38β, p38γ mutants, no such mechanism has been observed to activate the endogenous kinases 
but on p38α. [7, 9]. This mechanism may be reflecting a natural activation mechanism of the 
endogenous kinases. 
4.3.3 Dimerization 
Many protein kinase functions, including autophosphorylation in trans, require dimerization, 
possibly by activation segment exchange. Such dimers have been reported for 
autophosphorylating protein kinases, but only a few for mitogen-activated protein kinases 
(MAPKs). The fact that activation of p38α MAPK proceeds not only via the well-characterized 
action of dual T/Y specificity MKKs, but also via a non-canonical activation involving 
autophosphorylation, open the possibility that certain stimuli could induce dimerization of p38α. 
It was found that p38 dimers created in vitro by cysteine oxidation, were more active than p38 
monomers, establishing that dimerization could indeed affect catalytic activity. Recently, it has 
been shown that p38α forms a homodimer upon phosphorylation on Tyr323. In the dimer, a 
structural unit containing Tyr323 is formed at a dimerization contact region that stabilizes the 
HRD catalytic loop in a unique inactive geometry [140]. The dimer explains the regulation 
properties of p38α non-canonical autoactivation. However, no dimerization has been reported to 
the date for other p38 isoforms. 
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4.3.4 Downregulation of p38 MAPK pathway 
The magnitude and duration of p38 MAPK signal transduction are critical determinants of its 
biological effects. Activation of p38 MAPK occurs within minutes in response to most stimuli 
and is transient. 
MAP kinase phosphatases (MKPs) catalyze dephosphorylation of activated MAP kinase 
(MAPK) molecules and deactivate them, playing an important role in determining the 
magnitude and duration of MAPK activities. The MKP family members share the sequence 
homology and the preference for MAPK molecules, but they are different in substrate 
specificity among MAPK molecules, tissue distribution, subcellular localization and induction 
by extracellular stimuli.  
In mammalian cells, several protein phosphatases interact with and inactivate p38 MAPK 
pathway. MKP-1, the firstly discovered MKP, is induced rapidly after exposure to growth 
factors, heat shock and oxidative stress and seems to act on JNK and p38 rather than ERK1/2 
[60]. Besides, both PP2C (Ser/Thr phosphatase) and PTP (Tyr phosphatase) have been shown to 
regulate p38 MAPKs [158, 159]. Moreover, another family of dual-specificity phosphatases 
plays a key role in the regulation of these MAPKs, since, for example, the M3/6 and MKP-7 
phosphatases regulate JNK and p38 MAPKs, but not ER1/2 [93, 162]. 
 
5.  p38 MAPK pathway Inhibitors 
Pyridinyl imidazole compounds are the best-characterized inhibitors of the p38 pathway. 
Several compounds that belong to this group have been described SB203580, SB203590 or 
SB220025, SKF86002. The pyridinyl imidazoles only inhibit p38α and p38β isoforms, but not 
p38γ ad p38δ.  These inhibitors bind in an extended pocket in the ATP binding site, preventing 
ATP to bind, and the subsequent kinase activity [57, 71, 176, 189]. 
SB203580 is the most commonly used compound to inhibit p38α and p38β. Although it has 
beneficial effects in several inflammatory diseases or in Ischemia/Reperfusion injury, it cannot 
be used clinically due to liver toxicity [27, 39, 71, 105]. However, several analogues have been 
developed during the last years that are more potent and with reduced toxicity (SB220025, 
ML3403 or SB239063) [40, 121]. Among them, SB239063 that can readily be used in vivo has 
demonstrated beneficial effects in the infract rat model of Ischemia/Reperfusion injury [64].  
Despite the diverse compounds developed to specifically inhibit p38α and p38β, no highly 
specific inhibitors for p38γ and p38δ have been described, but BIRB796 that is a pan-p38 
MAPK inhibitor [126]. p38γ and p38δ inhibition occurs at higher BIRB796 concentrations than 
those that inhibit p38α and p38β, and at lower concentrations than those that inhibit the 
activation of JNK isoforms. 
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is an FDA-approved compound in Europe for 
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the treatment of the debilitating and fatal lung disease idiopathic pulmonary fibrosis (IPF) under 
the name of Esbriet, which has been shown to exert its protective effects through the inhibition 
of p38γ [10, 101, 125]. Moreover, the interaction of p38γ interaction with its PDZ containing 
substrates and their subsequent activation can be blocked with a small PDZ peptide [143, 145]. 
The recent observation that the residues that carry out the coordination of the phosphate groups 
are different in the four p38 isoforms, suggests that the inhibition of specific p38 MAPKs may 
be accomplished by targeting the non-conserved residues that are critical for stabilizing the 
active form of the kinase. The design and development of small molecules that selectively 
inhibit the p38 MAPK isoforms is still a challenge within the industry.  
6.  p38 MAPK pathway Substrate Specificity 
6.1  Docking Motifs 
The different MAPK subfamilies phosphorylate a distinct set of protein substrates. These 
substrates act as the critical effectors that enable cells to mount the appropriate responses to 
varied stimuli. A common phosphorylation site motif has been defined for MAPK family 
members, consisting of a Serine or a Threonine followed by a Proline in the position P+1. 
Besides, this motif includes a weak preference for aliphatic residues at the P+2 [150]. Therefore, 
although phosphorylation site motifs likely serve to direct the MAPK to phosphorylate a 
specific serine or threonine residue within a protein, the specificity in protein substrate 
recognition of the different MAPK subgroups cannot be directed by this sequence. It is true that 
mechanisms such as subcellular localization and the use of scaffolding proteins can contribute 
to kinase substrate targeting in vivo, however, MAPKs also exhibit a high degree of target 
specificity in vitro.  
Mutagenesis experiments with MAPKs have shown that residues downstream the 
phosphorylation site, are important for substrate recognition. These sequence motifs in the 
substrate interact with regions of the kinase outside the active site, called docking motifs [15, 
70]. 
Two types of docking motifs have been described in MAPKs and their substrates that serve to 
enhance affinity and specificity. The best-characterized docking site utilized by MAPKs is the 
D-site (also referred to as the D-domain), which consists of two or more basic residues followed 
by a short linker (LXL) and a cluster of hydrophobic residues [23]. D-domains can show 
specificity for families of MAPKs [63, 185]. Some D-domains show specificity within the 
p38MAPK family [63]. The D-domain can be positioned either N- or C-terminal to the 
phosphorylation site [12, 149, 162, 186]. The second major MAPK docking site, known as the 
DEF site (docking site for ERK FXF, also called the F-site), has been identified in a number of 
ERK substrates. DEF sites are generally characterized as an FX(F/Y)P sequence, typically 
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located between 6 and 20 amino acids C-terminal to the phosphorylation site. Although initially 
DEFs sites were described in ERK substrates, divergent DEF docking sites have been described 
to be recognized by other MAPKs. While p38α and p38β have a very similar DEF domain to 
ERK, with a high preference for aromatic residues at P+1 and P+3, p38γ and p38δ DEFs 
domains strikingly preferred aliphatic residues (Ile, Leu, Pro, and Val). This dramatic difference 
between the different p38 isoforms, could account, in part, for their substrate specificity. 
6.2  Protein Domains 
A feature that makes p38γ unique among the p38 MAPKs is its short C-terminal sequence 
KETXL, an amino acid sequence ideal for binding PDZ domains in proteins. SAPK3/p38γ 
binds to a variety of these proteins, such as alpha1-syntrophin, SAP90/PSD95 and SAP97/hDlg, 
and under stress conditions is able to phosphorylate them and modulate their activity [77, 143, 
145]. These PDZ domain-containing proteins are scaffold proteins usually targeted to the 
plasma membrane cytoskeleton at specialized sites such as the neuromuscular junction and gap 
junctions through protein-protein interactions. In the case of SAP97/hDlg its phosphorylation by 
p38γ provides a mechanism of dissociating it from the cytoskeleton [143], which indicates a 
role of this p38MAPK isoform in modulation of cytoskeletal organization. Although p38γ can 
also phosphorylate typical p38 MAPK substrates, the PDZ domain confers part of its substrate 
specificity. 
7.  Downstream targets 
 p38 isoforms are present in the nuclei and cytoplasm of quiescent cells  and have been shown 
to accumulate in the nuclei of cells subjected to certain stresses [135]. Upon stimulation, p38 
isoforms phosphorylate a large number of substrates in many cellular compartments, including 
the cytoplasm (cPLA2, MNK1/2, MK2/3, HuR, Bax, and Tau) and the nucleus (ATF1/2/6, 
MEF2, Elk-1, GADD153, Ets1, p53, and MSK1/2) [99, 142]. Although the substrate specificity 
of all p38 MAPK isoforms is known to overlap, there are some differences between the two 
subgroups of p38 MAPKs with regard to substrate selectivity of these kinases, such as particular 
protein domains or docking sites, described above.  
7.1  p38α  and p38β  substrates 
p38α and p38β physiological substrates include other protein kinases, transcription factors, and 
other proteins such as metabolic enzymes or phospholipases. p38β functions are mostly 
redundant with those of p38α. p38α MAPK is essential for embryonic development and it 
regulates different cellular functions such as proliferation, differentiation, cell death, adhesion, 
migration, as well as the response to stress and many metabolic pathways, among others. It does 
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so through regulation of transcription, mRNA stability, chromatin remodeling, protein 
synthesis, etc. [151].  
Cytoplasmic Substrates. Some of the p38α and p38β targets are downstream kinases, which 
are activated through phosphorylation and further phosphorylate additional targets. 
RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription 
factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, 
but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 
and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in 
response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by 
recruiting the transcription machinery [131]. On the other hand, two other kinase targets, 
MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly 
at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and 
by regulating eEF2K, which is important for the elongation of mRNA during translation [38, 61, 
141]. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, 
regulate protein synthesis by phosphorylating the initiation factor EIF4E2 [43, 102]. 
In the cytoplasm, the p38α and p38β MAPK is an important regulator of protein turnover. For 
example, CFLAR is an inhibitor of TNFα-induced apoptosis whose proteasome-mediated 
degradation is regulated by p38 MAPK phosphorylation. Ectodomain shedding of 
transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory 
stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such 
phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-α family 
ligands, which results in the activation of EGFR signaling and cell proliferation [182]. 
Additional examples of p38 MAPK substrates are the FGFR1. FGFR1 can be translocated from 
the extracellular space into the cytosol and nucleus of target cells, and regulates processes such 
as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation [154].  
Nuclear Substrates. In the nucleus, many transcription factors are phosphorylated and 
activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, 
ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A [54, 184]. The p38 
MAPKs are emerging as important modulators of gene expression by regulating chromatin 
modifiers and remodelers. The promoters of several genes involved in the inflammatory 
response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone 
H3 phosphorylation on Ser-10 (H3S10ph) in LPS-stimulated myeloid cells. This 
phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking 
promoters for increased NF-kappa-B recruitment [89, 94]. 
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7.2  p38γ  and p38δ  substrates 
Although p38γ and p38δ can also phosphorylate typical p38 MAPK substrates such as the 
transcription factors ATF2, Elk-1 or SAP1, they cannot phosphorylate MAPKAPK2 or 
MAPKAPK3, which are good substrates for other p38 MAPK isoforms [38, 68]. p38γ only 
weakly phosphorylates the p38α and p38β substrates MEF2A, MEF2C and MEF2D in vitro and 
barely stimulates their transcriptional activities in vivo, whereas p38δ does not phosphorylate 
any of them [116, 178]. 
PDZ domain containing proteins may be specific substrates for p38γ, such as SAP90/PSD95, 
the first physiological substrate described for this kinase [145] or SAP97/hDlg [143]. 
Nevertheless, p38γ and p38δ share many substrates that do not require PDZ domain binding 
interactions like the microtubule-associated protein Tau [58]. Tau function is modulated by 
phosphorylation, and its ability to bind and stabilize microtubules correlates inversely with its 
phosphorylation which may facilitate its self-assembly. It has been reported that p38δ 
phosphorylates Tau in vivo on Thr 50 which is phosphorylated in Alzheimer disease [58]. 
In correlation with p38γ high expression in skeletal muscle in comparison to other tissues, it has 
been reported that this kinase plays a fundamental role in skeletal muscle differentiation. Thus, 
endogenous p38γ protein levels increase when myoblast differentiate into myotubes [37, 165]. 
Moreover, it has been shown that over-expression of p38γ in skeletal muscle cells leads to 
differentiation from myoblast to myotubes, and that a dominant-negative mutant of p38γ 
prevented this differentiation process [103]. Furthermore, p38γ phosphorylates the transciption 
factor MyoD, one of the earliest markers of myogenic commitment, which results in a decrease 
in its transcriptional activity [67]. This MyoD repression plays a cardinal role in blocking the 
premature differentiation of skeletal muscle stem cells, the satellite cells. Additionally, p38γ 
regulates mitochondrial biogenesis and angiogenesis, and it is required for endurance exercise-
induced skeletal muscle adaptation [133]. 
p38δ has been associated with the cytoskeleton regulation as it has been reported to 
phosphorylate the cytoplasmic protein stathmin and Tau, which control microtubule dynamics 
[58, 69, 127, 188]. In addition, p38δ plays a role in the regulation of protein elongation by 
phosphorylating and inactivating the eukaryotic elongation factor 2 (eEF2) kinase [95, 96]. p38δ 
also regulates insulin secretion as well as in the survival of pancreatic beta cells, through an 
inhibitory phosphorylation of the protein kinase D1 (PKD1), which controls insulin exocytosis 
in pancreatic beta cells [156]. Furthermore, through the phosphorylation of the same protein and 
regulation of PTEN activity in neutrophils, p38δ controls neutrophil migration in an acute lung 
injury model [81]. p38δ has been suggested to play an important role in inducing keratinocyte 
differentiation by regulating the expression of Involucrin, which is a protein expressed during 
47
  
INTRODUCTION 
keratinocyte differentiation [50]. Activation of exogenously expressed p38δ by differentiation-
inducing agents such as a bioactive green tea polyphenol (EGCG), okadaic acid (OA) or the 
phorbol ester TPA, correlated with increased Involucrin promoter activity in keratinocytes via 
increased activity at AP1, Sp1 and C/EBP sites [11, 51]. The mechanisms by which p38δ may 
regulates keratinocyte differentiation is still unknown, although it has been reported that in 
keratinocytes expressing exogenous p38δ, this forms a complex with ERK1/ERK2 [51]. 
Additional data supporting the idea that p38δ may play a role in keratinocyte differentiation 
come from a study carried out in lesional psoriasis skin [86]. It has been shown that the activity 
of p38α, p38β and p38δ is augmented in lesional psoriasis skin compared with non-lesional 
psoriasis skin [86]. Alternatively, it has been also claimed that p38δ may have a dual role in 
keratinocytes contributing not only to the differentiation process, but also to their apoptosis in a 
PKCδ dependent manner, and in response to OA or hydrogen peroxide (H2O2) [52, 98]. 
Figure 4. The p38γ and 
p38δ MAPK pathway. 
Different stimuli such as 
growth factors, 
inflammatory cytokines or 
a wide variety of 
environmental stresses can 
activate p38 MAPKs. A 
number of representative 
downstream targets, 
including protein kinases, 
cytosolic substrates and  
transcription factors, are 
shown [36].  
8. Crosstalk with other signaling pathways 
Crosstalk between signaling pathways is very common in cell regulation, which usually depends 
on cell context and plays an important role in fine-tuning biological responses. There are many 
examples of crosstalk among different MAPK pathways. 
p38 inhibits ERK signaling in non-transformed cells. Generally, ERK activity promotes 
survival. The suppression of this activity by p38 is critical for induction of apoptosis in non-
transformed cells. p38 induces PP2A expression, and it dephosphorylates MEK to reduce ERK 
pathway activation [87]. Furthermore, p38α mediates a feedback control of TAK1 in 
macrophages upon LPS stimulation through TAB1 regulation, which not only limits the 
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activation of p38α but also synchronizes its activity with other signaling pathways that lie 
downstream of TAK1 (JNK and IKK) [30]. 
JNK can also inhibit p38α, as JNK activity inhibited both ERK and p38 signaling in mouse 
cardiomyocytes [128] and c-Jun deficient hepatocytes showed increased phosphorylation of 
p38α [155].  The JNK-ERK/p38 crosstalk may involve a p53-DUSP2 dependent pathway, as the 
c-Jun mediated inhibition of p38α observed in hepatocytes was p53 dependent [155] and 
DUSP2 was identified as a transcriptional target of p53 in mouse embryonic fibroblast and 
breast cancer cell lines [187]. 
Cell growth pathways and stress-sensing pathways are tightly regulated through signaling 
crosstalk. When faced with cellular damage or stress, cells can respond by shutting down cell 
growth, allowing repair to take place until the cell commits to further growth and division. Or 
alternatively, cells can promote growth and translation, presumably in order to promote the 
synthesis of stress response proteins and the turnover of damaged molecules. Therefore, there is 
a close relationship in between the master regulator of cell growth, mTOR pathway, and the p38 
MAPKs stress signaling pathway. For example, UV radiation, which activates stress pathways 
such as p38 and JNK through the induction of DNA damage, activates TORC1 in a number of 
cell types [21, 134, 192]. Besides, in mammalian and Drosophila tissue culture, as well as in 
Drosophila ovaries ex vivo, p38β can activate mTOR pathway in response to H2O2 and 
anisomycin [42]. 
The crosstalk between mTOR and p38 has been shown as well in the mammalian heart. In 
Ischemia/reperfusion, cardiac p38α promotes mTOR activation in response to oxidant stress to 
promote cell survival. p38α induces the decline of REDD1 protein levels,  promoting the 
interaction of Tsc2 with 14-3-3 proteins, which dissociates from mTOR leading to its activation 
[79]. 
Besides, both in vitro and in vivo experiments demonstrate that the p38-activated kinase MK2 
(also known as MAPKAPK2) also regulates mTOR activation, by the direct phosphorylation of 
Ser1210 on TSC2. Phosphorylation of TSC2 by MK2 creates a 14-3-3 binding site and thus, 
releasing mTOR from the TSC2 inhibition [109]. 
9. p38 MAPK Physiological Functions 
Knockout mice for p38α have been generated, but they die at midgestation due to placental 
defects and abnormal angiogenesis in the yolk sac [1, 120]. Whereas tissue-specific knockouts 
have implicated p38α in controlling inflammation, as well as the proliferation, differentiation 
and survival of different cell types [75, 123]. Recently, p38β, p38γ and p38δ and double 
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p38γ/p38δ knockout mice have also been generated, which are viable and fertile [13, 143]. 
Functional redundancy of all four p38MAPKs may contribute, at least in part, to the lack of 
evident phenotype of these mice [44]. Nonetheless, there are recent reports showing the 
implication of p38γ and p38δ in tissue regeneration, cancer, and metabolic diseases, further 
strengthening the interest of these pathways for the development of new therapeutic strategies.  
9.1 Role of p38MAPK Pathway in inflammation 
Inflammatory response is a basic protective immune process of the organism to defend our body 
from pathogens. Diseases induced by chronic inflammation damage millions of people’s health 
every year. Moreover, there is growing evidence that inflammation is a critical initiation factor 
inducing a variety of other major diseases such as cancer, atherosclerosis, Alzheimer’s disease, 
cardiovascular disease, neurological disorders, and pulmonary diseases [59, 106, 180]. 
Therefore, understanding better the molecular mechanisms and signaling pathways that regulate 
inflammation, could lead to the discovery of new therapeutic targets for the treatment of 
inflammatory-associated diseases. 
There is in vivo and in vitro evidence linking p38 MAPK signaling to the production of 
inflammatory mediators and pro-inflammatory cytokines in several cell types via transcriptional 
and post-transcriptional mechanisms [41, 137]. 
Myeloid- and epithelial cell- specific p38α knockout mice have been use to demonstrate the 
implication of this pathway in inflammatory responses in vivo. p38α has been involved in the 
regulation of cytokine production (TNFα, IL-1β, Il6, COX-2, IL-17, etc.) at transcriptional and 
post-transcriptional levels [100]. Moreover, p38α can regulate the production of endothelial 
vascular cell adhesion molecule-1 (VCAM-1), which participates in cell proliferation and 
differentiation of the immune response [4, 132]. p38α has also been implicated in the survival 
promotion of double-negative T cells [47]. 
Furthermore, p38α is associated with various inflammatory diseases, such as septic shock 
induced by LPS, collagen-induced arthritis, multiple sclerosis, diabetes, and acute lung 
inflammation, as well as joint diseases, including synovial inflammation, cartilage damage, and 
bone loss [72]. 
In contrast, p38β knockout mice present normal T-cell development and responses to TNFα and 
LPS in the immune system. The production of TNFα, IL-1β, IL-6 and MIP1 was not 
compromised in p38β−/− mice or in LPS stimulated macrophages derived from these mice. 
Consistent with this outcome, p38β deficiency did not affect the development of arthritis or 
inflammatory bowel disease, suggesting that p38β is not critical for these functions [13]. 
Nevertheless, p38β has been involved in the regulation of TPA-induced skin inflammation and 
tumor development [112]. 
On the other hand, mice lacking p38γ and p38δ present reduced inflammatory responses. 
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Besides, myeloid cells deficient in p38γ and p38δ are impaired in the LPS-induced production 
of several cytokines, which has been suggested to correlate with reduced levels of the MAPK 
kinase kinase (MAP3K) TPL-2 and extracellular signal-regulated kinase (ERK)1/2 signaling 
[138]. Interestingly, p38α activation does not appear to be affected by p38γ and p38δ 
downregulation [138]. This suggests that they regulate the inflammatory response by distinct 
mechanisms.  
A study of p38δ MAPK knockout (KO) mice as well as myeloid-restricted deletion of p38δ 
MAPK in mice has shown that p38δ is required for the recruitment of neutrophils to sites of 
inflammation. PKD1 phosphorylation by p38δ MAPK regulates PTEN activity to control 
neutrophil extravasation and chemotaxis in a model of inflammation-induced acute lung injury 
(ALI), which can cause acute respiratory distress syndrome (ARDS), a condition with a high 
mortality rate. Therefore, abnormal p38δ -PKD1 signaling may play an important role in both 
ALI and ARDS in humans [81]. 
p38γ and p38δ have been also involved in rheumatoid arthritis (RA). In RA patients, both 
kinases are expressed in the synovium. Moreover mice lacking p38γ and p38δ displayed 
reduced arthritis severity compared to control mice. The protection observed was associated 
with a lower expression of IL-1β and TNFα, as well as a reduction in T-cell proliferation, INFγ 
and IL-17 production [35]. 
Recently, p38δ MAPK has been implicated in the signaling pathway responsible for controlling 
IL-13 driven excess mucus production. This pathway is hyperactivated in patients that suffer 
from chronic obstructive pulmonary disease (COPD). In correlation with a possible role of p38δ 
in the disease, lungs from COPD patients present high p38δ expression levels [3]. 
9.2 Role of p38MAPK pathway in diabetes and obesity 
Inflammation and cellular dysfunction are features of obesity, diabetes and diabetic 
nephropathy, which are associated with intracellular activation of mitogen-activated protein 
kinase (MAPK) signaling pathways. Levels of activated p38α are elevated in the skeletal 
muscle, adipose tissue and kidneys of diabetic patients [2, 25, 97], suggesting that some p38 
responses may be important for the pathogenesis of diabetes and its complications.  
Several recent studies have shown that inhibition of p38α in p38β with SB203580 improves 
glucose transport in L6 and 3T3L1, myoblast and preadipocyte cell lines. These results correlate 
with the study of Carlson et al. (2003) showing that p38 activity participates in a 
downregulation of GLUT4 protein levels and is significantly higher in isolated adipocytes from 
type-2 diabetes patients [25].  
Furthermore, in vitro experiments have shown a positive role of p38α in adipogenesis. Most 
studies were performed in 3T3-L1 preadipocyte cell lines and used pyridinyl imidazole 
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inhibitors such as SB203580 to inhibit p38 activation [53]. More recently, Hata et al. 
demonstrated that Bone Morphogenic Protein-2 (BMP-2) oriented pluripotent mesenchymal cell 
lines C3H10T1/2 into the adipocyte lineage through activation of p38α/β [78].  
In contrast, p38 activation is strongly reduced in the liver of obese mice and its activation leads 
to improved glucose metabolism and reduces hepatic ER stress. This beneficial effect is 
achieved through the phosphorylation of XBP1 that enhances its nuclear localization [104]. 
Recent reports have highlighted the implication of p38δ and p38γ in metabolic diseases [114]. 
Sumara G., et al (2009) has reported that p38δ regulates insulin secretion as well as survival of 
pancreatic β -cells. Mice lacking p38δ display improved glucose tolerance due to enhanced 
insulin secretion from pancreatic β-cells, associated with a strong reduction in PKD inhibitory 
phosphorylation by p38δ. Besides, these mice are protected against high-fat-feeding-induced 
insulin resistance and oxidative stress-mediated β -cell failure. This regulation takes place 
through the inhibitory phosphorylation by p38δ of PKD [156]. 
9.3 Role of p38MAPK pathway in cardiovascular physiology 
and dysfunction 
While p38 has been shown to have a key role in skeletal muscle development [92], its function 
in cardiac development has not been as extensively studied. Recent studies point to a possible 
role for p38 in cardiac development. For example, p38α activity is required for cardiomyocyte 
differentiation of P19CL6 cells, and this is mediated via its activation of the transcription factor 
AP-1 [55]. Further evidence of the importance of p38 in cardiomyocyte differentiation comes 
from the discovery that p38α promotes cardiogenesis over neurogenesis in ES cells [5]. 
Unfortunately, while cell culture studies have strongly implicated p38α as an important player 
in cardiogenesis, there is little to no in vivo data supporting this hypothesis. As mentioned 
previously, p38α−/− embryos are embryonic lethal due to defects in placental angiogenesis. 
However, cardiac-specific deletion of p38α results in normal development of the heart [66]. 
The role of p38 MAPK pathway in cardiac pathology has been much more extensively studied. 
Cardiovascular mortality is one of the most important health problems in human populations 
nowadays. Two leading causes of cardiac morbidity are pressure overload cardiac hypertrophy 
resulting from hypertension and cardiomyocyte apoptosis and necrosis following ischemic 
injuries. 
p38α MAPK activation has been described upon ischemia/reperfusion in mice and in humans 
failing hearts secondary to ischemic heart disease [16, 33]. Shear stress from pressure overload 
can also activate stress-activated protein kinases pathways [172]. Moreover, p38α has been 
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shown to be activated in cultured neonatal cardiomyocytes by hypertrophic stimulation [31, 
122] and in mouse hearts in response to pressure overload [171]. 
Although the four p38 MAPKs are expressed in the heart, p38α and p38γ are the predominant 
isoforms.  Studies have proposed both a protective and damaging roles of p38MAPK in the 
stressed myocardium. This seemed to be dependent in part in the system studied.  
The role of p38 MAPKs in cardiac hypertrophy has been suggested in first place by studies 
using over-expressed active forms of their upstream activators MKK3 and MMK6 in 
cardiomyocytes. In these studies it was found that the active mutants induced characteristic 
hypertrophic responses [172, 191]. Moreover, over-expression of MKK3 in cardiomyocytes 
leads to an increase in apoptosis [172]. Interestingly, the differences between MKK3 and 
MKK6 can point out distinct roles of p38 isoforms. Furthermore, p38 MAPK pathway is 
activated in cardiomyocytes upon hypertrophic stimuli, and the inhibition of p38α/β with 
SB203580 is sufficient to block the hypertrophic growth [191]. One year after, Yibin Wang et 
al. (1998) reported that forced activation of p38β activity in culture cardiomyocytes results in 
characteristic features of hypertrophy, whereas the activation of p38α activity leads to the 
induction of myocyte apoptosis. According with this result, the p38α cardiac-specific knockout 
mice showed that p38α plays a critical role in the cardiomyocyte survival pathway in response 
to pressure overload, while cardiac hypertrophic growth is unaffected despite its dramatic down-
regulation [123]. Although some groups have reported a role of p38α in the regulation of 
cardiac hypertrophy, most of the studies were performed by overexpressing the dominant-
negative p38α, a non-physiological method, or by indirect strategies that could be altering the 
function of other p38 isoforms [20, 130]. 
Due to the lack of pharmacological inhibitors, p38γ and p38δ have been far less extensively 
studied. There is only one study that reported on the role of these kinases in cardiac 
hypertrophy. Dharmendra Dingar et al. (2010) characterized the expression and subcellular 
localization in cardiomyocytes of the p38 MAPK isoforms in physiological conditions and in 
response to chronic pressure overload. Chronic pressure overload induced by transverse aorta 
constriction (TAC) does not induce changes in quantity of p38α mRNA. In contrast, p38β and 
p38δ mRNA increased within 1 day of pressure overload and remained elevated whereas p38γ 
mRNA showed an initial increase but had returned to basal levels by day 7. However, although 
increases in mRNA abundance were observed for p38β, p38γ, and p38δ, the protein level of 
each isoform was unaltered. Confocal immunofluorescence studies revealed p38α and p38γ in 
both the cytoplasm and nucleus. After chronic pressure overload, p38γ accumulated in the 
nucleus whereas the distribution of p38α remained unaffected. These differences in localization 
would result in access to different substrates and hence distinct functional effects [49].
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OBJECTIVES 
Since the discovery of the first p38 isoform, more than 15 years ago, the p38 MAPK 
family has been implicated in the regulation of a diverse array of cellular processes. 
However, most of the reports refer to p38α and p38β isoforms, which have been 
extensively characterized thanks to the availability of highly specific inhibitors and 
knockout mouse models. Nonetheless, we still know very little about the role of the 
alternative p38 MAPKs, p38γ and p38δ. Thus, the main objective of this thesis is to 
understand deeper the importance of p38γ and p38δ in homeostasis and disease.  
Study the implication of p38 MAPK pathway, specifically of p38γ and p38δ, in 
acute inflammatory responses. 
1.1.  To study the role of the up-stream kinases MKK3 and MKK6 using LPS-
induced acute hepatitis as a model of acute inflammatory response. 
1.2. To assess the implication of the different p38 isoforms in LPS-induced acute 
hepatitis. 
1.3. To unveil the specific cell types in which p38γ and p38δ are expressed and 
important for LPS-induced acute hepatitis. 
1.4. To understand the molecular mechanism through which p38 MAPKs regulate 
this process. 
 
 Address the role of p38γ and p38δ in chronic inflammatory responses associated to 
metabolic alterations. 
1.1. To analyze the expression levels of p38γ and p38δ in patients suffering from 
Non-Alcoholic Fatty Liver Disease (NAFLD). 
1.2. To study if the mouse model of steatosis induced by MCD diet could replicate 
the changes observed in human NAFLD patients. 
1.3. To unveil the role of p38γ and p38δ in chronic inflammation associated to 
steatosis and its impact in the disease progression. 
1.4. To assess the role of p38γ and p38δ in chronic inflammation associated to 
obesity and its impact in the disease progression. 
 
Understand the role and regulation of p38γ and p38δ the heart. 
1.5. To analyze the cardiac expression and activation levels of these kinases during 
postnatal stages of cardiac development. 
1.6. To address the role of p38γ and p38δ in postnatal cardiac growth. 
1.7. To investigate the role of p38γ and p38δ in cardiac-overload induced 
hypertrophy. 
1.8. To address the molecular mechanism through which these p38 isoforms control 
cardiac growth. 
1.9. To understand their regulation by upstream MKKs in postnatal cardiac growth.
 
57
  58
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
59
  60
  
 
RESULTS 
ARTÍCULO 1: Eukaryotic elongation factor 2 controls TNF-α translation in LPS-
induced hepatitis. 
 
Autores: González-Terán B, Cortés JR, Manieri E, Matesanz N, Verdugo Á, Rodríguez 
ME, González-Rodríguez Á, Valverde ÁM, Martín P, Davis RJ, Sabio G. 
Publicado en Journal of Clinical Investigations. 2013 Jan;123(1):164-78.  
doi: 10.1172/JCI65124. 
 
RESUMEN 
Las infecciones y el daño tisular desencadenan una respuesta inflamatoria para contener 
o eliminar el agente causante del daño. La producción controlada de citoquinas por los 
leucocitos regula la respuesta inmunitaria. Sin embargo, su producción exacerbada 
puede causar más daño que el agente patógeno inicial, como ocurre en la sepsis o 
hepatitis aguda. El lipopolisacárido bacteriano (LPS) ha sido implicado en la 
patogénesis de la hepatitis aguda a través de la inducción de la citoquina pro-
inflamatoria TNF-α. Los niveles de TNF-α se consideran un determinante crítico en el 
inicio y la progresión de la disfunción hepatica. Un posible mecanismo de control de los 
niveles de TNF-α es a nivel de su elongación proteica, puesto que permitiría una 
adaptación rápida a las necesidades fisiológicas. Sin embargo, no se conocen bien los 
mecanismos que controlan la fase de elongación durante el proceso de traducción . En 
este estudio mostramos que p38γ y p38δ son necesarias en macrógafos y células de 
kupffer para una correcta síntesis de TNFα en respuesta a LPS. La vía de señalización 
MKK3/6-p38γ/δ media la fosforilación inhibitoria de la quinasa del factor de elongación 
eucariótico 2 (eEF2K), lo que lleva a la activación del factor de elongación eucariótico 
2 (eEF2) y a la subsiguiente elongación de la proteína TNF-α en respuesta a LPS. Estos 
resultados muestran un nuevo mecanismo molecular para la regulación de la producción 
de TNF-α y sugieren nuevas potenciales dianas terapéuticas para el tratamiento de 
enfermedades mediadas por esta citoquina pro-inflamatoria. 
Aportación Personal al trabajo: He participado tanto en el diseño experimental, como 
en la realización de los experimentos y en la escritura del artículo.
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Eukaryotic elongation factor 2 controls TNF-α 
translation in LPS-induced hepatitis
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Bacterial LPS (endotoxin) has been implicated in the pathogenesis of acute liver disease through its induction of 
the proinflammatory cytokine TNF-α. TNF-α is a key determinant of the outcome in a well-established mouse 
model of acute liver failure during septic shock. One possible mechanism for regulating TNF-α expression 
is through the control of protein elongation during translation, which would allow rapid cell adaptation to 
physiological changes. However, the regulation of translational elongation is poorly understood. We found that 
expression of p38γ/δ MAPK proteins is required for the elongation of nascent TNF-α protein in macrophages. 
The MKK3/6-p38γ/δ pathway mediated an inhibitory phosphorylation of eukaryotic elongation factor 2 (eEF2) 
kinase, which in turn promoted eEF2 activation (dephosphorylation) and subsequent TNF-α elongation. These 
results identify a new signaling pathway that regulates TNF-α production in LPS-induced liver damage and sug-
gest potential cell-specific therapeutic targets for liver diseases in which TNF-α production is involved.
Introduction
Infection and tissue injury trigger a protective inflammatory 
response that mobilizes a variety of effector mechanisms to con-
tain and eliminate the injurious agent (1). Hepatic and circulating 
inflammatory cytokines initiate a positive feedback loop on the 
innate immune system (2); although cytokine production pro-
tects against pathogenic stimuli, it can cause more damage than 
the initiating event if its magnitude and duration are not strictly 
controlled by intrinsic negative regulators (1).
The cytokine TNF-α has been identified as a key regulator of the 
inflammatory response in animal models of fulminant hepatitis 
(3). Elevated concentrations of this proinflammatory cytokine are 
also found in acute and chronic inflammatory conditions, includ-
ing trauma, sepsis, and rheumatoid arthritis (4). Upon binding to 
its receptors, TNF-α initiates several intracellular signaling cas-
cades that influence cell survival, death, differentiation, prolifera-
tion, and migration (5, 6).
TNF-α signaling is particularly important in the liver. While it 
mediates hepatocyte survival and proliferation, it is also impli-
cated in liver failure, since it triggers hepatocyte apoptosis and 
leads to upregulation of key adhesion molecules and chemokines 
involved in leukocyte migration and infiltration (6, 7). A well-
established mouse model of acute liver failure and septic shock is 
the in vivo administration of bacterial LPS and D-galactosamine 
(D-gal), which strongly induce endogenous TNF-α and other 
cytokines that cause liver damage (8, 9).
TNF-α signaling can be mediated by protein kinases and phos-
phatases, in particular the MAPK family members ERK, JNK, 
and p38 MAPK. The p38 MAPK pathway transduces a variety 
of extracellular signals regulating cellular responses to stress, 
being implicated in cell proliferation, differentiation, and apop-
tosis (10, 11). Four p38 MAPK family members have been identi-
fied: p38α, p38β, p38γ, and p38δ, also known as stress-activated 
kinase 2 a (SAPK2a), SAPK2b, SAPK3, and SAPK4 (10, 12, 13). 
The p38 MAPK family can be further divided into 2 subsets, 
with p38α and p38β in one group and p38γ and p38δ in the 
other. All these kinases are activated by double phosphorylation 
mediated by the upstream kinases MKK3 and MKK6 (14, 15). 
To date, the best-characterized p38 isoform is p38α. This iso-
form is required for macrophage inflammatory responses (1), 
but in hepatocytes prevents endotoxin-induced liver damage 
(16, 17). Studies using inhibitors suggested that p38α and p38β 
cooperate in inflammatory processes; however, p38β-knockout 
mice show no differences in several in vivo and in vitro models 
of inflammation (18). Less is known about the role of the p38γ 
and p38δ MAPK. p38δ is known to phosphorylate eukaryotic 
elongation factor 2 (eEF2) kinase (eEF2K), inhibiting its activity 
(19). eEF2K blocks mRNA translation into protein through an 
inhibitory phosphorylation of eEF2.
The rate-limiting step in mRNA translation is thought to be the 
initiation step; however, far less is known about the regulation of 
the elongation step of protein biosynthesis (20). The process of 
peptide-chain elongation is at least partially regulated by eEF2 
phosphorylation/dephosphorylation events induced by diverse 
stimuli (21). Moreover, the phosphorylation state of the upstream 
kinase eEF2K can be modulated by signaling molecules that regu-
late the activity of this factor, such as mTOR and MAPKs, includ-
ing p38 kinases (19, 21–23). Because these kinases are activated 
by different stimuli, it is expected that the regulation of eEF2 will 
be important in cell adaptation to different physiological states. 
Here, we show that p38δ and p38γ expressed in myeloid cells 
promote eEF2 activity and, in consequence, TNF-α production 
and the inflammatory response. By blocking p38γ/δ activity in 
myeloid macrophages, we were able to suppress hepatitis caused 
by LPS-induced TNF-α expression.
Conflict of interest: The authors have declared that no conflict of interest exists.
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Results
MKK3 and MKK6 collaborate in LPS-induced hepatitis. To study the 
role of p38 MAPK signaling in hepatitis, we examined the effect of 
D-gal+LPS treatment on mice deficient for the upstream kinases 
MKK3 and MKK6. No differences in mortality where detected in 
Mkk3–/– or Mkk6–/– mice compared with WT animals (Supplemen-
tal Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI65124DS1). However, Mkk3–/– mice pres-
ent less severe liver hemorrhage (Supplemental Figure 1B) and 
Mkk6–/– liver apoptosis was significantly reduced (Supplemental 
Figure 1
ΔMKK3/6 mice are protected against LPS-induced liver damage. WT and Mkk3–/–Mkk6–/+ mice (ΔMKK3/6) were treated with D-gal+LPS or saline. (A) 
Survival curves after D-gal+LPS injection (n = 21). Survival curves were created with the Kaplan-Meier method and compared by log-rank (Mantel-
Cox) test. (B) Livers were removed at 6 hours after injection. Panels show representative H&E-stained liver sections and livers. The chart presents 
hemorrhagic area as a percentage of the total area (n = 6–8). Scale bar: 50 μm. (C) Serum transaminase activity at 4 and 6 hours after injection 
(n = 10). (D) Liver extracts were examined by immunoblot with antibodies to cleaved PARP, cleaved caspase 3, caspase 3, phospho-Jun and GAPDH 
(n = 6–8). (E) ELISA analysis of serum TNF-α and IL-6 at different times after injection (n = 16). Data are means ± SD. **P < 0.01; ***P < 0.001 (2-way 
ANOVA coupled to Bonferroni’s post tests).
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Figure 1C). Levels of alanine transaminase (ALT) and aspartate 
aminotrasferase (AST), 2 well-established markers of hepatic 
necrosis, were not altered in Mkk3–/– mice, but were significantly 
reduced in Mkk6–/– mice, thus showing an effect on liver necrosis 
(Supplemental Figure 1D).
The p38 MAPK pathway is a key regulator of the expression 
of inflammatory cytokines, including IL-6 and TNF-α, the main 
determinant of LPS-stimulated liver damage (24–27). Circulating 
levels of TNF-α and IL-6 after D-gal+LPS injection did not differ 
between WT mice and the Mkk3–/– or Mkk6–/– mice (Supplemen-
tal Figure 2A). In vitro stimulation of isolated BM macrophages 
from these mice with LPS also revealed no differences in pro-
liferation rate or released TNF-α and IL-6 levels (Supplemental 
Figure 2, B and C). Moreover, supernatants from WT, Mkk3–/–, 
and Mkk6–/– macrophages induce apoptosis similarly in cultured 
hepatocytes (not shown), thus indicating that the partial protec-
tion against LPS-induced liver apoptosis was not due to circulat-
ing macrophages.
Neutrophil infiltration can cause mild to severe liver dam-
age (28), and p38α was recently shown to control neutrophil 
cytokine production (29). We examined liver myeloid leukocytes 
based on CD11b, Gr-1, F4/80, and Ly6C markers (Supplemental 
Figure 2D and ref. 30). Analysis of liver cell populations revealed 
that D-gal+LPS injection increased liver infiltration by neutro-
phils (CD11b+Gr-1hi) in WT mice, but this effect was impaired in 
Mkk3–/– and Mkk6–/– mice (Supplemental Figure 1E). To investigate 
the potential involvement of liver neutrophils and macrophages in 
the protection detected in Mkk3–/– and Mkk6–/– mice, we isolated 
leukocytes from the livers of WT, Mkk3–/–, and Mkk6–/– mice and 
stimulated them with LPS. Whereas the percentage of neutrophils 
expressing TNF-α was the same in all genotypes, the percentage of 
monocytes (CD11b+Gr-1intermediate) expressing TNF-α was higher in 
WT mice than in Mkk3–/– and Mkk6–/– mice (Supplemental Figure 
1F), indicating that the protection against LPS-induced liver apop-
tosis could be mediated by liver inflammatory monocytes.
Mkk3–/–Mkk6–/+ mice are protected against LPS-induced liver failure. 
MKK3 and MKK6 show functional redundancy in the activation 
of p38 MAPK (14), and while single mutants are viable, doubly 
deficient Mkk3–/–Mkk6–/– and Mkk3–/+Mkk6–/– mice die early in 
embryogenesis. To minimize interference from redundant actions, 
we used Mkk3–/– Mkk6–/+ (ΔMKK3/6) mice, which are viable (14). 
As expected, ΔMKK3/6 mice were protected against LPS-induced 
hepatotoxicity, showing milder hemorrhage and better survival 
than WT mice (Figure 1, A and B). Immunoblot analysis demon-
strated that D-gal+LPS injection activated caspase 3 and PARP 
cleavage in WT liver but not in ΔMKK3/6 livers (Figure 1D). 
Moreover, circulating transaminases were reduced in ΔMKK3/6 
mice, indicating a reduction in liver necrosis (Figure 1C). These 
data demonstrate that MKK3/6 deficiency severely limits LPS-
stimulated hepatic apoptosis. Examination of serum TNF-α after 
D-gal+LPS injection revealed that the marked increase in TNF-α 
concentration observed in WT and singly deficient mice was not 
detected in ΔMKK3/6 mice (Figure 1E). Serum IL-6 was also lower 
in ΔMKK3/6 mice (Figure 1E). The loss of LPS-stimulated TNF-α 
expression in ΔMKK3/6 mice might account for the finding that 
LPS activation of JNK pathway in the livers of WT mice was not 
seen in ΔMKK3/6 mice (Figure 1D).
MKK3 and MKK6 are required for neutrophil migration after LPS injec-
tion. The lower TNF-α production in ΔMKK3/6 mice could be a 
consequence of the lower leukocyte infiltration in liver. To address 
this, we analyzed myeloid cell migration after D-gal+LPS injection. 
Quantification of liver chemokines showed that in WT mice, LPS 
treatment increased mRNA expression of molecules important for 
migration of macrophages (MCP1 and ICAM) and neutrophils 
(KC, MIP2), whereas induction of these chemokines and adhesion 
molecules was decreased in the livers of ΔMKK3/6 mice (Figure 
2A). Phenotypic characterization of liver-infiltrating leukocytes 
from control and D-gal+LPS–treated livers revealed a significant 
increase in neutrophils in the inflammatory cell infiltrate of WT 
mice that was impaired in ΔMKK3/6 mice (Figure 2B), consistent 
with the reduced disease severity (28). However, the percentages 
of macrophages and monocytes did not differ between genotypes 
(Figure 2B). These findings correlated with lower RNA expression 
of neutrophil markers (Elastase 2, Ly6G) in the livers of LPS-inject-
ed ΔMKK3/6 mice (Supplemental Figure 3A).
The reduced liver neutrophil infiltration in ΔMKK3/6 mice 
could be due either to impaired neutrophil release from BM or 
to a defect in cell migration. The levels of circulating neutrophils 
after LPS injection showed a sharp increase in WT mice that was 
absent in ΔMKK3/6 mice (Figure 2C). These data show that the 
reduced neutrophil infiltration in liver is in part caused by low-
ered neutrophil mobilization from the BM. To investigate whether 
the low circulating levels of TNF-α in ΔMKK3/6 mice might be 
responsible for this alteration, we injected TNF-α+D-gal into WT 
and ΔMKK3/6 mice, resulting in increased circulating neutrophil 
levels in both genotypes (Supplemental Figure 3B). These data 
indicate that the defect in migration is secondary to the low pro-
duction of TNF-α in ΔMKK3/6 mice.
MKK3 and MKK6 regulate TNF-α production by macrophages. To 
investigate the molecular mechanism underlying reduced circu-
lating TNF-α in ΔMKK3/6 mice, we treated BM-derived macro-
phages from WT and ΔMKK3/6 mice with LPS. Whereas treat-
ment of WT macrophages with LPS activated JNK, ERK, and p38 
MAPK, in ΔMKK3/6 macrophages the activation of p38 MAPK 
was impaired (Supplemental Figure 3C). The ΔMKK3/6 macro-
phages also secreted markedly reduced amounts of TNF-α and 
IL-6 compared with WT macrophages, confirming that MKK3/6 
deficiency causes major defects in TNF-α production (Supple-
mental Figure 3D). Further analysis showed that neutrophils and 
Kupffer cells, 2 other myeloid cell types implicated in liver dam-
age, also secreted reduced amounts of TNF-α and IL-6 (Supple-
mental Figure 3, E and F). However, in vivo analysis indicated that 
although the percentage of liver neutrophils expressing TNF-α 
after D-gal+LPS injection was the same in both genotypes, the 
percentage of monocytes and macrophages expressing TNF-α was 
higher in WT livers (Figure 2D).
To confirm that reduced cytokine production by liver mac-
rophages is responsible for the protection against hepatocyte 
apoptosis in ΔMKK3/6 mice, we stimulated primary hepatocytes 
with conditioned medium from LPS-treated BM-derived macro-
phages. Conditioned medium from LPS-treated WT macrophages 
increased hepatocyte apoptosis, measured by cleavage of caspase 
3 and PARP, whereas conditioned medium from LPS-treated 
ΔMKK3/6 macrophages had no effect (Supplemental Figure 3G).
MKK3 and MKK6 are not required for TNF-α–induced liver damage. 
Our results so far show that MKK3/6 deficiency causes decreased 
TNF-α production in a TNF-α–dependent hepatitis model. This 
implies that ΔMKK3/6 mice are defective for TNF-α secretion, but 
not TNF-α responsiveness. To test this, we treated mice with TNF-α, 
finding that TNF-α caused similar mortality and liver damage in 
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Figure 2
ΔMKK3/6 mice have lower liver inflammation 
after LPS injection. WT and ΔMKK3/6 mice were 
treated with D-gal+LPS or saline. (A) Total RNA 
was extracted from livers 6 hours after treat-
ment and chemokine mRNA levels determined 
by qRT-PCR. mRNA expression was normal-
ized to Gapdh (n = 5–8). (B) Liver myeloid 
subsets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, 
CD11b+Gr-1–) were assessed by flow cytom-
etry of liver leukocytes isolated from WT and 
ΔMKK3/6 mice 4 and 6 hours after treatment. 
Representative dot plots are shown. Bar charts 
show each myeloid population as the percent-
age of total intrahepatic leukocyte population 
(n = 7). (C) Neutrophils as a percentage of circu-
lating leukocytes, measured in total blood 4 hours 
after injection (n = 5–8). (D) TNF-α and IL-12 pro-
duction by liver myeloid subsets were analyzed 
by intracellular staining in neutrophils (CD11b+ 
Gr-1hi), monocytes (CD11b+Gr-1intermediate) and 
CD11b+Gr-1– myeloid cells isolated from WT and 
ΔMKK3/6 mice 4 and 6 hours after injection. Rep-
resentative dot plots are shown for all treatment 
groups, and bar charts show TNF-α–positive 
cells as the percentage of each myeloid popu-
lation (n = 7). Data are means ± SD. *P < 0.05; 
**P < 0.01; ***P < 0.001 (2-way ANOVA coupled 
to Bonferroni’s post tests).
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WT and ΔMKK3/6 mice (Figure 3, A and B). Immunoblot analy-
sis demonstrated that TNF-α stimulated a similar degree of cas-
pase 3 and PARP cleavage (Figure 3C). Moreover, TNF-α induced 
the same levels of neutrophil liver infiltration in both genotypes 
(Figure 3D). To confirm that the protection was due to defec-
tive cytokine production and not to a protective loss of respon-
siveness to TNF-α, we treated primary hepatocytes from WT or 
ΔMKK3/6 mice with TNF-α and the protein synthesis inhibitor 
cycloheximide (CHX). Both hepatocyte populations presented the 
same level of apoptosis (Figure 3E). These data demonstrate that 
ΔMKK3/6 mice do not exhibit resistance to TNF-α–induced hepa-
titis and indicate that the primary protection against LPS-induced 
hepatitis in these mice is due to an inability to produce TNF-α.
MKK3 and MKK6 are required in the hematopoietic compartment for 
LPS-induced liver damage. The source of TNF-α in mouse models 
of hepatitis is the hematopoietic compartment (31, 32). There-
Figure 3
ΔMKK3/6 mice are not protected against TNF-α–induced liver damage. WT and ΔMKK3/6 mice were i.v. injected with 10 μg/kg ΤΝF-α plus 1 g/kg D-gal 
(TNF-α/Gal) or with saline. (A) Survival curves after TNF-α/Gal injection (n = 13). Survival curves were created with the Kaplan-Meier method and 
compared by log-rank (Mantel-Cox) test. (B) Representative H&E-stained sections of livers extracted 6 hours after injection. The chart presents hem-
orrhagic area as a percentage of the total area (n = 8). Scale bar: 50 μm. (C) Liver extracts were examined by immunoblot analysis for cleaved PARP, 
cleaved caspase 3, caspase 3, phospho-Jun, and GAPDH (n = 6–8). (D) Liver myeloid subsets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, CD11b+Gr-1–) 
were assessed by flow cytometry of liver leukocytes isolated from WT and ΔMKK3/6 mice 4 and 6 hours after treatment. Representative dot plots 
are shown. Bar charts show each myeloid subset as a percentage of the total intrahepatic leukocyte population (n = 4–6). (E) Immunoblot of cleaved 
caspase 3, caspase 3, and GAPDH in WT and ΔMKK3/6 primary hepatocytes treated with TNF-α (20 ng/ml) plus CHX (100 μg/ml). Data are means 
± SD. No significant differences were found (2-way ANOVA coupled to Bonferroni’s post tests).
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Figure 4
ΔMKK3/6 hematopoietic cells protect mice against hepatitis. Lethally irradiated WT mice were reconstituted with BM from WT or ΔMKK3/6 
mice. Mice were treated with D-gal+LPS 2 months after transplantation. (A) 2 × 107 freshly prepared CD45.2 whole BM mononuclear cells were 
transplanted into lethally irradiated B6.SJL (CD45.1) mice, and engraftment by CD45.2 cells (%) was analyzed by antibody staining and FACS 
of peripheral blood after 4 months. Left panels: representative FACS dot plot of CD45.1 and CD45.2 expression in cells isolated from the blood 
of transplanted mice. Right panels: representative FACS dot plot of CD45.1 and CD45.2 expression in F4/80-positive cells isolated from the 
liver of transplanted mice (n = 3). (B) Survival curves after D-gal+LPS injection (n = 10). Survival curves were created with the Kaplan-Meier 
method and compared by log-rank (Mantel-Cox) test. (C) Representative H&E-stained sections of livers extracted 6 hours after injection. The 
chart presents hemorrhagic area as a percentage of the total area (n = 5–8). Scale bar: 50 μm. (D) Serum transaminase activity at 4 and 6 
hours after injection (n = 5–8). (E) ELISA of serum TNF-α and IL-6 at different times after injection (n = 5–8). Data are means ± SD. *P < 0.05; 
**P < 0.01; ***P < 0.001 (2-way ANOVA coupled to Bonferroni’s post tests).
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fore, if defective TNF-α expression accounts for the protection of 
ΔMKK3/6 mice against TNF-α–dependent hepatitis, transplan-
tation of the hematopoietic compartment of ΔMKK3/6 mice to 
immunodeficient donors should confer this protection. To test 
the role of hematopoietic cells, we constructed radiation chime-
ras by transplanting BM from WT and ΔMKK3/6 donor mice 
into lethally irradiated congenic WT and ΔMKK3/6 recipients. 
Efficient reconstitution of B6.SJL (CD45.1) mice with BM from 
WT C57BL/6J (CD45.2) or ΔMKK3/6 (CD45.2) mice was con-
firmed by flow cytometry analysis of peripheral blood leukocytes 
stained with antibodies to CD45.1/CD45.2. Moreover, analysis of 
Kupffer cells (F4/80+) in the liver of recipients after transplanta-
tion showed that more than 90% of Kupffer cells originated from 
the donor mice (Figure 4A).
We found that lethally irradiated mice reconstituted with 
ΔMKK3/6 BM were indeed protected against LPS-induced mor-
tality and exhibited lower levels of LPS-stimulated serum TNF-α 
and hepatic damage than mice reconstituted with WT BM (Figure 
4, B–E). These data confirm that MKK3 and MKK6 expressed in 
hematopoietic cells play a critical role in the expression of TNF-α 
that leads to the development of hepatitis.
Inhibition of p38γ and p38δ protects against LPS-induced hepatitis. 
MKK3 and MKK6 are the main regulators of the α, β, γ, and δ 
p38 MAPK isoforms. To determine which isoforms mediate 
MKK3/MKK6-induced TNF-α expression, we analyzed the effect 
on D-gal+LPS–induced liver damage of 2 inhibitors: SB203580, 
which inhibits p38α and p38β, and BIRB796, which inhibits 
all isoforms (33). We treated mice with BIRB796, SB203580, or 
DMSO prior to LPS injection. We first examined the specific 
action of these inhibitors on MAPK pathway activity. Both com-
pounds efficiently inhibited p38α/β, as shown by the loss of the 
phosphorylation of the known p38α substrate HSP27 (Supple-
mental Figure 4A and ref. 34). In contrast, only BIRB796 was 
able to inhibit p38δ activation, as indicated by suppression of the 
phosphorylation of its substrate, eEF2K (19). No changes in ERK 
or JNK phosphorylation were observed (Supplemental Figure 4A). 
Injection of BIRB796 into WT mice protected against D-gal+LPS–
induced liver damage, whereas SB203580 exacerbated liver dam-
age (hemorrhage, apoptosis, and necrosis) (Supplemental Figure 
4, B–D). Injection of BIRB796 also reduced serum levels of IL-6 
and TNF-α in D-gal+LPS–treated mice (Supplemental Figure 
4E). These results suggest that LPS-induced liver injury might be 
mediated by p38γ and p38δ.
Myeloid expression of p38γ and p38δ is required for LPS-induced hep-
atitis. To investigate the role of p38γ and p38δ in LPS-induced 
hepatitis, we generated mice with myeloid cell–specific ablation of 
these p38 isoforms, separately and in combination. Mice carrying 
conditional loxP-flanked alleles for p38γ, p38δ, and p38γ/δ (p38γfl, 
p38δfl, and p38γ/δfl mice) were crossed with Lyzs-cre transgenic 
mice (35), yielding p38γLyz-KO, p38δLyz-KO, and p38γ/δLyz-KO mice. 
Immunoblot analysis confirmed efficient ablation of the appro-
priate kinases in macrophages, neutrophils, and Kupffer cells 
(Supplemental Figure 5, A and B).
Compared with control Lyzs-cre transgenic mice, p38δLyz-KO 
and p38γ/δLyz-KO mice showed a delay in mortality in response 
to injection of D-gal+LPS (Figure 5A). These mice were also 
protected against liver damage and apoptosis, showing mild-
er liver hemorrhaging, reduced serum levels of ALT and AST, 
and reduced caspase 3 cleavage (Figure 5, B–E). Analysis of 
cytokines revealed significantly lower circulating TNF-α and 
IL-6 in LPS-injected p38δLyz-KO and p38γ/δLyz-KO mice than in 
similarly treated Lyzs-cre controls (Figure 5F). Other chemo-
kines involved in leukocyte migration (MIP1α and MIP1β) were 
also reduced (Supplemental Figure 6). In contrast, p38γLyz-KO 
mice presented only a modest effect on circulating TNF-α levels 
and no differences in the levels of other cytokines (Figure 5F 
and Supplemental Figure 6).
The phenotype found in p38γ/δLyz-KO mice might reflect the 
function of these kinases in several myeloid cell populations impli-
cated in D-gal+LPS damage (such as neutrophils, Kupffer cells, 
and macrophages). Analysis of these cell types in Lyzs-cre mice 
revealed expression of p38γ and p38δ in macrophages, predomi-
nant expression of p38δ in neutrophils, and exclusive expression 
of p38γ in Kupffer cells (Supplemental Figure 5A). Moreover, p38γ 
is strongly activated in Kupffer cells by LPS or TNF-α treatment 
(Supplemental Figure 5B), as judged by the impaired p38 phos-
phorylation observed by FACS in Kupffer cells from p38γ/δLyz-KO 
mice. Furthermore, analysis of phospho-p38 by Western blot con-
firmed that p38γ was the isoform activated in these cells after LPS 
treatment (Supplemental Figure 5C). LPS and TNF-α also activat-
ed p38γ and p38δ in macrophages (Figure 6), while in neutrophils, 
p38α was the only isoform activated after either stimulus (Supple-
mental Figure 5, B and D). Since neutrophils, Kupffer cells, and 
macrophages express p38γ, p38δ, or both isoforms, any of these 
cell populations could have a role in the protection observed in 
p38γ/δLyz-KO mice. We therefore analyzed the different leukocyte 
populations that infiltrated the liver after D-gal+LPS injection. 
Analysis of liver-infiltrating leukocytes showed lower numbers 
of neutrophils in LPS-injected p38γ/δLyz-KO mice than in similarly 
treated Lyzs-cre mice. However, this reduction was not significant 
in LPS-injected p38δLyz-KO mice (Figure 5G). None of the myeloid-
specific p38-deficient mice showed alterations in the percentages 
of infiltrated macrophages or monocytes. Collectively, these data 
show that p38γ/δLyz-KO mice are more strongly affected than either 
of the single conditional knockouts; however, p38δLyz-KO animals 
have a stronger phenotype than p38γLyz-KO mice, indicating partial 
Figure 5
p38γ/δLyz-KO mice are protected against LPS-induced liver damage. 
p38γLyz-KO, p38δLyz-KO, p38γ/δLyz-KO, and control Lyzs-cre transgenic 
mice were injected with D-gal+LPS or saline. (A) Mouse survival after 
D-gal+LPS injection (n = 14). Survival curves were created with the 
Kaplan-Meier method and compared by log-rank (Mantel-Cox) test. (B) 
Livers were removed at 6 hours after injection. Panels show representa-
tive H&E-stained liver sections and livers (n = 5–8). Scale bar: 50 μm. (C) 
Hemorrhagic area as a percentage of the total area on H&E-stained liver 
sections (n = 5–8). (D) Immunoblot analysis of liver extracts (n = 5–8). 
(E) Serum transaminase activity at 6 hours after injection (n = 8–10). (F) 
ELISA of serum TNF-α and IL-6 at different times after injection (n = 10). 
#P < 0.01 for Lyzs-cre versus p38δLyz-KO mice in TNF-α; *P < 0.001 for 
Lyzs-cre versus p38γ/δLyz-KO mice for TNF-α and for Lyzs-cre versus 
p38γ/δLyz-KO or p38δLyz-KO mice in IL-6 (n = 6–8). (G) Liver myeloid sub-
sets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, CD11b+Gr-1–) were assessed 
by flow cytometry of liver leukocytes isolated from p38γLyz-KO, p38δLyz-KO, 
p38γ/δLyz-KO, and control Lyzs-cre transgenic mice 6 hours after injec-
tion. Representative dot plots are shown. Bar charts show each myeloid 
population as a percentage of the total intrahepatic leukocyte population 
(mean ± SD; n = 4–6). Circulating neutrophils in total blood were mea-
sured as a percentage of circulating leukocytes 4 hours after injection 
(n = 5–8). Data are means ± SD. **P < 0.01; ***P < 0.001 (2-way ANOVA 
coupled to Bonferroni’s post tests).
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gests an involvement of cytokine and chemokine production by acti-
vated Kupffer cells and infiltrated macrophages in the pathogenesis 
of liver damage (39). We therefore examined cytokine production by 
macrophages and Kupffer cells upon LPS treatment. ELISA analysis 
demonstrated that LPS-induced production of TNF-α and IL-6 was 
lower in p38γ/δLyz-KO macrophages and Kupffer cells than in Lyzs-
cre control cells (Figure 6A and Supplemental Figure 7C). Moreover, 
only the supernatant from macrophages of p38γ/δLyz-KO animals was 
unable to induce apoptosis in primary hepatocytes (Supplemen-
tal Figure 7A), and analysis of this supernatant indicated a defect 
in cytokine production (Figure 6A and Supplemental Figure 7B). 
Similarly, induction of apoptosis by supernatant from control Lyzs-
cre macrophages was blocked by addition of anti–TNF-α antibody, 
resulting in a protection similar to that obtained with p38γ/δLyz-KO 
supernatant (Supplemental Figure 7C). This finding thus indicates 
that the low TNF-α levels in p38γ/δLyz-KO macrophages and Kupffer 
cells could account for the protection against D-gal+LPS–induced 
liver damage.
p38γ and p38δ mediate TNF-α translation in myeloid cells by phos-
phorylating eEF2K. p38 MAPK can promote cytokine expression 
at the level of transcription, after transcription (by promoting 
mRNA stability), and translation (27, 40). Il6 mRNA expression 
was reduced in p38γ/δLyz-KO macrophages, but levels of Tnfa mRNA 
were comparable to those in Lyzs-cre macrophages (Figure 6B). 
The stability of Tnfa mRNA also showed no difference between the 
2 genotypes (Supplemental Figure 7F). The translational action of 
p38δ has been linked to eEF2 kinase, the enzyme that inactivates 
eEF2. This kinase is inhibited by p38δ-mediated phosphoryla-
tion on Ser359 and also by ribosomal protein S6 kinase–mediated 
phosphorylation on Ser366 (19, 23). Since little is known about 
the regulation of eEF2K in macrophages, we investigated the effect 
of p38γ/δ deletion on the phosphorylation of eEF2K and its down-
stream substrate eEF2. LPS stimulation of Lyzs-cre macrophages 
induced eEF2K phosphorylation on Ser359, but this was markedly 
impaired in p38γ/δLyz-KO macrophages (Figure 6C). This observa-
tion was also corroborated in Kupffer cells (Supplemental Figure 
7D). eEF2K phosphorylation in Lyzs-cre macrophages correlated 
with dephosphorylation of eEF2, implying activation of elonga-
tion. In contrast, p38γ/δLyz-KO macrophages sustained high levels of 
eEF2 phosphorylation after the stimulus, suggesting that elonga-
tion is abolished.
To assess whether eEF2 controls TNF-α elongation, we exam-
ined the binding of eEF2 to Tnfa mRNA in immunoprecipitates 
of mRNA-eEF2 complexes in RAW cells. RAW extracts were incu-
bated with anti-eEF2 or an isotype control antibody, and the 
presence of Tnfa mRNA in the immunoprecipitates was exam-
ined by quantitative (q) real-time PCR. High relative levels of 
Tnfa mRNA were detected in the anti-eEF2 immunoprecipitate, 
and this association was increased by LPS treatment (Figure 
6, E and F). High mRNA levels for Hif1a, a known eEF2 target, 
were also detected in the anti-eEF2 immunoprecipitate (Fig-
ure 6F). In contrast, Il6 mRNA levels did not differ between the 
anti-eEF2 and isotype control immunoprecipitates (Figure 6F). 
Pretreatment of RAW cells with BIRB796 abolished the asso-
ciation of eEF2 with Tnfa mRNA (Figure 6G). Moreover, Tnfa 
mRNA was detected in anti-eEF2 immunoprecipitates from 
LPS-treated Lyzs-cre or WT BM–derived macrophages but not 
in immunoprecipitates from similarly treated p38γ/δLyz-KO or 
ΔMKK3/6 macrophages (Figure 6, H and I). Together, our data 
indicate that Tnfa mRNA is a selective target of eEF2 and that 
redundancy between p38γ and p38δ, with a predominant role of 
p38δ. This overlapping action has been shown before and might 
account for the limited protection observed in single conditional 
knockouts (36, 37). We therefore used p38γ/δLyz-KO mice for further 
experiments. Further studies showed that the reduced neutrophil 
infiltration in liver is, in part, caused by lowered neutrophil mobi-
lization from the BM (Figure 5G), probably due to the defective 
production of TNF-α. Furthermore, measurement of TNF-α–
stimulated chemotaxis in a chamber assay revealed a slightly lower-
than-control mobility in p38γ/δLyz-KO neutrophils (Supplemental 
Figure 8A), and this effect was not increased by stimulation with a 
cytokine cocktail (Supplemental Figure 8B). Neutrophils produce 
several cytokines, and this function can be controlled by p38α (29). 
Examination of cytokine production in our system showed that 
p38γ/δLyz-KO neutrophils express slightly reduced levels of TNF-α 
and IL-6 after LPS treatment, but not sufficient to explain the phe-
notype observed (Supplemental Figure 8C).
To investigate whether the lower neutrophil infiltration in 
the livers of p38γ/δLyz-KO mice could account for the protection 
observed, we investigated whether neutrophil-specific depletion 
in Lyzs-cre mice results in milder liver damage upon D-gal+LPS 
treatment, similar to the phenotype of p38γ/δLyz-KO mice. GR1 is 
highly expressed on neutrophils, and anti-GR1 antibody treat-
ment has been shown to specifically deplete neutrophils (38). 
Treatment of mice with anti-GR1 one day before D-gal+LPS 
injection completely depleted Gr1+ neutrophils (Supplemental 
Figure 8D). Neutrophil depletion did not affect liver damage in 
Lyzs-cre mice, and neither did it abolish the protection observed in 
p38γ/δLyz-KO, as assessed by the levels of ALT and AST, cleaved cas-
pase 3, and PARP, or liver damage observed in H&E-stained sec-
tions (Supplemental Figure 8, E–G).
These data indicate that neutrophils do not play a dominant role 
in the protection against D-gal+LPS–stimulated hepatic damage 
observed in p38γ/δLyz-KO mice and therefore indicate that a different 
myeloid cell type underlies this phenotype. Available evidence sug-
Figure 6
p38γ/δLyz-KO macrophages promote TNF-α translation through phosphory-
lation of eEF2 kinase. (A–D) BM-derived macrophages from p38γ/δLyz-KO 
and Lyzs-cre mice were treated with LPS (10 μg/ml) or TNF-α (20 ng/ml). 
Data were analyzed by 2-way ANOVA coupled to Bonferroni’s post tests. 
(A) ELISA of TNF-α and IL-6 in supernatants. (B) qRT-PCR of Tnfa and 
Il6 mRNA normalized to Gapdh. (C) Immunoblot of BM-derived macro-
phage (BMM) lysates. (D) Flow cytometry of phospho-p38 in BM-derived 
macrophages stimulated with LPS and TNF-α for 30 minutes. Intracellular 
phospho-p38 is depicted in black; gray corresponds to the isotype control. 
(E–I) Cells were treated with LPS. Tnfa mRNA was detected by qRT-PCR 
in immunoprecipitates (1 mg protein) obtained with anti-eEF2. mRNA 
amounts are expressed relative to the amount detected in control IgG 
immunoprecipitates. Data were analyzed by Student’s t test unless oth-
erwise indicated. (E) Tnfa mRNA in RAW 264.7 cell immunoprecipitates. 
(F) Tnfa, Hif1a, and Il6 mRNA in RAW 264.7 cell immunoprecipitates. 
The presence of eEF2 was determined by immunoblot (upper panel) 
and quantified with ImageJ (1-way ANOVA coupled to Bonferroni’s post 
tests). (G) RAW 264.7 cells were pretreated with DMSO or BIRB796 
(10 μM) for 30 minutes before stimulation with LPS (60 minutes). Tnfa 
mRNA was measured in immunoprecipitates. (H and I) Tnfa mRNA in 
immunoprecipitates of BM-derived macrophages from Lyzs-cre and 
38γ/δLyz-KO mice (H) or WT or ΔMKK3/6 mice (I) after stimulation (60 min-
utes). eEF2 in immunoprecipitates was detected by immunoblot (upper 
panel). Data are means ± SD (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001.
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trol cytokine production in myeloid cells. Our findings raise 3 key 
areas of interest: the specific role of myeloid cells, the involvement 
of p38γ/δ compared with that of the other kinases of the same 
family, and how acute inflammatory responses can be controlled 
through tight regulation of translational elongation.
Myeloid cells such as Kupffer cells and other macrophages are 
well known to be a critical source of TNF-α in LPS-induced hep-
atitis (14, 32). This specific role of hematopoietic cells is consis-
tent with our finding that the protective effects of MKK3/6 defi-
ciency are also present in irradiated WT mice reconstituted with 
ΔMKK3/6 BM (Figure 5). Furthermore, this protection was also 
observed in mice specifically lacking p38γ/δ in the myeloid com-
partment (Figure 6). Two cell types of special relevance in acute 
hepatitis are neutrophils and monocytes/macrophages (includ-
ing Kupffer cells), and both of these BM-derived cell populations 
are essential for the innate immune response (42). Monocytes/
macrophages bind to microbial constituents (such as LPS and 
cell wall constituents of Gram-positive bacteria), producing 
large amounts of pro- and antiinflammatory cytokines (3). Neu-
trophil recruitment and activation occur through TNF-α–medi-
ated chemokine production (3). This is evidenced by our find-
ing that low expression of TNF-α in ΔMKK3/6 or p38γ/δLyz-KO 
mice results in decreased chemokine production and neutrophil 
migration, an effect reversed by injection with TNF-α. We did 
not find, however, any evidence for a role of p38γ/δ in neutro-
phil migration, and we found only a minor effect on cytokine 
expression. This contrasts with the recent finding that p38α can 
control cytokine production by neutrophils (29), illustrating the 
different roles and clinical potential of p38 kinase isoforms as 
targets for preventing LPS-induced damage.
Previous reports have identified p38α as a key kinase involved in 
TNF-α production (43). p38α MAPK deficiency in macrophages 
results in decreased TNF-α production, with a modest effect on 
IL-6 expression (44). However, specific inhibition of this kinase 
has been shown to be hepatotoxic, hindering its clinical use. For 
example, the p38α inhibitor AMG 548 showed more than 85% 
inhibition of ex vivo LPS-induced TNF-α in healthy males, but 
its production and clinical use were suspended due to random 
liver enzyme elevations that were not dose or exposure dependent 
(45). Our results show that specific inhibition of p38α/β with 
SB203580 intensifies D-gal+LPS–induced liver damage, whereas 
BIRB796, which inhibits all 4 p38 isoforms (α/β/γ/δ) improves 
liver condition, including a reduction in apoptosis and necrosis. 
The toxicity associated with SB203580 might be caused by inhibi-
tion of p38α in hepatocytes, since mice with specific p38α defi-
ciency in hepatocytes have increased JNK activity and increased 
susceptibility to liver damage (17, 43). In clinical use, BIRB796 also 
produces some liver enzyme elevations (46), most likely because 
of inhibition of p38. Our findings indicate that the generation of 
inhibitors that specifically target p38γ/δ kinases might avoid the 
adverse effects found with p38α inhibitors.
Our results further show that p38γ/δ control macrophage pro-
duction of TNF-α by promoting protein elongation during trans-
lation by eEF2. Protein synthesis is tightly regulated at transcrip-
tional and posttranscriptional levels. Owing to the relatively long 
life time of mRNA transcripts, transcriptional regulation is com-
monly involved in slow, long-term cell responses, whereas immedi-
ate cell responses require posttranscriptional regulation of mRNA 
stability or translation. Two physiological situations requiring 
rapid regulation of protein synthesis are starvation and inflam-
the MKK3/6-p38γ/δ pathway, by releasing eEF2K-mediated inhi-
bition of eEF2 activity, promotes the translational elongation of 
TNF-α in macrophages.
eEF2 controls TNF-α translation elongation. To confirm eEF2 control 
of TNF-α translation elongation, we used a recombinant lentivi-
rus expressing an eEF2 shRNA (shEF2), which causes robust eEF2 
knockdown in RAW cells (Supplemental Figure 9A). In macro-
phages, shEF2-mediated loss of eEF2 caused a decrease in TNF-α 
production of a magnitude similar to that caused by loss of p38γ/δ 
(Figure 7A). In contrast, p38γ/δ-dependent IL-6 production was 
eEF2 independent (Figure 7A). These data indicate that the expres-
sion of TNF-α is controlled by eEF2, while the reduced IL-6 pro-
duction in p38γ/δLyz-KO mice is caused by a different mechanism, 
most likely the loss of p38γ/δ-regulated Il6 gene transcription.
To test the role of eEF2 in vivo, we injected mice with the shEF2 
lentivirus or control shRNA lentivirus 1 week before exposure to 
D-gal+LPS. Blood levels of TNF-α were strongly reduced by the 
shEF2-injected mice compared with controls (Figure 7B). More-
over, this reduction in TNF-α was associated with protection 
against hepatic cell death, measured by cleavage of caspase 3 and 
PARP and protection against hepatic necrosis, and measured by 
liver hemorrhage and blood levels of ALT and AST (Figure 7, C–E). 
Collectively, these data indicate that p38γ/δ MAPK proteins are 
required for the translation elongation of ΤΝF-α in macrophages 
mediated by phosphorylation of eEF2K and the activation of eEF2.
Discussion
In this study,we show that protein kinases p38γ/δ mediate the 
development of LPS-induced acute hepatitis by acting within a 
protein kinase signaling network that regulates the production of 
TNF-α by hematopoietic cells. MKK3 and MKK6 activate p38γ/δ 
(14, 15), which in turn phosphorylate and inactivate eEF2 kinase 
(41). Once eEF2K is inactivated, eEF2 is dephosphorylated and 
activated, allowing the translational elongation of nascent TNF-α. 
To our knowledge, this is the first report that eEF2 or p38γ/δ con-
Figure 7
eEF2 controls TNF-α elongation, and its gene silencing protects 
against LPS-induced liver damage. (A) BM-derived macrophages from 
Lyzs-cre and p38γ/δLyz-KO mice were transduced with GFP+ lentivirus 
expressing eEf2 shRNA (shEF2) or with empty vector (shΦ). ELISA of 
TNF-α and IL-6 in culture supernatants was performed 16 hours after 
LPS (10 μg/ml) stimulation. One-way ANOVA coupled to Bonferroni’s 
post tests (n = 6). (B–F) WT mice were i.v. injected with shEF2 or shΦ 
GFP+ lentiviral vectors. After 7 days, mice were injected with D-gal+LPS 
or saline. Data are means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 
(2-way ANOVA coupled to Bonferroni’s post tests). (B) ELISA of TNF-α 
and IL-6 in mouse serum 6 hours after treatment (n = 6). (C) Represen-
tative livers and H&E-stained sections after removal at 6 hours after 
injection The chart presents hemorrhagic area as a percentage of the 
total area (n = 6). Scale bar: 50 μm. (D) Serum transaminase activity at 
6 hours after injection (n = 6). (E) Immunoblot analysis of liver extracts 
(n = 6). (F) Mouse survival after D-gal+LPS injection (n = 10). Survival 
curves were created with the Kaplan-Meier method and compared by 
log-rank (Mantel-Cox) test. (G) The MKK3/6-p38γ/δ-eEF2K pathway is 
necessary for LPS-induced hepatitis. LPS induces leukocyte egress 
from BM and cytokine/chemokine production in peripheral blood and 
by Kupffer cells. This leads to massive leukocyte infiltration in the liver 
and hepatocellular injury. TNF-α plays a dominant role in LPS-induced 
liver injury. Activation of the MKK3/6-p38γ/δ-eEF2K pathway in macro-
phages/Kupffer cells controls TNF-α production at the mRNA elonga-
tion level in acute inflammatory responses to LPS.
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perfusion of the liver (56). Primary monolayer cultures were established by 
plating 1.5 × 105 viable cells/cm2 in 6-well collagen IV–coated plates. After 
16 hours, primary hepatocytes were stimulated for 24 hours with TNF-α 
(20 ng/ml) plus CHX (100 μg/ml) or with 500 μl of macrophage-condi-
tioned medium for 12 hours. Neutrophil migration assays were performed 
using BD Falcon FluoroBlok 96 Multi-Well insert systems. Neutrophils 
were stained for 1 hour with 1.5 μM calcein AM. Then, 1 × 105 cells were 
plated per well in the upper chamber in 50 μl of culture medium without 
FBS. Lower chambers contained 200 μl of culture medium alone or supple-
mented with the chemoattractant (20 ng/ml TNF-α or 1/10 cytokine cock-
tail). Fluorescence emission was measured at different time points with 
a fluorescent plate reader with bottom-reading capability (Fluoroskan 
Ascent; Thermo Scientific).
Serum analysis. Serum activities of ALT and AST were measured using the 
ALT and AST Reagent Kit (Biosystems Reagents) with a Benchmark Plus 
Microplate Spectrophotometer. Serum concentrations of cytokines were 
measured by multiplexed ELISA with a Luminex 200 analyzer (Millipore).
Biochemical analysis. Tissue extracts were prepared using Triton lysis buf-
fer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 
2 mM EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 
1 mM phenylmethylsulfonyl fluoride, and 10 μg/ml aprotinin and leu-
peptin). Extracts (30 μg protein) and immunoprecipitates (prepared from 
2 mg protein) were examined by protein immunoblot analysis with anti-
bodies to ERK1/2, phospho-ERK1/2, phospho-MKK3/6, p38α MAPK, 
phospho-p38, phospho-hsp27, phospho-JNK1/2, JNK1/2, caspase 3, 
cleaved caspase 3, cleaved PARP, and phospho-eEF2 kinase (Ser366), all 
from Cell Signaling and MKK3 (BD Biosciences — Pharmingen), MKK6 
(Stressgen), and GAPDH and eEF2 (Santa Cruz Biotechnology Inc.). The 
anti-p38γ and p38δ antibodies were raised against the peptides PPRQL-
GARVPKETAL and PIARKDSRRRSGMKL, respectively, which correspond 
to the C termini of the proteins.
Immunohistochemistry. Livers were fixed in 4% paraformaldehyde, pro-
cessed, and embedded in paraffin. Sections (5 μm) were stained with H&E.
Isolation of liver-infiltrating mononuclear leukocytes. Mouse livers were col-
lected, and a single-cell suspension was obtained and passed through a 
70-μm strainer. Leukocytes were collected from the interphase of centri-
fuged Ficoll gradients. Cells were counted with a CASY Cell Counter (57). 
Then 106 Cells were labeled by surface staining (PE-conjugated anti-CD11b 
and PerCP-conjugated anti–Gr-1; Invitrogen), and another 106 cells were 
stimulated in vitro with LPS (10 μg/ml) plus brefeldin A,which inhibits 
protein transport from ER to Golgi, leading to the accumulation of protein 
inside the ER (BD GolgiPlug) (1:1000) for 2 hours. The LPS-stimulated 
cells were then labeled by surface staining (PE-conjugated anti-CD11b 
and PerCP-conjugated anti–Gr-1; Invitrogen), fixed, permeabilized, and 
stained for intracellular TNF-α (APC-conjugated anti–TNF-α from BD 
Biosciences) and IL-12 (PE-conjugated anti–IL-12 from BD Biosciences). 
Flow cytometry was performed with a FACScan cytofluorometer (FACS 
Canto BD), and data were examined using FlowJo software.
Phospho-p38 FACS analysis. Primary myeloid cells were isolated (neutrophils, 
BM macrophages, and Kupffer cells) and stimulated for 30 minutes with LPS 
(10 μg/ml). Cells were fixed overnight in 70% methanol at –20°C and stained 
with anti–phospho-p38 antibody (Cell Signaling) or control rabbit IgG fol-
lowed by FITC–anti-rabbit IgG. Signal was detected by flow cytometry.
RNA-immunoprecipitation assay. RAW 264.7 cells (mouse leukemic 
monocyte macrophage cell line) were stimulated with LPS (10 μg/ml) 
and RNA-immunoprecipitation assays (RIPs) were performed using anti-
bodies against eEF2 (Santa Cruz Biotechnology Inc.). The efficiency of 
immunoprecipitation was checked by immunoblot analysis. RNA was 
isolated from the input lysate, isotype control immunoprecipitate, and 
the anti-eEF2 immunoprecipitate. After reverse transcription, the levels of 
matory conditions. In starvation conditions, mTOR stops protein 
synthesis at the elongation step — the step that consumes most 
metabolic energy — by inhibiting eEF2, thereby preventing cell 
energy depletion. Less is known about the mechanisms involved in 
the termination of the inflammatory response once it has achieved 
its goal. This process needs to be rapidly regulated in order to 
avoid more tissue damage. Our results suggest that control of pro-
tein elongation might be an important mechanism by which cells 
rapidly shut down production of proinflammatory proteins that 
could extend tissue damage in the body, such as TNF-α during an 
inflammatory response. This might be an important mechanism 
by which cells tightly regulate cytokine production induced by 
stress kinases activated during inflammation.
In summary, we conclude that p38γ/δ in myeloid cells promote 
TNF-α production by activating its translation without changes 
in mRNA levels. This is achieved by phosphorylation of eEF2K, 
releasing the inhibitory action of this kinase on eEF2. This post-
transcriptional regulation might be an important mechanism 
regulating cytokine secretion during the innate immune response 
and provides potential targets for the treatment of liver diseases.
Methods
Mice. Mkk3–/– (B6.129-Map2k3tm1Flv) (47, 48) and Mkk6–/– (B6.129-Map2k6tm1Flv) 
mice (49) were as previously described (14). p38γ (B6.129-Mapk12tm1) and 
p38δ (B6.129-Mapk13tm1) mice were crossed with B6.129P2-Lyz2tm1(cre)Ifo/J 
and backcrossed for 10 generations to the C57BL/6J background (Jackson 
Laboratory) and genotyped by PCR analysis of genomic DNA. Radiation 
chimeras were generated by exposing recipient mice to 2 doses of ionizing 
radiation (525 Gy) and reconstituting them with 2 × 107 donor BM cells 
by injection into the tail vein. Hepatitis was induced by i.p. injection with 
50 μg/kg E. coli 0111:B LPS (Sigma-Aldrich) plus 1 g/kg D-gal (Sigma-Aldrich) 
or by i.v. injection with 10 μg/kg ΤΝF-α (R&D Systems) plus 1 g/kg GalN. 
When required, inhibitors were administered by i.p. injection at 15 mg/kg as 
previously reported (50, 51). For in vivo neutrophil depletion, 300 μg/mouse 
of anti-Gr1 or the same volume of saline were i.v. injected 24 hours before 
challenge with LPS. Specificity of the depletion of cell populations was deter-
mined by flow cytometry of blood samples collected during the experiment.
Lentivirus vector production and infection of mice. Lentiviruses were produced 
as described (52). Transient calcium phosphate cotransfection of HEK-
293 cells was done with the pGIZP empty vector or pGIZP.shEF2 vector 
( Thermo Scientific) together with pΔ8.9 and pVSV-G. The supernatants 
containing the LV particles were collected 48 and 72 hours after removal 
of the calcium phosphate precipitate and were centrifuged at 700 g at 4°C 
for 10 minutes and concentrated (×165) by ultracentrifugation for 2 hours 
at 121 986 g at 4°C (Ultraclear Tubes, SW28 rotor and Optima L-100 XP 
Ultracentrifuge; Beckman). Viruses were collected by adding cold sterile PBS 
and were titrated by qPCR.
Mice were injected in the tail vein with 200 μl lentiviral particles suspend-
ed in PBS. Seven days after infection, mice were injected with LPS+D-gal.
Cell culture. Primary BM-derived macrophages were prepared and cul-
tured as described previously (53). To isolate primary Kupffer cells from 
mouse livers, we performed collagenase perfusion and differential centrif-
ugation using Percoll (Pharmacia) as described previously (54). BM neu-
trophils were purified by positive selection using biotinylated GR-1 (BD 
Biosciences — Pharmingen) and MACS streptavidin microbeads (Miltenyi 
Biotec). Neutrophil purity was 95% or greater, as assessed by flow cytom-
etry (55). Cytokines in the culture medium were measured by multiplexed 
ELISA using a Luminex 200 analyzer (Millipore) and a mouse cytokine kit 
(Millipore). For primary hepatocyte isolation, liver parenchymal cells were 
prepared from 8- to 12-week-old anesthetized mice by in situ collagenase 
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TNF-α mRNA were determined by qRT-PCR. Relative mRNA levels were 
calculated by subtracting background from the level of the target mRNA 
and then using the standard ΔΔCT formula.
qRT-PCR. The expression of mRNA was examined by qRT-PCR using a 
7900 Fast Real Time thermocycler and FAST SYBR GREEN assays (Applied 
Biosystems). Relative mRNA expression was normalized to Gapdh mRNA 
measured in each sample. Hif-1α, Gr-1, KC (Cxcl1), Mip-2 (Cxcl2), Mcp-1, and 
Icam-1 were amplified using the primers shown in Supplemental Table 1.
Statistics. Differences between groups were examined for statistical sig-
nificance using 2-tailed Student’s t test or ANOVA coupled to Bonfer-
roni’s post-test. Kaplan-Meier analysis of survival was performed using 
the log-rank test.
Study approval. Animal studies were approved by the local ethics commit-
tee and by the IACUC of the University of Massachusetts Medical School. 
All animal procedures conformed to EU Directive 86/609/EEC and Rec-
ommendation 2007/526/EC regarding the protection of animals used for 
experimental and other scientific purposes, enacted under Spanish law 
1201/2005.
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eEF2 controls TNFα  translation in LPS-
induced hepatitis  
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Figure S1. Mkk3-/- and Mkk6-/- mice are partially protected against LPS-induced liver 
damage. 
Wild-type (WT), Mkk3-/- and Mkk6-/- mice were treated by intraperitoneal (i.p.) injection with 50 
µg/kg LPS plus 1g/kg D-Gal (D-Gal+LPS) or saline. 
(A) Survival curves after D-Gal+LPS injection (n=10). Survival curves were created with the 
Kaplan-Meier method and compared with Log-rank (Mantel-Cox) test. 
(B) Livers were removed at 6 h post-injection. Panels show representative H&E-stained liver 
sections (scale bar 50µm) and livers (n= 6). 
(C) Liver extracts were examined by immunoblot with antibodies to cleaved PARP, cleaved 
caspase 3, caspase 3 and GAPDH (n=6). 
(D) Serum transaminase activity at 4 and 6 h post injection (n=6) 
(E) Liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, CD11b+ Gr-1-) were 
characterized by flow cytometry of leukocytes isolated from WT, Mkk3-/- and Mkk6-/- livers at 
4 and 6 h after treatment. Bar charts show each myeloid population as a percentage of the total 
intra-hepatic leukocyte population; representative dot plots are shown below (n=4-7). 
(F) TNFα and IL-12 production by liver myeloid populations was analyzed by intracellular 
staining in neutrophils (CD11b+ Gr-1high), monocytes (CD11b+ Gr-1interm) and CD11b+ Gr-1- 
myeloid cells isolated from WT, Mkk3-/- and Mkk6-/- livers and treated in vitro with LPS (10 
µg/ml) plus brefeldin A (1:1000) for 2 h. Representative dot plots are shown, and the bar charts 
show the percentages of TNFα-positive cells in each myeloid population. (n=4-7). 
Data are means ± SD (n= 5-10). *P < 0.05; **P<0.01 (Two-way ANOVA coupled to Bonferroni 
post-test).  
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Figure S2.  Mkk3-/- and Mkk6-/- mice have normal levels of TNFα 
(A) Mice were treated by intraperitoneal (i.p.) injection with D-Gal+LPS (LPS/Gal), and serum 
cytokines (ΤΝFα & IL-6) were measured at different times after injection by multiplexed 
ELISA (n = 10). 
(B) Primary bone marrow macrophages from Mkk3-/-, Mkk6 -/- and WT mice were treated with 
LPS (10 µg/ml) in culture. The concentration of ΤΝFα and IL-6 in the tissue culture medium 
was measured by ELISA (n = 4). 
(C) Proliferation of Mkk3-/-, Mkk6-/- and WT bone marrow macrophages (BMM) was assayed by 
crystal violet staining after LPS stimulation. 
(D) Representative images of flow cytometry analysis of leucocytes from WT liver based on 
CD11b+ and Gr-1expression levels. Three distinct populations are shown: Cd11b+ Gr-1high 
(neutrophils), Cd11b+ Gr-1intermediate (monocytes/ macrophages) and Cd11b+ Gr-1-
(macrophages). The Cd11b+ subsets from WT livers were triple-stained for Cd11b, Gr-1 and 
indicated markers (black), and gated for SSC. Gray histograms indicate isotype control (n=7). 
Data are means ± SD. No significant differences were found (Two-way ANOVA coupled to 
Bonferroni post-test). 
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Figure S3. ΔMKK3/6 mice show defective TNFα production and neutrophil migration 
(A) WT and MKK3/6-deficient mice were injected with LPS/Gal or saline. After 6 h, liver RNA 
was extracted, and neutrophil marker mRNAs were determined by quantitative real-time PCR. 
mRNA expression was normalized to the amount of Gapdh mRNA (n = 8).  
(B) Neutrophils were measured as the percentage of circulating leukocytes in total blood collected 
from WT and MKK3/6-deficient mice 4 h after TNF/Gal treatment.  
(C) Primary BMM from WT and ΔMKK3/6 mice were treated with LPS (10µg/ml) in culture for 
the times indicated. Cell lysates were examined by immunoblot (n= 5). 
(D) ELISA analysis of the concentrations of ΤΝFα and IL-6 in the culture medium of WT and 
Mkk3-/- Mkk6-/+ deficient macrophages (n = 6). 
(E) ELISA analysis of the concentrations of ΤΝFα and IL-6 in the culture medium of WT and 
Mkk3-/- Mkk6-/+ deficient liver-isolated Kupffer cells (n = 6). 
(F) ELISA analysis of the concentrations of ΤΝFα and IL-6 in the culture medium of WT and 
Mkk3-/- Mkk6-/+ deficient BM- isolated neutrophils (n=6). 
(G) Primary bone marrow macrophages from WT and ΔMKK3/6 mice were treated with LPS 
(10µg/ml) for the times indicated. The macrophage-conditioned culture medium was collected, 
filtered and used to stimulate primary WT hepatocytes (12 h) in combination with 
cycloheximide (100µg/ml). As a control, LPS was added directly to hepatocytes treated with 
culture medium from untreated macrophages. Hepatocyte lysates were examined by 
immunoblot (n=5). 
Data are means ± SD. *P < 0.05; **P<0.01; ***P<0.001 (Two-way ANOVA coupled to 
Bonferroni post-test). 
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Figure S4. BIRB796 protects mice against D-Gal+LPS-induced hepatitis  
Mice were i.p. injected with DMSO, BIRB796 (15mg/kg) or SB 203580 (15mg/kg). After 30min, 
mice were i.p. injected with D-Gal+LPS. 
(A) Liver extracts were examined by immunoblot with antibodies to phospho-HSP27, phospho-
EF2K (Ser359), phospho-JNK1/2, JNK1/2, phospho-ERK1/2, ERK1/2. D = DMSO; B = 
BIRB796; SB = SB203580, (n=8). 
(B) Representative H&E-stained liver sections at 6 h after treatment. Scale bar 50µm (n=8). 
(C) Serum transaminase activity at 6 h after treatment (n = 10).  
(D) Liver extracts (6 h) were examined by immunoblot with antibodies to cleaved PARP, cleaved 
caspase 3, caspase 3 and GAPDH (n=8). 
(E) Serum cytokines (ΤΝFα, IL6) were measured at different times post-injection by multiplexed 
ELISA (n = 8).   
Data are means ± SD. *P < 0.05; **P<0.01; ***P<0.001 (Two-way ANOVA coupled to 
Bonferroni post-test).  
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Figure S5. Myeloid expression and activation of p38γ and δ. 
(A) p38γ protein expression was analyzed by immunoprecipitation of cell extracts from bone 
marrow-isolated neutrophils (300µg protein) or BM-derived macrophages (800µg protein), or 
by immunoblot of cell extracts from liver-isolated Kupffer cells (20µg protein). p38δ protein 
expression was analyzed by immunoprecipitation of cell extracts from bone marrow-isolated 
neutrophils, liver-isolated Kupffer cells (300µg protein) and BM-derived macrophages (800µg 
protein). 
(B-C) BM-isolated neutrophils and Kupffer cells isolated from the liver of Lysz-cre mice and 
p38γ/δLyz-KO transgenic mice were stimulated with LPS or TNFα for 30 min. 
(B) After stimulation, cells were fixed, permeabilized, and stained for phospho-p38. Signal was 
detected by flow cytometry. Histograms depict intracellular phospho-p38 expression (blue 
histogram). Red line represents the isotype control. 
(C) Cell lysates were examined by immunoblot with antibodies to phospho-p38, p38 delta, p38 
gamma, p38 alpha and GAPDH. 
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Figure S6. p38δLyz-KO  and   p38γ /δLyz-KO mice show defective chemokine production 
p38γLyz-KO,  p38δLyz-KO ,  p38γ/δLyz-KO and control Lyzs-cre transgenic mice were injected with 
D-Gal+LPS or vehicle. 
(A) Serum cytokines and chemokines were measured at different times post-injection by 
multiplexed ELISA (mean ± SD; n = 10). *P < 0.05; ***P<0.001 for between-group 
differences in IL-10 and G-CSF. Statistically significant differences in MIP-1α and MIP-1β 
levels are indicated as $P < 0.001 (Lyz-cre versus p38γ/δLyz-KO mice) and #P < 0.01 (Lyz-cre 
versus p38δLyz-KO mice). 
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Figure sup 7. p38δLyz-KO  and p38γ /δLyz-KO macrophages show defects in cytokine production 
(A) Lyzs-cre and p38γ/δ deficient bone marrow macrophages were treated with LPS (10 or 
100µg/ml) for 10 h. Macrophage-conditioned culture medium was collected, filtered and used 
to stimulate primary WT hepatocytes (12 h) in combination with cyclohexamide (100µg/ml). 
As a control, LPS (10 or 100µg/ml) was added directly to hepatocytes treated with culture 
medium from unstimulated macrophages. Hepatocyte lysates were examined by immunoblot 
(n=5).The concentration of cytokines in the culture medium of Lyzs-cre, p38γ/δ and p38δ 
deficient bone marrow macrophages was measured by ELISA (n=6).   
(B) ELISA analysis of the concentration of cytokines in the culture medium of Lyzs-cre, 
p38γ/δ and p38δ deficient bone marrow macrophages (n = 6).   
(C) Kupffer cells from the liver of Lysz-cre mice and p38γ/δLyz-KO transgenic mice were stimulated 
with LPS (10µg/ml) for 30 min.  
(D) Cell lysates were examined by immunoblot with antibodies to phospho-eEF2K (serine 359) 
and GAPDH. 
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(E) Primary bone marrow macrophages from Lysz-cre and p38γ/δLyz-KO mice were treated with 
LPS (10 µg/ml) for 10 h. The macrophage-conditioned culture medium was collected, filtered 
and then incubated for 1 h with cycloheximide (100µg/ml) plus TNFα blocking antibodies or 
IgG antibodies, in the combinations indicated in the figure. The conditioned media was then 
used to stimulate primary WT hepatocytes for 12 h. Hepatocyte lysates were examined by 
immunoblot (n=5). 
(F) To analyze TNFα and IL6 mRNA stability, Lyzs-cre and p38γ/δ deficient bone marrow 
macrophages were stimulated with LPS (10µg/ml), and actinomycin (10µg/ml) was added 1 h 
later. mRNA was isolated at the times indicated, and analyzed by quantitative real-time PCR. 
mRNA expression was normalized to the amount of Gapdh mRNA (n = 4).  
Data are means ± SD. **P<0.01; ***P<0.001 (Two-way ANOVA coupled to Bonferroni post-test). 
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Figure S8. Role of p38γ/δ in neutrophils and LPS-induced liver injury 
(A-C) Neutrophils were isolated from the bone marrow of Lysz-cre and p38γ/δLyz-KO transgenic 
mice and stimulated with LPS for the indicated times. Data are means ± SD. **P<0.01; 
***P<0.001 (Two-way ANOVA coupled to Bonferroni post-test). 
(A) TNFα induced chemotaxis and cytokine cocktail-induced chemotaxis (B) in neutrophils. (A-B) 
Cells pre-labeled with 1.5 µM calcein AM were incubated with 20ng/ml TNFα or culture 
medium alone for 2 h using the BD FluoroBlok multiwell insert system. Fluorescence was 
measured at the indicated times after the addition of the chemoatractant using a Thermo 
Scientific Fluoroskan Ascent reader. TNFα-induced chemotaxis is expressed as the fold 
increases in fluorescence compared with cells treated with culture medium alone. Data are 
represented as mean ± SD of six replicate wells. 
(C) ELISA analysis of the concentrations of ΤΝFα and IL-6 in the culture medium of Lysz-cre and 
p38γ/δ deficient bone marrow-isolated neutrophils (n = 6). 
(D-G) Neutrophil depletion with Gr-1 mAb does not alter LPS-induced liver injury. Lysz-cre and 
p38γ/δLyz-KO mice were injected i.v. with PBS or Gr-1 mAb (250 µg) and after 24 h were injected 
i.p. with LPS+D-Gal or saline. 
(D) The percentage of neutrophils (Cd11b+Gr-1high) in the peripheral blood of Lysz-cre mice 
87
Barbara González-Terán  Page 11 
injected with Gr-1 mAb or saline was determined by FACS after staining with Cd11b and Gr-1 
antibodies. 
(E) Livers were removed at 6 h post-LPS injection. Panels show representative H&E-stained liver 
sections (scale bar 50µm) and livers (n= 4-8). 
(F) Serum transaminase activity at 6 h after LPS treatment (n = 4-8). Data are means ± SD. 
***P<0.001 (Two-way ANOVA coupled to Bonferroni post-test). 
(G) Liver extracts (6 h) were examined by immunoblot with antibodies to cleaved PARP, cleaved 
caspase 3, caspase 3 and GAPDH (n=4-8). 
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Figure S9. eEf2 silencing by lentiviral transduction of mouse BM-derived macrophage 
cultures. 
(A) GFP expression by RAW 264.7 cells transduced with GFP+ lentivirus expressing shRNA 
against eEf2 (shEF2 clon3) or with empty vector (ShΦ) by fluorescence microscopy. 
Magnification 10x. 
(B) RAW 264.7 cells were transduced with three different lentiviruses, each one expressing a 
different shRNA clone against eEf2. Gene silencing efficiency was determined by immunoblot 
of cell extracts (top) and by qRT-PCR of eEf2 mRNA (bottom). mRNA expression was 
normalized to the amount of Gapdh mRNA. Data are means ± SD. **P<0.01 (One-way 
ANOVA coupled to Bonferroni post-test).  
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Supplemental Experimental Procedures 
Tissue culture. 
Conditioned medium from bone marrow-derived macrophages was obtained after 
stimulation of cells on day 7 of differentiation with LPS (10µg/ml) for 10 or 24 h The 
collected medium was sterile filtered to eliminate BM macrophages and frozen (-20ºC) 
until use. Primary hepatocytes were treated with the conditioned medium for 13 h. 
 
qRT-PCR primers. 
Primers were purchased from Sigma Aldrich. 
Hif-1 α Forward Primer    ACCTTCATCGGAAACTCCAAAG 
Reverse Primer    CTGTTAGGCTGGGAAAAGTTAGG 
Gr-1 Forward Primer   GACTTCCTGCAACACAACTACC 
Reverse Primer    ACAGCATTACCAGTGATCTCAGT 
KC Forward Primer    CTGGGATTCACCTCAAGAACATC 
Reverse Primer    CAGGGTCAAGGCAAGCCTC 
Mip-2 Forward Primer    CCAACCACCAGGCTACAGG 
Reverse Primer    GCGTCACACTCAAGCTCTG 
Mcp-1 Forward Primer    TTAAAAACCTGGATCGGAACC 
Reverse Primer    GCATTAGCTTCAGATTTACGG 
Icam-1 Forward Primer    GTGATGCTCAGGTATCCATCC 
Reverse Primer    CACAGTTCTCAAAGCACAGCG 
Tnfα 
Forward Primer    CCCTCACACTCAGATCATCTT 
Reverse Primer    GCTACGACGTGGGCTACAG 
Il-6 
Forward Primer    TAGTCCTTCCTACCCCAATTT 
Reverse Primer    TTGGTCCTTAGCCACTCCTTC 
 
Statistical analysis. 
Differences between groups were examined for statistical significance using Student’s t-
test, analysis of variance (ANOVA) coupled to the Bonferroni post-test, or the log-rank 
test. 
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RESUMEN 
La esteatosis, la acumulación excesiva de grasa en el hígado que causa inflamación y 
daño hepático, es una de las enfermedades más comunes en las sociedades 
desarrolladas. Está asociada a la obesidad o la ingesta excesiva de alcohol, y puede 
tener consecuencias muy graves como el desarrollo de cirrosis, diabetes o cáncer 
hepático. Sin embargo, hoy en día no existen tratamientos efectivos para la esteatosis. 
p38γ y p38δ han sido involucradas en el desarrollo de diferentes enfermedades con un 
fuerte componente inflamatorio. En este estudio mostramos que pacientes con 
enfermedad de hígado graso no alcohólica (NAFLD) presentan en el hígado niveles 
elevados de p38δ. Además, ratones deficientes en estas quinasas específicamente en 
células mieloides están protegidos frente al desarrollo de esteatosis y complicaciones 
asociadas. Este efecto protector es debido a una migración deficiente de los neutrófilos 
carentes en p38γ/δ al hígado dañado. Así mismo, este trabajo resalta la importancia de 
los neutrófilos en el inicio y progresión de la esteatosis a través de la inflamación 
generada y la inducción de cambios en el metabolismo hepático. Por tanto, sugerimos 
que p38γ y p38δ en células mieloides constituyen potenciales dianas terapéuticas para el 
tratamiento de la esteatosis hepática. 
 
Aportación Personal al trabajo: He participado tanto en el diseño experimental, como 
en la realización de los experimentos y en la escritura del artículo. 
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p38c and p38d reprogram liver metabolism by
modulating neutrophil infiltration
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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major health problem
and the main cause of liver disease in Western countries. Although
NAFLD is strongly associated with obesity and insulin resistance, its
pathogenesis remains poorly understood. The disease begins with an
excessive accumulation of triglycerides in the liver, which stimulates
an inflammatory response. Alternative p38mitogen-activated kinases
(p38c and p38d) have been shown to contribute to inflammation
in different diseases. Here we demonstrate that p38d is elevated in
livers of obese patients with NAFLD and that mice lacking p38c/d
in myeloid cells are resistant to diet-induced fatty liver, hepatic
triglyceride accumulation and glucose intolerance. This protective
effect is due to defective migration of p38c/d-deficient neutrophils to
the damaged liver. We further show that neutrophil infiltration in
wild-type mice contributes to steatosis development by means of
inflammation and liver metabolic changes. Therefore, p38c and p38d
in myeloid cells provide a potential target for NAFLD therapy.
Keywords diabetes; inflammation; obesity; steatosis; stress kinases
Subject Categories Immunology; Metabolism; Molecular Biology of Disease
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of
chronic liver disease in Western countries and estimates of its
worldwide prevalence range from 6 to 35% (Vernon et al, 2011).
NAFLD refers to a wide spectrum of liver damage, ranging from
simple steatosis caused by intracellular triglyceride accumulation to
inflammation (non-alcoholic steatohepatitis [NASH]), fibrosis, and
cirrhosis (Marchesini et al, 2003). NAFLD is a main cause of crypto-
genic cirrhosis and may also predispose to hepatocarcinoma (Farrell
& Larter, 2006).
The pathogenesis of NAFLD is strongly associated with insulin
resistance, obesity and type 2 diabetes (Fabbrini et al, 2010).
However, the mechanisms involved in the accumulation of triglyc-
erides in the liver and subsequent hepatocellular damage are multi-
factorial and not completely understood. Metabolic deregulation
and hepatic steatosis have been linked to stress signaling (Sabio &
Davis, 2010; Sabio et al, 2010), and the activation of stress kinases
in steatosis and obesity suggests a role for these proteins in this
disease (Sabio & Davis, 2010). The stress-activated protein kinase
group consists of two subfamilies: p38 mitogen-activated kinases
(p38 MAPKs) and c-Jun N-terminal kinases (JNKs). While the role
of JNKs in the development of steatosis has been widely studied
(Sabio et al, 2008, 2009), less is known about the role of the p38
MAPK signaling pathway. In mammals, four p38 MAPK isoforms
have been identified: p38a, -b, -c, and -d. Despite biochemical
evidence of specific roles for the individual isoforms, redundancy
and embryonic lethality have impeded attempts to establish their
distinct functions in vivo (Sabio & Davis, 2014). Embryos lacking
p38a die due to defects in placental development (Adams et al,
2000; Allen et al, 2000; Tamura et al, 2000), but mice lacking p38b,
-c, and -d are viable without any obvious defects under basal
conditions (Beardmore et al, 2005; Sabio et al, 2005). Kinases p38c
and -d were recently shown to control inflammation by regulating
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macrophage production of tumor necrosis factor (TNF)-a (Risco
et al, 2012; Gonzalez-Teran et al, 2013) and T-cell activation
(Criado et al, 2014); moreover, p38d also influences neutrophil
inflammatory responses in the lung (Ittner et al, 2012).
Since chronic inflammation is central to the progression of
NAFLD, we aimed to define the role of p38c and p38d in the devel-
opment of this disorder. We detected elevated liver expression of
p38d in a cohort of obese patients with NAFLD and found that p38c
and p38d are responsible for the development of steatosis and NASH
in three animal models of NAFLD: mice fed a high-fat diet (HFD),
mice fed a high-fat fructose diet (HFF), and mice fed a methionine–
choline-deficient (MCD) diet. Lack of p38c and p38d in myeloid cells
impaired neutrophil migration to the liver and thus protected
against steatosis and further hepatic damage. These results highlight
the importance of p38 kinases and neutrophils in NAFLD and open
a new avenue for the treatment of this disease.
Results
p38c and p38d are overexpressed in NAFLD
Analysis of liver biopsies from obese NAFLD patients (body mass
index [BMI] > 35 kg/m2) revealed elevated mRNA expression of
MAPK13 (p38delta) compared with non-obese individuals without
NAFLD, and a similar tendency was detected for MAPK12
(p38gamma) (Fig 1A). Further, among individuals with a BMI
< 35 kg/m2, hepatic MAPK12 and MAPK13 mRNA was elevated in
individuals with liver steatosis compared with control individuals
without liver disease (Fig 1B). Western blot analysis confirmed
higher liver expression of p38d protein in obese individuals with
steatosis (Fig 1C). To corroborate these results in a mouse model of
steatosis, we studied the expression and activation of p38c and p38d
in livers from mice fed a methionine–choline-deficient (MCD) diet,
which induces macrovesicular steatosis and is widely used in NASH
research (Anstee & Goldin, 2006). MCD diet increased the mRNA
expression of p38d (Fig 1D) and induced the activation of p38c and
p38d after 1 week (Fig 1E). This activation remained high during
the 3 weeks of the diet (Fig 1E and F). These results indicate a
possible role of p38c and p38d in the development of steatosis.
Mice lacking p38c and p38d are protected against MCD-
induced steatosis
To study how these kinases affect the development of fatty liver, we
fed a MCD diet to WT mice and mice lacking p38c (p38c/), p38d
(p38d/), and both p38c and p38d (p38c/d/). Compared with
MCD-diet WT mice, MCD-diet p38c/ and p38d/ mice showed
only a slightly milder liver steatosis as evaluated by H&E and Oil
Red staining (Appendix Fig S1A); in contrast, the development of
steatosis and inflammation was strongly attenuated in p38c/d/
mice (Fig 2A and Appendix Fig S2A). These findings were con-
firmed by biochemical analysis of hepatic triglyceride content
(Fig 2B and Appendix Fig S1B). Moreover, whereas MCD diet
increased serum levels of alanine transaminase (ALT) in WT,
p38c/, and p38d/ mice, the level in p38c/d/ mice was signifi-
cantly lower, indicating milder liver necrosis (Fig 2C and
Appendix Fig S1C). The appearance of steatosis protection only in
mice doubly deficient for p38c and p38d probably reflects the previ-
ously described partial functional redundancy between the two
isoforms (Risco et al, 2012; Gonzalez-Teran et al, 2013).
An early event in MCD-induced choline deficiency is the appear-
ance in liver of oxidized lipids, DNA, and proteins. Assay of thiobar-
bituric acid reactive substances in the livers of MCD-fed animals
detected lower oxidized lipid content in p38c/d/ mice than in WT
animals, correlating with lower levels of hydrogen peroxide in the
double-knockout mice (Fig 2D). Liver fibrosis is a hallmark of
NASH. Livers of MCD-diet WT mice expressed higher levels of
Col1a1 and Acta2 than MCD-diet p38c/d/ mice (Fig 2E), correlat-
ing with higher Masson’s trichrome staining (Fig 2F). These results
demonstrate that p38c/d/ mice are protected against MCD-diet-
induced steatosis and NASH.
Inflammation plays a key role in the pathogenesis of NAFLD,
and the development of hepatic steatosis is associated with
increased liver infiltration by myeloid cells (Tiniakos et al, 2010).
p38c/d kinases regulate inflammation through the control of TNF-a
production in macrophages and Kupffer cells (Risco et al, 2012;
Gonzalez-Teran et al, 2013), and p38d modulates neutrophil
motility in lung disease (Ittner et al, 2012), prompting us to exam-
ine the mRNA expression levels of myeloid cell markers and pro-
inflammatory cytokines in mice fed the MCD diet. Liver expression
▸Figure 1. p38c and p38d are up-regulated in NAFDL.A Left: qRT–PCR analysis of mRNA expression of MAPK12 (p38gamma) and MAPK13 (p38delta) in liver extracts prepared from obese patients with alcoholic fatty liver
disease (NAFLD) and control individuals without NAFLD. mRNA expression was normalized to the amount of Gapdh mRNA (n = 11–74). Right: representative H&E-
stained liver sections. Scale bar: 50 lm.
B Left: qRT–PCR analysis of mRNA expression of MAPK12 (p38gamma) and MAPK13 (p38delta) in liver extracts prepared from control patients with NAFLD/non-alcoholic
steatohepatitis (NASH) and control individuals without NAFLD/NASH. mRNA expression was normalized to the amount of Gapdh mRNA (n = 9–11). Right:
representative H&E-stained liver sections. Scale bar: 50 lm.
C Quantification of immunoblot analysis of p38d expression in liver extracts prepared from obese patients with NAFLD and individuals without NAFLD. Representative
blots are shown (n = 7–40).
D qRT–PCR analysis of Mapk12 (p38gamma) and Mapk13 (p38delta) mRNA expression in liver extracts prepared from wild-type mice (WT) fed a diet deficient in
methionine and choline (MCD) or control diet (ND) for 3 weeks; mRNA expression was normalized to the amount of Gapdh mRNA (n = 5–10).
E Immunoprecipitation analysis of activation and protein levels of p38c and p38d isoforms in liver extracts prepared from WT fed a MCD or ND diet for the times
indicated.
F Immunoprecipitation analysis of activation and protein levels of p38c and p38d isoforms in liver extracts prepared from WT fed a MCD or ND for 3 weeks (n = 5).
Western blot against vinculin was used to assay the protein amount in the total lysate (TL) used for each IP. Protein expression was normalized to vinculin.
Data information: Data are means  SEM. *P < 0.05; **P < 0.01. Statistical significance by two-tailed Student’s t-test. Characteristics of patients and controls were
compared by means of v2 or Mann–Whitney U-tests.
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Figure 2. p38c/d/ mice are protected against steatohepatitis and fibrosis.
A Representative H&E- and Oil Red-stained liver sections prepared from WT and p38c/d/ mice fed a ND or the MCD diet for 3 weeks. Scale bar: 50 lm.
B, C Liver triglycerides (B) and plasma transaminase activity (ALT) (C) measured in WT and p38c/d/ mice after 3 weeks of MCD diet.
D TBARS and hydrogen peroxide detected in liver samples from mice fasted overnight after the 3-week MCD diet.
E qRT–PCR analysis of Col1a1, Acta2, and Timp1 mRNA expression. mRNA expression was normalized to the amount of Gapdh mRNA.
F Representative Masson’s trichrome-stained liver sections prepared from WT and p38c/d/ mice fed a ND or the MCD diet for 3 weeks. Scale bar: 50 lm.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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levels of the myeloid cell marker F4/80 and the cytokines Tnfa and
Il6 were significantly lower in p38c/d/ mice than in WT mice
(Appendix Fig S2B). However, analysis of M1 and M2 macrophage-
differentiation markers revealed no differences in M1 (Ifng, Il23)
and M2 markers (Il10, Il13 or Arg) between WT and p38c/d/ mice
(Appendix Fig S2C).
Effect of myeloid cell expression of p38c and p38d on MCD-
induced steatosis
To elucidate the role of myeloid-expressed p38c/d in the develop-
ment of steatosis, we analyzed mice lacking p38c/d in myeloid cells.
These mice have complete deletion of p38c and p38d in macro-
phages, and neutrophils infiltrated in liver and spleen while only
partial deletion of p38d was observed in dendritic cells
(Appendix Fig S3A). Control mice expressing Cre recombinase
(Lyzs-Cre mice) developed the typical hepatic steatosis in response
to the MCD diet, with associated liver accumulation of triglycerides
and hepatocyte necrosis indexed by serum ALT (Fig 3A–C). In
contrast, the response of p38c/dLyzs-KO mice to the MCD diet was
milder for all three parameters (Fig 3A–C), demonstrating a
protection similar to that seen in global p38c/d/ mice. The p38c/
dLyzs-KO mice also had lower circulating levels of TNF-a and IL-6
than Lyzs-Cre mice after the MCD diet (Fig 3D), and gene expression
analysis revealed significantly lower levels of the pro-inflammatory
and myeloid cell markers Il6, Gr1, Lyzs, and F4/80 (Fig 3E). In
contrast, there were no between-genotype differences in the M1/M2
polarization of liver-infiltrated macrophages (Fig 3F).
Myeloid-specific p38c and p38d deficiencies do not affect diet-
induced obesity, but protect against steatosis and diabetes
To confirm that the protection against liver steatosis in MCD-diet
p38c/dLyzs-KO mice was independent of the model used to induce the
disease, we fed Lyzs-Cre and p38c/dLyzs-KO mice with a high-fat diet
(HFD). Weight gain was the same in p38c/dLyzs-KO and Lyzs-Cre
mice (Fig 4A), consistent with their similar lean and fat mass
(Fig 4B). Liver mass was slightly lower in p38c/dLyzs-KO mice
(Fig 4C), while white adipose tissue mass was similar in both
genotypes (Fig 4D). Histological analysis revealed less severe liver
HFD-induced steatosis in the p38c/dLyzs-KO mice (Fig 5A and B),
correlating with lower circulating ALT levels (Fig 5C). We found
higher energy expenditure in p38c/dLyzs-KO animals with no dif-
ferences in the respiratory exchange quotient [VCO2]/[VO2]
between p38c/dLyzs-KO and Lyzs-Cre mice (Fig 4E).
To study whether the protection against steatosis ameliorates
HFD-induced diabetes, we performed a glucose tolerance test
(GTT). HFD-fed p38c/dLyzs-KO mice showed significantly higher
glucose tolerance (Fig 5D) and lower fasting glucose (Fig 5E) than
age-matched Lyzs-Cre controls on the same diet. These results indi-
cate that the protection against steatosis in mice lacking p38c/d in
myeloid cells also protects against HFD-induced diabetes.
A diet high in cholesterol, saturated fat, and fructose (HFF) has
been found to recapitulate features of metabolic syndrome and
NASH better than the traditional HFD (Charlton et al, 2011). Histo-
logical analysis of p38c/dLyzs-KO and Lyzs-Cre mice fed a HFF diet
revealed less severe liver steatosis in the p38c/dLyzs-KO mice
(Appendix Fig S3B and F), inflammation and fibrosis (Appendix
Fig S3F), correlating with lower triglyceride accumulation and
circulating ALT levels (Appendix Fig S3C and D). This protection
against liver steatosis was associated with an improvement in
fasting glucose (Appendix Fig S3E).
p38c-floxed mice have below-normal expression of p38c in
muscle and fat (data not shown), raising the possibility that this
defective expression might contribute to the protection against
steatosis. To exclude this, we generated radiation chimeras by trans-
planting p38c/dLyzs-KO or Lyzs-Cre bone marrow cells into lethally
irradiated WT mice and fed a HFD or MCD diet. Efficient reconstitu-
tion of B6.SJL (CD45.1) mice with p38c/dLyzs-KO or Lyzs-Cre bone
marrow from C57BL/6J (CD45.2) mice was confirmed by staining
peripheral blood leukocytes and liver-infiltrated leukocytes with
antibodies to CD45.1/CD45.2 and analysis by flow cytometry
(Fig 6A). Histological analysis showed milder steatosis (Fig 6B and
C and Appendix Fig S4A), correlating with lower circulating ALT
levels (Fig 6D and Appendix Fig S4B) after MCD or HFD in CX BM
p38c/dLyzs-KO than in the control CX BM Lyzs-Cre mice. Protection
against HFD-induced steatosis associated with lower fasting glucose
in CX BM p38c/dLyzs-KO (Fig 6E). These results confirmed that this
protection is a specific consequence of the loss of p38c/d in bone
marrow-derived cells.
p38c and p38d control neutrophil infiltration during steatosis by
regulating neutrophil adhesion
The protection of p38c/d myeloid KO mice against steatosis and
liver inflammation, together with the low levels of myeloid cell
markers in the livers of these animals suggested a possible effect on
liver infiltration in animals fed a MCD diet or HFD. Characterization
of liver-infiltrating leukocyte subsets in mice fed either diet revealed
that the diet-induced increase in liver-infiltrating neutrophil counts
(CD11b+Gr-1high) was significantly bigger in Lyzs-Cre mice than in
p38c/dLyzs-KO mice (Fig 7A), and similar results were observed in
radiation chimeras restored by bone marrow from Lyzs-Cre mice
versus p38c/dLyzs-KO mice (Appendix Figs S4C and S5). This result
correlated with lower levels of circulating neutrophils in p38c/dLyzs-KO
mice after both diets (Fig 7B and C).
Figure 3. p38c/dLyzs-KO mice are protected against steatohepatitis induced by MCD diet.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a MCD diet for 3 weeks.
A Representative H&E- and Oil Red-stained liver sections. Scale bar: 50 lm.
B, C Liver triglycerides (B) and plasma ALT (C) at the end of the diet period.
D Measurement of plasma TNF-a and IL-6.
E qRT–PCR analysis of myeloid cell markers and cytokine mRNA expression from liver tissue; mRNA expression was normalized to the amount of Gapdh mRNA.
F qRT–PCR analysis of M1 and M2 polarization cell markers from liver-infiltrated macrophages. mRNA expression was normalized to the amount of Gapdh mRNA.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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Figure 4. p38c and p38d deficiency in myeloid cells improves glucose metabolism in an obesity model.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a high-fat diet (HFD) for 10 weeks.
A Body weight measured at the indicated times during HFD treatment.
B Fat mass and lean mass determined by MRI at the end of the diet period.
C, D Liver mass and white fat (WF) mass.
E Respiratory exchange quotient, energy expenditure, and locomotor activity, detected in metabolic cages.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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Neutrophils are the first immune cell type to respond to inflamma-
tion and can induce a chronic inflammatory state by promoting
macrophage recruitment and interacting with antigen-presenting cells
(Mantovani et al, 2011; Talukdar et al, 2012). Neutrophil levels by
defensin 1–3 and neutrophils activation by nitrotyrosine staining, a
measure of NO production, were elevated in the livers of obese
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D
Figure 5. p38c/dLyzs-KO mice are protected against steatohepatitis induced by HFD.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a HFD for 10 weeks.
A, B Representative H&E- and Oil Red-stained liver sections (scale bar: 50 lm) (A) and liver triglycerides (B).
C Plasma ALT at the end of the diet period.
D Glucose tolerance measured at the end of the diet period. Blood glucose concentration was measured in mice given an intraperitoneal glucose injection (1 g/kg)
after overnight fasting.
E Basal blood glucose in overnight-fasted ND and HFD-fed Lyzs-Cre and p38c/dLyzs-KO mice.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 refers to p38c/dLyzs-KO versus Lyzs-Cre; ##P < 0.01; ###P < 0.001 refers to ND
versus HFD (one-way ANOVA coupled to Bonferroni’s post-tests or Newman–Keuls post-test for liver triglycerides).
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patients with NAFLD (Appendix Fig S6A and B). To test the possible
role of neutrophil p38c/d expression in the etiology of inflammation-
induced liver steatosis, we first compared the capacity of WT and
p38c/d-neutrophils to migrate to steatotic liver. For this, we
performed a competitive cell migration assay that allows direct and
simultaneous comparison of the migration of multiple cell subsets in
the same mouse. MCD-diet WT mice were i.v. injected with a 1:1 mix
of DiO-labeled WT and DiD-labeled p38c/d/ neutrophils (6 × 106
cells in total). WT neutrophils arrived at the steatotic liver 1 h after
injection, but recruitment of p38c/d/ neutrophils was markedly
curtailed (Fig 7D and E). The more extensive recruitment of WT
neutrophils appear to be not due to better survival since neutrophils
from both genotypes showed the same survival ratio; however, we
cannot rule out some role of p38c/d in neutrophil survival
(Appendix Fig S7A).
Using intravital microscopy (IVM), we further quantified TNF-a-
stimulated neutrophil migration in the microcirculation of the
cremaster muscle of mice reconstituted with bone marrow (BM)
from Lyzs-Cre or p38c/dLyzs-KO mice (Movies EV1 and EV2).
Numbers of rolling neutrophils were slightly higher in mice receiv-
ing p38c/dLyzs-KO BM, accompanied by higher rolling velocity and
contrasting with lower numbers of adherent neutrophils (Fig 7F).
This higher rolling velocity is consistent with increased expression
of L-selectin observed in neutrophils lacking p38c/d. Moreover, the
defective adhesion might be explained by the lower expression in
p38c/dLyzs-KO neutrophils of CD11b, an integrin that regulates
neutrophil adhesion and migration (Appendix Fig S7B). These
results show that neutrophil adhesion and recruitment are compro-
mised in the absence of p38c/d. Neutrophil rolling under flow
conditions is mediated by L-selectin (Abbassi et al, 1993). To test
the involvement L-selectin in the impaired rolling of p38c/dLyzs-KO
neutrophils, we assayed neutrophil migration under flow conditions
on plates coated with the CD11b ligand ICAM-1 and the L-selectin
ligand E-selectin. Our results indicated that p38c/dLyzs-KO neutro-
phils presented a higher rolling velocity than Lyzs-Cre neutrophils
(Appendix Fig S7C).
To investigate whether the altered migration capacity of p38c/
dLyzs-KO neutrophils is due to an autonomous effect or a defective
production of chemokines, we performed a parabiosis experiment.
Efficiency of parabiosis was evaluated by using congenic markers to
distinguish blood cells in parabiotic pairs, in which one partner was
CD45.1+. Parabiotic exposure of p38c/dLyzs-KO mice to the circula-
tion of WT (CD45.1) mice, both fed the MCD diet, was enough to
worsen the steatosis phenotype of p38c/dLyzs-KO (Appendix Fig
S8A). The exacerbated steatosis correlated with a higher proportion
of CD45.1 (WT) neutrophils in p38c/dLyzs-KO livers compared to the
proportion observed in livers from Lyzs-Cre mice (Appendix Fig
S8B). There were no differences in macrophage infiltration
(Appendix Fig S8B), indicating that the wild-type circulation specifi-
cally increases liver neutrophil infiltration in p38c/dLyzs-KO mice.
Neutrophils thus appear to be crucial to the steatosis protection in
p38c/dLyzs-KO mice.
Neutrophil-specific p38d deficiency protects against steatosis
The most abundant p38 isoform in neutrophils is p38d (Ittner et al,
2012). To test the implication of neutrophil p38d in liver steatosis,
we crossed p38d-floxed mice with Mrp8-Cre mice (Passegue et al,
2004) to generate mice lacking p38d specifically in neutrophils
(p38dMrp8-KO mice; Appendix Fig S9A). H&E and Oil Red staining of
liver sections revealed that these mice were partially protected
against MCD-induced steatosis (Appendix Fig S9B). Moreover,
p38dMrp8-KO mice had below-normal levels of MCD-induced ALT
(Appendix Fig S9C). This protection was associated with low
Figure 6. p38c/dLyzs-KO hematopoietic cells protect mice against HFD-induced steatosis.
Lethally irradiated WT mice were reconstituted with BM from Lyzs-Cre (Cx BM Lyzs-Cre) or p38c/dLyzs-KO mice (Cx BM p38c/dLyzs-KO). Two months after the transplant, mice
were fed the HFD for 10 weeks.
A Freshly prepared CD45.2 whole BM mononuclear cells (2 × 107) were transplanted into lethally irradiated B6.SJL (CD45.1) mice, and engraftment by CD45.2 cells (%)
was analyzed by antibody staining and FACS of peripheral blood and liver CD45+ cells. Charts show CD45.1 and CD45.2 expression in blood cells (left) and liver cells
(right) isolated from transplanted mice (n = 3). Representative FACS dot plots of CD45.1 and CD45.2 expression are shown beneath the charts.
B Representative H&E- and Oil Red-stained liver sections. Scale bar: 50 lm.
C Liver triglyceride content.
D Plasma transaminase ALT activity.
E Fasted glucose, detected at the end of the diet period in overnight-fasted mice.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
◀
▸Figure 7. p38c/dLyzs-KO neutrophils have deficient migration to the liver.A Flow cytometry analysis of liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, CD11b+ Gr-1) isolated from Lyzs-Cre and p38c/dLyzs-KO mice fed a MCD
for 3 weeks or HFD for 10 weeks. Representative dot plots are shown, and bar charts show the diet-induced increase in each population as a percentage of the
total intrahepatic CD11b+ leukocyte population. Myeloid infiltrating cells isolated from livers were sorted by FACS and stained with H&E. Representative cells are
shown next to the appropriate myeloid subsets.
B, C Neutrophils and monocytes as a percentage of total circulating leukocytes, measured in total blood in animals fed the MCD diet for 3 weeks (B) or the HFD for
10 weeks (C).
D, E WT mice fed the MCD diet were i.v. injected with a 1:1 mix of DiO-labeled Lyzs-Cre neutrophils and DiD-labeled p38c/dLyzs-KO neutrophils (6 × 106 cells in total;
n = 10). One hour after injection, liver-infiltrating neutrophils were assessed by flow cytometry (D) and fluorescence micrography on liver sections (E).
F Intravital microscopy quantification of the rolling and adhesion frequencies and rolling velocities of neutrophils recruited to venules irrigating inflamed (TNF-a-
injected) cremaster muscle.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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Figure 8. Neutrophil depletion protects against steatosis.
Osmotic minipumps containing saline or Ly6G antibody were implanted subcutaneously in Lyzs-Cre and p38c/dLyzs-KO mice. These animals were fed a ND or MCD for 3 weeks.
A Neutrophils and monocytes as a percentage of circulating leukocytes, measured in total blood.
B Representative H&E- and Oil Red-stained liver sections after 3 weeks of treatment. Scale bar: 50 lm.
C, D Liver triglyceride (C) and plasma transaminase activity (ALT) (D) at the end of the diet period.
E Total RNA was extracted from livers, and chemokine and cytokine mRNA levels were determined by qRT–PCR. mRNA expression was normalized to the amount of
Gapdh mRNA.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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neutrophil infiltration of the liver compared with MCD-diet-fed
Mrp8-Cre mice (Appendix Fig S9D). These results indicate that the
protection against steatosis is at least partially due to the expression
of p38d in neutrophils.
Neutrophil depletion protects against steatosis development
Early neutrophil accumulation triggers monocyte migration and
inflammation (Savill et al, 1989), and diminished neutrophil accu-
mulation can ameliorate NAFLD (Nathan, 2006). To clarify whether
defective neutrophil migration contributes to the milder hepatic
steatosis in MCD-diet p38c/dLyzs-KO mice, we depleted neutrophils in
MCD-diet Lyzs-Cre mice by administering anti-Ly6G antibody.
Administration of this antibody (0.4 mg/kg per day i.v. for 7 days)
reduced the levels of circulating neutrophils without affecting mono-
cytes (Fig 8A), and treatment for 21 days significantly improved
liver steatosis and reduced triglyceride accumulation to an extent
similar to that observed in the MCD-diet p38c/dLyzs-KO mice; in
contrast, anti-Ly6G treatment of MCD-diet p38c/dLyzs-KO mice did
not appear to provide further benefit (Fig 8B and C). Anti-Ly6G anti-
body treatment of MCD-diet Lyzs-Cre animals also reduced liver
necrosis assessed by serum ALT levels (Fig 8D). Moreover, while
liver expression of Il6 was not affected neutrophil depletion in
Lyzs-Cre mice also significantly reduced liver expression of the pro-
inflammatory markers Tnfa and Lyzs (Fig 8E).
Neutrophil depletion protects against steatosis by modulating
lipid metabolism
We next measured the fatty-acid oxidation metabolite b-hydroxybu-
tyrate, to investigate whether the improvement in hepatic steatosis
in MCD-diet p38c/d/, p38c/dLyzs-KO, and Ly6G-treated mice was
linked to an increase in lipid oxidation. p38c/d/, p38c/dLyzs-KO,
and Ly6G-treated mice all had higher levels of serum b-hydroxy-
butyrate than similarly fed WT or Lyzs-Cre mice (Fig 9A–C), and
this higher lipid oxidation correlated with the higher energy expen-
diture observed in p38c/dLyzs-KO mice (Fig 4E).
To confirm an effect of impaired neutrophil infiltration on liver
lipid metabolism, we examined the effect of MCD-diet on hepatic
gene expression in Lyzs-Cre, p38c/dLyzs-KO, and anti-Ly6G-treated
Lyzs-Cre mice by RNA-seq (Fig 9D–G). Differentially regulated
genes that potentially contribute to the hepatic phenotype of the
neutrophil-deficient mice were identified by comparing gene expres-
sion patterns with MCD-diet-fed Lyzs-Cre mice (Fig 9D–G). Most
gene alterations observed in p38c/dLyzs-KO mice were also detected
in anti-Ly6G-treated Lyzs-Cre mice (Fig 9D). Gene ontology analysis
of genes that changed in the same manner in both mice identified
significant (adjusted P < 0.001) association of neutrophil deficiency
with elevated oxidative lipid metabolism and decreased inflamma-
tion (Fig 9E), including genes regulated by PPAR-a (peroxisome
proliferator-activated receptor-alpha) and by IL-2b and TNF-a
(Fig 9E). Neutrophil deficiency thus causes increased lipid oxidation
and decreased inflammation (Fig 9E–G).
Discussion
The alternative p38 MAPKs p38c and p38d regulate inflammatory
processes through several mechanisms. Here, we demonstrate that
expression of both kinases in myeloid cells is necessary for the
development of liver steatosis and inflammation in animal models
of NAFLD. Further, these kinases control neutrophil migration to
the liver, and hepatic neutrophils contribute to liver steatosis by
promoting liver inflammation and lipogenic metabolism. Deletion of
p38c/d expression in the myeloid compartment curtails neutrophil
recruitment to the liver, protecting animals against diet-induced
steatosis and associated liver damage, and effect that is also
partially mediated by the lack of p38d in neutrophils. These findings
indicate a major role of p38c/d in controlling neutrophil recruitment
during inflammation and suggest that inhibition of neutrophil
trafficking is a potential treatment route for steatosis.
The analysis of NAFLD mouse models clearly demonstrates that
the protection in p38c/d/ mice is attributable to the loss of p38c/d
expression in hematopoietic cells. The bone marrow transfer
experiments and conditional KO animal results confirm that p38c
and d expressions by hematopoietic cells drive steatosis in both diet-
induced steatosis models. Neutrophils were recently shown to be
important mediators of alcoholic fatty liver disease (Bertola et al,
2013), and p38d is known to control neutrophil inflammatory
response in lung by regulating PKD1 activity (Ittner et al, 2012).
Our analysis shows that loss of p38c and p38d in neutrophils might
be responsible for the protection observed in the KO animals. Livers
from mice lacking p38c and p38d had lower neutrophil infiltration,
and neutrophils lacking these kinases could not be recruited to the
liver in a competition assay, indicating a cell autonomous effect.
The low adhesion and higher rolling velocity detected in neutrophils
lacking p38c and p38d are broadly consistent with previous reports
using p38d/ animals (Ittner et al, 2012). We also observed lower
▸Figure 9. Neutrophils control liver metabolic changes in steatosis development.A–C Plasma levels of 3-hydroxybutyrate in WT and p38c/d/ (A), Lyzs-Cre and p38c/dLyzs-KO mice (B) and Lyzs-Cre Ly6G Ab treated after MCD diet (C) (n = 5–10).
D Overlap of gene expression changes between Lyzs-Cre mice treated with anti-Ly6G and p38c/dLyzs-KO at the end of the MCD diet period n = 4 (each n is a mix of
two different animals).
E Hierarchical clustering of the expression profiles of genes differentially expressed both between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between Lyzs-Cre
treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice. Genes up-regulated in both comparisons (red cluster) were mainly regulated by PPAR-a, SREBF1, and
SREBF2, while the enriched upstream regulators of genes down-regulated in both conditions versus the control group (blue cluster) were IL-1b, TNF-a, and PDGFB-b.
F IPA (http://ingenuity.com) functional categories enriched in the set of genes differentially expressed between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between
Lyzs-Cre treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice (n = 4).
G Genes differentially expressed between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between Lyzs-Cre treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice and
involved in liver steatosis according to IPA.
Data information: Data are means  SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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CD11b and higher L-selectin membrane expression, which could
account for these defects in adhesion and rolling observed in the
neutrophils lacking p38c and p38d. Moreover, lack of p38d alone is
insufficient to reduce neutrophil infiltration after the MCD diet and
protect against liver steatosis. The ability of p38c to compensate for
the loss of p38d is somewhat surprising given the low expression
level of p38c in neutrophils (Gonzalez-Teran et al, 2013; Han et al,
2013). A possible explanation is that p38d/ neutrophils might
increase the activation or expression of p38c as a compensatory
mechanism. It is also possible that p38c in another myeloid cell type
(e.g. resident macrophages) contributes to neutrophil migration by
controlling cytokine and chemokine production. However, the
results of competition migration assays in which resident macro-
phages are WT, and of the parabiosis experiment, argue against this
possibility. Further experiments will be needed to determine the
specific roles of p38c and p38d in different myeloid subsets and how
these two isoforms can compensate each other. However, a role of
neutrophils is clear because lack of p38d only in neutrophils is
enough to protect against steatosis.
On the other hand, the fact that neutrophil-specific deletion of
p38d has a more marked effect on phenotype than the whole-body
p38d KO might indicate that p38d has an opposing role in another
tissue and thereby modulates biological actions in a tissue-specific
fashion. Opposing effects in different tissues have been shown for
the stress kinase JNK: deletion of this kinase in the liver induces
steatosis whereas deletion in fat is protective (Sabio et al, 2008,
2009).
Our data point out an important role of p38c/d in neutrophils.
The same level of protection against diet-induced steatosis observed
in p38c/dLyzs-KO mice was also achieved in mice depleted of neutro-
phils with anti-Ly6G antibody. Moreover, deletion of p38d in neutro-
phils reduces hepatic neutrophils infiltration and partially protected
against steatosis. These observations strongly suggest that neutro-
phil recruitment to the liver is essential for the initiation and
progression of NAFLD and that neutrophil p38c/d expression contri-
butes to the progression of this disease. The central role for neutro-
phils in NAFLD is consistent with their roles in ethanol-induced
liver damage (Bertola et al, 2013) and macrophage recruitment to
damaged tissue in obesity (Mansuy-Aubert et al, 2013) and with the
description of neutrophil elastase as an important mediator of
obesity-induced diabetes (Talukdar et al, 2012; Mansuy-Aubert
et al, 2013). The importance of infiltrating neutrophils in liver
inflammatory responses is also indicated by the underexpression of
inflammatory genes in MCD-diet-fed p38c/dLyzs-KO and neutrophil-
depleted mice and by the increased lipid oxidation and reduced lipo-
genesis in the neutrophil-depleted mice.
The data from mouse models correlate well with the overexpres-
sion p38d and p38c in livers of individuals with NAFLD, regardless
of BMI, which could indicate the involvement of these kinases in
the development of steatosis. This elevated p38d expression could
be due to increased neutrophil influx to these livers, as neutrophils
are known to express high levels of p38d (Ittner et al, 2012;
Gonzalez-Teran et al, 2013). Accordingly, we also observed
elevated neutrophil activity in the livers of obese patients with
NAFLD. It would be interesting to characterize the cell-type
contribution to p38d and p38c expression in human liver. However,
we cannot rule out important roles for p38d and p38c expressed
in other cell types involved in steatosis development.
In summary, our findings indicate that neutrophil infiltration trig-
gers the development of NAFLD and that p38c/d regulate this
process by controlling neutrophil infiltration. Therefore, inhibition
of p38c/d might represent a novel therapeutic target for NAFLD in
humans, with the potential to limit injury and possibly prevent
progression to NASH and cirrhosis.
Materials and Methods
Study population and sample collection
The study population included a group of obese adult patients with
body mass index (BMI) ≥ 35 kg/m2 and a liver biopsy compatible
with NAFLD. Participants were recruited from patients undergoing
elective bariatric surgery at the University Hospital of Salamanca.
As controls, we included individuals with BMI < 35 kg/m2 who
underwent laparoscopic cholecystectomy for gallstones. These indi-
viduals were divided into two groups according to the presence of
NAFLD: (i) controls without NALFD (n = 11) if they had no labora-
tory or histopathological evidence of NAFLD or other liver diseases;
(ii) controls with NAFLD (n = 9) if they had a liver biopsy compati-
ble with NAFLD. Therefore, three groups of subjects were included
in the study: obese patients (BMI ≥ 35 kg/m2) with NAFLD, controls
with BMI < 35 without liver disease, and controls with BMI
< 35 kg/m2 and with NAFLD. Baseline characteristics of these
groups are listed in Appendix Table S1.
Participants were excluded if they had a history of alcohol use
disorders or excessive alcohol consumption (> 30 g/day in men and
> 20 g/day in women), chronic hepatitis C or B, or if laboratory
and/or histopathological data showed causes of liver disease other
than NAFLD. The study was approved by the Ethics Committee of
the University Hospital of Salamanca and all subjects provided writ-
ten informed consent to undergo liver biopsy under direct vision
during surgery.
Data were collected on demographic information (age, sex, and
ethnicity), anthropomorphic measurements (BMI), smoking and
alcohol history, coexisting medical conditions, and medication use.
Before surgery, fasting venous blood samples were collected for
determination of complete cell blood count, total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), total
cholesterol, high-density lipoprotein, low-density lipoprotein,
triglycerides, creatinine, glucose, and albumin.
A portion of each liver biopsy was fixed in 10% formalin and
stained with hematoxylin–eosin and Masson’s trichrome for stan-
dard histopathological analysis. The remaining portion was stored
at 80°C for later protein was extraction. The presence of NAFLD
was diagnosed using standard criteria, and severity of the disease
was established using the NAFLD activity score (NAS) described by
Kleiner (Kleiner et al, 2005).
Mice
Mice deficient for p38c (B6.129-Mapk12tm1) and p38d (B6.129-
Mapk13tm1) were crossed with B6.129P2-Lyz2tm1(cre)Ifo/J mice or
with B6.Cg-Tg(S100A8-cre,-EGFP)1Ilw/J mice backcrossed for 10
generations to the C57BL/6J background (Jackson Laboratory).
Genotype was confirmed by PCR analysis of genomic DNA.
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Radiation chimeras were generated by exposing recipient mice to 2
doses of ionizing radiation (625 Gy) and reconstituting them with
2 × 107 donor BM cells by injection into the tail vein. Proper
reconstitution was checked in B6.SJL (CD45.1) control mice
transplanted with CD45.2 BM mononuclear cells by immunostaining
and FACS analysis of peripheral blood and liver CD45+ cells. Mice
were fed a standard chow diet or a methionine–choline-deficient
(MCD) diet for 3 weeks (Research Diets Inc). Alternatively, mice
were fed a high-fat diet (HFD) or a high-fat and high-fructose (HFF)
diet (Research Diets Inc) for 10 weeks. For neutrophil depletion,
mice were treated with anti-Ly6G antibody (0.4 mg/kg per day,
21 days) via subcutaneously implanted mini-osmotic pumps
(Alzet); saline was administered as a control. All animal procedures
conformed to EU Directive 86/609/EEC and Recommendation 2007/
526/EC regarding the protection of animals used for experimental
and other scientific purposes, enacted under Spanish law 1201/
2005.
Hepatic peroxidation
Liver extracts were prepared by sonication (15 cycles) in cytoplas-
mic lysis buffer [25 mM Tris–HCl (pH 7.5), 10 mM NaCl, 1 mM
EDTA, 100 mM MgCl2, 1% NP-40, 0.1 mM phenylmethylsulfonyl
fluoride, and 10 lg/ml aprotinin and leupeptin]. Malondialdehyde
and hydrogen peroxide were assayed with the TBARS Assay kit
(Cayman) and the Amplex Red Hydrogen Peroxide/Peroxidase
Assay Kit (Invitrogen).
Glucose tolerance test
Glucose tolerance test was performed as described (Mora et al,
2005).
Isolation of liver-infiltrating mononuclear leukocytes
Mouse livers were collected, and a single-cell suspension was
obtained and passed through a 70-lm strainer. Leukocytes were
collected from the interphase of centrifuged Ficoll gradients.
Flow cytometry
Isolated liver-infiltrating leukocytes were counted with a CASY Cell
Counter (57) and then labeled by surface staining (Streptavidin-
PERCP/biotin-conjugated anti-CD11b and APC-conjugated anti-Gr-1;
Invitrogen). Flow cytometry was performed with a FACScan cytoflu-
orometer (FACS Canto BD), and data were collected and analyzed
with FlowJo software.
Intravital microscopy
Intravital microscopy of the cremaster muscle after TNF-a injection
(0.5 lg, intrascrotal injection) was performed as reported
(Sreeramkumar et al, 2013) using an Axio Examiner Z.1 work-
station (Zeiss, Germany). Fluorescently conjugated anti-Ly6G
(1 mg/mouse) was injected immediately before acquisition to
specifically identify neutrophils. Recorded videos were analyzed
using Slidebook software (Intelligent Imaging Innovations). At least
30 venules were analyzed from 3 mice per group.
Competitive cell migration assay
Lyzs-Cre and p38c/dLyzs-KO neutrophils were isolated from bone
marrow by labeling with biotin-conjugated anti-Ly6C/G antibody
(BD Pharmigen) and magnetic streptavidin microbeads (Miltenyi
Biotec) and then separating them on MACS MS columns (Miltenyi
Biotec). Isolated Lyzs-Cre neutrophils were stained with DiO and
p38c/dLyzs-KO neutrophils were stained with DiD (Vybrant Cell-
Labeling Solution, Molecular Probes). Cell viability was checked by
DAPI staining followed by FACS. The labeled cells were then mixed
at a 1:1 ratio and injected (6 × 106 cells) into MCD-diet WT mice.
After 1 h, liver-infiltrating mononuclear leukocytes were isolated and
directly detected by FACS. Fluorescent neutrophils were also detected
by confocal microscopy in OCT-cryopreserved liver sections.
Statistical analysis
Differences between experimental groups were examined for statisti-
cal significance by two-tailed Student’s t-test or one-way ANOVA
coupled to Bonferroni’s and Newman–Keuls post-test. Characteris-
tics of patients and controls were compared by means of Mann–
Whitney U-test for quantitative variables and v2 or Fisher’s tests for
qualitative variables.
For more Materials and Methods, see the Appendix.
Expanded View for this article is available online.
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Appendix Fig. S1. p38γ-/-  and p38δ-/-  mice are partially protected against 
steatohepatitis. 
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WT, p38γ-/- and p38δ-/- mice were fed a control diet (ND) or a diet deficient in 
methionine and choline (MCD) for 3 weeks. (A) Representative H&E and oil red 
stained liver sections. Scale Bar: 50µm. (B) Liver triglyceride and (C) plasma 
transaminase activity (ALT) at the end of the diet period. (D-E) Flow cytometry 
analysis of liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, CD11b+ Gr-1-) 
isolated from WT, p38γ-/- and p38δ-/- mice fed the MCD diet for 3 weeks. 
Representative dot plots are shown (D), and bar charts (E) show the diet-induced 
increase in each population relative to controls fed a ND as a percentage of the total 
intra-hepatic CD11b+ leukocyte population. (F) Neutrophils as a percentage of 
circulating leukocytes, measured in total blood in animals fed a MCD diet for 3 weeks. 
Data are means ± SEM. (n=5-10). *P<0.05; **P< 0.01; ***P< 0.001 (1-way ANOVA 
coupled to Bonferroni’s post tests). 
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Appendix Fig. S2. p38γ/δ-/- mice are protected against liver inflammation induced 
by MCD diet. WT, p38γ/δ-/- mice were fed a ND or the MCD diet for 3 weeks. (A) 
Quantification of liver H&E stained sections from WT and p38γ/δ-/- mice for steatosis, 
inflammation and pigment. Total RNA was extracted from livers, and (B) myeloid cell 
markers and cytokine mRNA levels and (C) M1 and M2 macrophages markers 
determined by qRT-PCR; mRNA expression was normalized to the amount of Gapdh 
mRNA. Data are means ± SEM. (n=5-10). *P<0.05; **P<0.01; ***P<0.001 (1-way 
ANOVA coupled to Bonferroni’s post tests). 
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Appendix Fig. S3. p38γ/δLyzs-KO mice are protected against steatohepatitis induced 
by HFF. (A) PCR analysis of p38δ (left) and p38γ (right) deletion in macrophages (1), 
neutrophils (2), and dentritic cells (3, 4) infiltrated in liver and spleen from p38γ/δLyzs-
KO. (B-F) Lyzs-Cre and p38γ/δLyzs-KO mice were fed a high cholesterol, high saturated 
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fat, and high fructose (HFF) diet for 10 weeks. (B) Representative H&E and oil red 
stained liver sections (Scale Bar: 50µm) and (C) liver triglycerides (n=5-10). (D) 
Plasma ALT at the end of the diet period. (E) Basal blood glucose in overnight-fasted 
and fed Lyzs-Cre and p38γ/δLyzs-KO mice (n=5-10). (F) Representative picrosirius red 
stained liver sections (Scale Bar: 50µm) and quantification of H&E stained liver 
sections for steatosis and inflammation.  Data are means ± SEM. (n=5-10) *P<0.05; 
**P<0.01; ***P<0.001 refers to p38γ/δLyzs-KO versus Lyzs-Cre; ##P<0.01; ###P<0.001 
refers to ND versus HFD (1-way ANOVA coupled to Bonferroni’s post tests or t-test). 
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Appendix Fig. S4. Lyzs-Cre hematopoietic cells protect mice against MCD-diet–
induced steatosis. Lethally irradiated WT mice were reconstituted with BM from Lyzs-
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Cre (Cx BM Lyzs-Cre) or p38γ/δLyzs-KO mice (Cx BM p38γ/δLyzs-KO). Two months after 
the transplant, mice were fed the MCD diet for 3 weeks. (A) Representative H&E and 
oil red-stained liver sections. Scale bar: 50 µm. (B) Serum transaminase ALT activity 
after MCD diet. (C) Flow cytometry analysis of liver myeloid subsets (CD11b+ Gr-1high, 
CD11b+ Gr-1intermediate, and CD11b+ Gr-1-) isolated from Cx BM Lyzs-Cre and Cx BM 
p38γ/δLyzs-KO mice fed the MCD diet for 3 weeks. Representative dot plots are shown, 
and bar charts show the diet-induced increase in each population relative to controls fed 
a ND as a percentage of the total intra-hepatic CD11b+ leukocyte population. (D) 
Neutrophils and monocytes as a percentage of circulating leukocytes, measured in total 
blood in animals fed a MCD diet for 3 weeks. Data are means ± SEM. (n=5-10) 
*P<0.05; **P<0.01 (1-way ANOVA coupled to Bonferroni’s post tests or t-test). 
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Appendix Fig. S5. Lyzs-Cre hematopoietic cells protect mice against HFD-induced 
liver neutrophil infiltration. Lethally irradiated WT mice were reconstituted with BM 
from Lyzs-Cre (Cx BM Lyzs-Cre) or p38γ/δLyzs-KO mice (Cx BM p38γ/δLyzs-KO). Two 
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months after the transplant, mice were fed the HFD for 10 weeks. Flow cytometry 
analysis of liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, and CD11b+ 
Gr-1-) isolated from Cx BM Lyzs-Cre and Cx BM p38γ/δLyzs-KO mice fed the HFD for 
10 weeks. Representative dot plots are shown, and the bar charts show the diet-induced 
increase in each population relative to controls fed a ND as a percentage of the total 
intra-hepatic CD11b+ leukocyte population. Data are means ± SEM. (n=5-10) **P<0.01 
(t-test). 
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Appendix Fig. S6. Neutrophil infiltration during steatosis development. Liver 
biopsies from obese patients with NAFLD and from control patient without NAFLD 
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were stained (A) anti-human neutrophil defensin 1-3 (scale bar: 100 µm) and 
quantification of neutrophil infiltration by mm2 of liver parenchyma. (B) Representative 
slides of liver biopsies stained with anti-nitrotyrosine antibody and quantification of 
neutrophil infiltration by mm2 of liver parenchyma. Scale bar: 50 µm. Data are means ± 
SEM. (n=5-10) *P<0.05, **P<0.01 (t-test). 
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Appendix Fig. S7. Myeloid p38γ/δ  deletion affects expression of L-Selectin and 
CD11b. (A) BM-isolated neutrophils isolated from Lysz-Cre mice and p38γ/δLyz-KO 
transgenic mice labeled with DiO (Lyzs-Cre neutrophils) and DiD (p38γ/δLyzs-KO 
neutrophils) were stained with DAPI and their survival were analyzed by flow 
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cytometry. Representative dot plots of DAPI-negative cell population were shown. (B) 
BM-isolated neutrophils isolated from Lysz-Cre mice and p38γ/δLyz-KO transgenic mice 
were stimulated with FMLP 1µM or vehicle for 30 min. After stimulation, cells were 
stained with anti-L-selectin APC and anti-CD11b FITC.  Signal was detected by flow 
cytometry. Histograms depict basal L-Selectin (left) or CD11b (right) membrane 
expression in Lysz-cre neutrophils (grey) and in p38γ/δLyz-KO neutrophils (light blue) or 
fmlp induced L-Selectin (left) or CD11b (right) membrane expression in Lysz-Cre 
neutrophils (black) and in p38γ/δLyz-KO neutrophils (dark blue). The shaded light grey 
line represents the isotype control. (C) Microscopy quantification of the rolling 
velocities of neutrophils recruited to slides covered with E-Selectin and ICAM-1. Data 
are means ± SEM. *P<0.05; ***P<0.001 (1-way ANOVA coupled to Bonferroni’s post 
tests or t-test). 
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Appendix Fig. S8. Parabiosis assay, in which the circulation of a p38γ/δLyzs-KO 
mouse is shared with that of a WT partner mouse. CD45.1+ WT mice were sutured 
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to either CD45.2+ Lyzs-Cre or p38γ/δLyzs-KO mice by parabiosis surgery. Two weeks 
after surgery mice were fed a MCD diet for 3 weeks. (A) Up: Illustration of parabiotic 
couples. Bottom: Representative H&E stained liver sections from Lyzs-Cre (CD45.1), 
p38γ/δLyzs-KO (p38γ/δLyzs-KO) and p38γ/δLyzs-KO (CD45.1) parabiotic mice. Scale bar: 50 
µm. (B) Quantification of flow cytometry analysis of liver myeloid subsets (CD11b+ 
Gr-1high (neutrophils) and CD11b+ Gr-1intermediate (macrophages)) isolated from Lyzs-Cre 
(CD45.1), p38γ/δLyzs-KO (p38γ/δLyzs-KO) and p38γ/δLyzs-KO (CD45.1) parabiotic mice. Bar 
charts show the diet-induced increase in each population relative to percentage of each 
subsets found in the blood of Lyzs-Cre (CD45.1), p38γ/δLyzs-KO (p38γ/δLyzs-KO) and 
p38γ/δLyzs-KO (CD45.1) parabiotic mice. Data are means ± SEM. (n=5-10) **P<0.01 (1-
way ANOVA coupled to Bonferroni’s post tests). 
126
	   18	  
 
Appendix Fig. S9. Neutrophil-specific p38δ deficiency protects against MCD-
induced steatosis. (A) Immunoblot analysis of p38δ expression in bone marrow 
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neutrophils (10µg) and bone marrow-derived macrophages isolated (100 µg) from 
MRP8-Cre and p38δMRP8-KO mice. MRP8-Cre and p38δMRP8-KO mice were fed a MCD 
diet for 3 weeks. (B) Representative H&E and oil red stained liver sections. Scale Bar: 
50µm. (n=5-10). (C) Plasma ALT at the end of the diet period.(D) Flow cytometry 
analysis of liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, CD11b+ Gr-1-) 
isolated from MRP8-Cre and p38δMRP8-KO mice after the diet. Representative dot plots 
are shown and bar charts of each population relative as a percentage of the total intra-
hepatic CD11b+ leukocyte population. Data are means ± SEM (n=5-10). **P<0.01 (t-
test). 
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Appendix Table  S1. Characteristics of patients and controls 
 
Variable Obese patients 
with NAFLD  
(n = 73)  
Controls without 
NAFLD 
(n = 11) 
Controls with 
NAFLD (n= 9) 
Age (years) 44.6 (10.2) 42.1 (10.8) 66.2 (12.8)** 
Female:male ratio 52:21 7:4 2:7*** 
Hypertension (n) 36 (49.3)* 0 4 (44.4) 
Diabetes mellitus (n) 22 (30.1) 0 1 (11.1) 
BMI (kg/m2) 49.1 (7.9)* 26.8 (5.0) 26.1 (2.8) 
Fasting blood sugar (mg/dL) 108.7 (41.1) 89.8 (11.3) 101.8 (12.8) 
AST (IU/L) 23.2 (11.7) 22.4 (4.7) 30.1 (18.,9) 
ALT (IU/L) 30.4 (17.4) 25.3 (12.8) 46.3 (37.5) 
Bilirubin (mg/dL) 0.4 (0.1) 0.6 (0.6) 0.7 (0.3)*** 
Albumin (mg/dL) 4.3 (0.3) 4.4 (0.3) 4.5 (0.6)*** 
Total cholesterol (mg/dL) 191.4 (36.6) 186.5 (36.1) 190.5 (50.4) 
Triglycerides (mg/dL) 144.7 (80.6) 108.5 (51.9) 100.5 (32.5) 
LDL-cholesterol (mg/dL) 112.2 (35.2) 105.1 (35.5) 125.7 (44.3) 
HDL-cholesterol (mg/dL) 48.9 (16.1) 58.6  (19.0) 44.7 (13.1) 
NAS score 5.1 (1.6)* 0 2.4 (2.1)** 
    Steatosis  2.2 (0.8)* 0 1.2 (1.2)** 
    Lobular inflammation  1.4 (0.9)* 0 0.6 (0.7)** 
    Hepatocyte ballooning 1.4 (0.6)* 0 0.8 (0.9)** 
 
Variables are presented as mean (standard deviation) or absolute frequency (percentage) 
and are compared by means of Mann-Whitney U test or χ2 test. NAFLD: non alcoholic 
fatty liver disease. BMI: body mass index. AST: aspartate aminotransferase. ALT: 
alanine aminotransferase. NAS: NAFLD Activity Score.  *	  Significantly	  different	  from	  other	  groups	  	  **Significantly	  different	  from	  other	  groups	  ***Significantly	  different	  from	  obese	  with	  NAFLD	  group	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APPENDIX MATERIALS & METHODS  
Reagent  
Anti-Ly6C/G antibody (BD Pharmigen), magnetic streptavidin microbeads (Miltenyi 
Biotec), DiD and DiO (Vybrant Cell-Labeling Solution, Molecular Probes), TNFα, 
aprotinin and leupeptin (Sigma), Ficoll (GE healthcare), haematoxylin and eosin 
(American Master Tech Scientific), protein-G-Sepharose (Amersham), OCT (Tissue-
Tek), Red oil (American Master Tech Scientific), Fast sybr green (Applied Biosystems). 
 
Parabiosis 
CD45.1+ WT mice were sutured to either CD45.2+ Lyzs-Cre or p38γ/δLyzs-KO mice and 
parabiosis surgery was performed as previously described (Casanova-Acebes et al, 
2013). Briefly, mice were anesthetized with isofluorane, shaved at the corresponding 
lateral aspects and a longitudinal incision of skin was made along one side of each 
mouse. The olecranon and knee joints were attached by a single 5-0 polypropylene 
suture and tie, and the dorsal and ventral skins were approximated by continuous suture. 
After surgery, mice recieved a single dose of flunixin meglumine (1 mg/kg, Schering-
Plough, Segré, France). Two weeks after parabiotic surgery, mice were fed a MCD diet 
for 3 weeks. 
 
Immunoblot analysis 
Tissue extracts were prepared in Triton lysis buffer [20 mM Tris (pH 7.4), 1% Triton X-
100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 mM 
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/mL of aprotinin 
and leupeptin]. Extracts (20-50 µg protein) and immunoprecipitates (prepared from 2-
10 mg protein) were examined by immunoblot. For the immunoprecipitation assay, 
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liver extracts were incubated with 4 µg of anti-p38 delta or anti-p38 gamma coupled to 
protein-G-Sepharose. After incubation for 4 hours at 4°C, the captured proteins were 
centrifuged at 10,000 g, the supernatants discarded and the beads washed four times in 
lysis buffer. Beads were boiled for 5 minutes 95°C in 10µl sample buffer.  The 
antibodies employed were anti-phospho p38 and anti-human p38δ (Cell Signaling); 
anti-p38γ and anti-p38δ (Gonzalez-Teran et al, 2013; Han et al, 2013); and anti-vinculin 
(Sigma). Immunecomplexes were detected by enhanced chemiluminescence (NEN).  
 
Histology 
Tissue samples were fixed in 10% formalin for 48h, dehydrated and embedded in 
paraffin. Sections (8µm) were cut and stained with haematoxylin and eosin (American 
Master Tech Scientific), picrosirius red (Sigma) and Masson trichromic (Merck). Tissue 
sections were sequentially stained with a biotinylated antibody to marker neutrophil 
activator nitrotyrosine (Hycultbiotech), streptavidin-conjugated horseradish peroxidase 
(Abcam), and the substrate 3,3’-diaminobenzidene (Vector Laboratories), followed by 
brief counterstaining with Mayer’s haematoxylin (Sigma). Sections (8 µm) prepared 
from tissue frozen in OCT compound (Tissue-Tek) were stained with Red oil 
(American Master Tech Scientific).   
 
Measurement of hepatic triglyceride 
Hepatic triglyceride content was measured in livers from mice starved overnight. Total 
lipids were extracted from liver samples (25 mg) in an 8:1 mixture of chloroform and 
methanol (4 h). The extracts were mixed with 1N sulfuric acid and centrifuged (10 
min). Triglycerides were measured with a commercial kit (Sigma). 
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Metabolic cages 
Mice were housed under controlled temperature and lighting with free access to food 
and water. Food and water intake, energy expenditure, respiratory exchange ratio, and 
physical activity were monitored (3 days) in metabolic cages (TSE Systems, Bad 
Homburg, Germany). Fat and lean masses were detected by magnetic resonance 
imaging. 
 
RNA-Seq Library Preparation, Sequencing, and Analysis 
RNA-seq experiments were performed on biological quadruplicates. A total of 10 µg of 
total RNA was used for each RNA-seq library preparation according to the 
manufacturer’s instructions (Illumina). RNA quality was verified using Bioanalyzer 
(Agilent); only RNA with a RIN of >9 was used. Libraries were prepared and 
sequenced (Illumina; GAII) in a pair-end, 36 bp format, except for the concentrated 
samples, which were sequenced by Hi-seq in a single-end, 50 bp format. Reads from 
each sample were aligned to the mouse genome (mm9 build) using TopHat (version 
1.1.0). Differential expression was quantified using Cuffdiff (Trapnell et al., 2010) 
(version 1.0.3). Differentially expressed genes are those that have a log2 fold change of 
>0.58 or <0.58 and a q value of <0.05 compared with the control condition. We also 
required that the differentially expressed genes used for downstream analysis have a 
FPKM greater than 0.1 in the control condition. The raw data for the RNA-seq 
experiment were deposited in Gene Expression Omnibus, with the accession 
GSE58174. 
 
RNA analysis 
Expression of mRNA was examined by qRT-PCR using a 7900 Fast Real Time 
thermocycler and FAST SYBR GREEN assays (Applied Biosystems). Relative mRNA 
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expression was normalized to Gapdh mRNA measured in each sample. Primers used 
were as follows: Mapk12 (Fw: AAGGGCTTTTACCGCCAGG; Rv: 
GGCGCAACTCTCTGTAGGC); Mapk13 (Fw: ATGAGCCTCACTCGGAAAAGG; 
Rv: GCATGTGCTTCAAGAGCAGAA); Lyzs (Fw: 
ATGGAATGGCTGGCTACTATG; Rv: ACCAGTATCGG CTATTGATCT); F4/80 
(Fw: CCCCAGTGTCCTTACAGAGTG; Rv: GTGCCCAGA GTGGATGTCT); Gr1 
(Fw: GACTTCCTGCAACACAACTAC; Rv: ACAGCATTAC CAGTGATCTCA); 
Tnfa (Fw: CCCTCACACTCAGATCATCTT; Rv: GCTACGAC GTGGGCTACAG); 
Il6 (Fw:TAGTCCTTCCTACCCCAATTT; Rv: TTGGTCCTTA GCCACTCCTTC); Kc 
(Fw: CTGGGATTCACCTCAAGAACA; Rv: CAGGGTCAA GGCAAGCCTC); Ifng 
(Fw:	  ATGAACGCTACACACTGCATC; Rv: CCATCCTTTTGCCAGTTCCTC); Il10 
(Fw: GCTCTTACTGACTGGCATGAG; Rv: CGCAGCTCTAGGAGCATGTG); Il13 
(Fw: CCTGGCTCTTGCTTGCCTT; Rv: GGTCTTGTGTGATGTTGCTCA); Il23 
(Fw: ATGCTGGATTGCAGAGCAGTA; Rv: ACGGGGCACATTATTTTTAGTCT); 
Arg1 (Fw: CTCCAAGCCAAAGTCCTTAGAG; Rv: 
AGGAGCTGTCATTAGGGACATC); Timp1 (Fw:GCAACTCGGACCTGGTCATAA; 
Rv: CGGCCCGTGATGAGAAACT); Col1a1 (Fw: GCTCCTCTTAGGGGCCACT; 
Rv: CCACGTCTCACCATTGGGG); Acta2 (Fw: GTCCCAGACATCAGGGAGTAA; 
Rv: TCGGATACTTCAGCGTCAGGA); Csf1 (Fw: 
GGCTTGGCTTGGGATGATCCT; Rv: GAGGGTCTGGCAGGTACTC); Cd68 (Fw: 
TGTCTGATCTTGCTAGGACCG; Rv: GAGAGTAACGGCCTTTTTGTG); Ym1 (Fw: 
CAGGTCTGGCAATTCTTCTGA; Rv: GTCTTGCTCATGTGTGTAAGT); Gapdh 
(Fw: TGAAGCAGGCATCTGAGGG; Rv: CGAAGGTGGAAGAGTGGGA) (all 
mouse). Human primers used were as follows: MAPK12 (Fw: 
CATGAGAAGCTAGGCGAGGAC; Rv: GCATCTGGTACACGAGGAACT); 
133
	   25	  
MAPK13 (Fw: AAAAGGGCTTCTACAAGCAGG; Rv: 
TCGGGGACACGTAGGTCTT); GAPDH (Fw: 
CCATGAGAAGTATGACAACAGCC; Rv: GGGTGCTAAGCAGTTGGTG). 
 
Neutrophils FACS analysis 
Lyzs-Cre and p38γ/δLyzs-KO neutrophils were isolated from bone marrow by labelling 
with biotin-conjugated anti-Ly6C/G antibody (BD Pharmigen) and magnetic 
streptavidin microbeads (Miltenyi Biotec), and then separating them on MACS columns 
(Miltenyi Biotec). Isolated Lyzs-Cre neutrophils were stimulated for 30 minutes with 
FMLP (1µM) or vehicle. Cells were stained with 1:100 anti–L-selectin APC and anti-
CD11b FITC antibodies (BD Biosciences). For Lyzs-Cre and p38γ/δLyzs-KO neutrophils 
isolation from the blood of parabiotic couples, mice were bled from cheeks, followed by 
red blood cells lysis and isolated neutrophils were stained with 1:100 anti-CD45.2 
PerCP-Cy5.5 (eBioscience), anti-CD45.1 PE-Cy7, anti-Gr1 APC, anti-CD11b FITC and 
1:5000 DAPI antibodies (BD Bioscience). MRP8-Cre and p38γ/δMRP8-KO neutrophils 
isolated from blood or liver were stained with anti-Gr1 APC and anti-CD11b FITC and 
1:5000 DAPI antibodies. Signal was detected by flow cytometry. 
Myeloid cells isolated from liver of Lyzs-Cre and p38γ/δLyzs-KO mice 3 weeks after 
MCD diet were stained with anti-CD45.2 PerCP-Cy5.5, anti-Gr1 APC, anti-F4/80 PE-
Cy7 and anti-CD11c FITC and biotin labeled anti-CD11b followed with streptavidin-
eFluor450. Cells were sorted by using BDFACSAria II cytofluorimeter. Sorted liver 
myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, and CD11b+ Gr-1-) were 
stained with H&E and analyzed by using Leica DM2500 light microscope.  
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Blood and plasma analyses 
Alanine transaminase (ALT) activity in plasma was measured using the ALT Reagent 
kit (Pointe Scientific). 3-Hydroxybutyrate levels were quantified using an enzymatic kit 
(Autokit	  3-­‐HB	  R1	  and	  R2	  sets,	  WAKO).  
Blood glucose was measured with an Ascensia Breeze 2 glucose meter (Bayer), and 
percentages of circulating neutrophils and monocytes were measured with a Pentra80 
hematologic analyser. Serum concentrations of cytokines were measured by 
multiplexed ELISA with a Luminex 200 analyser (Biorad). 
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RESUMEN 
Alcanzar un tamaño apropiado del corazón es esencial para mantener la homeostasis del 
organismo y, alteraciones en los procesos de crecimiento de este órgano puede derivar 
en el desarrollo de cardiomiopatías. El corazón alcanza su tamaño adecuado durante el 
periodo postnatal del desarrollo por hipertrofia de los cardiomiocitos. Así mismo, el 
corazón puede hipertrofiarse como una respuesta adaptativa en respuesta a una mayor 
demanda funcional. Sin embargo, los mecanismos involucrados en la regulación de este 
proceso no se conocen con claridad. En este trabajo se muestra que la activación de 
p38γ y p38δ aumenta durante el desarrollo postnatal del corazón y en respuesta a 
estímulos hipertróficos. p38γ/δ promueven el crecimiento hipertrófico del corazón a 
través de la fosforilación de la proteína inhibitoria de mTORC1 y mTORC2, DEPTOR, 
que induce su degradación y la subsecuente activación de mTOR. Ratones deficientes 
en una de éstas o ambas quinasas, presentan un corazón de menor tamaño al de ratones 
control, alto niveles de DEPTOR, baja actividad de la vía de señalización mTOR y una 
síntesis proteica reducida. Este estudio aporta nuevos conocimientos sobre los 
mecanismos que utilizan los cardiomiocitos para crecer y adaptarse. Además, podría 
facilitar el diseño de nuevas estrategias terapéuticas para el tratamiento de alteraciones 
cardíacas provocadas por el crecimiento anómalo del corazón. 
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p38g and d promote heart hypertrophy
by targeting the mTOR-inhibitory protein
DEPTOR for degradation
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Disrupted organ growth leads to disease development. Hypertrophy underlies postnatal heart
growth and is triggered after stress, but the molecular mechanisms involved in these
processes are largely unknown. Here we show that cardiac activation of p38g and p38d
increases during postnatal development and by hypertrophy-inducing stimuli. p38g/d
promote cardiac hypertrophy by phosphorylating the mTORC1 and mTORC2 inhibitor
DEPTOR, which leads to its degradation and mTOR activation. Hearts from mice lacking one
or both kinases are below normal size, have high levels of DEPTOR, low activity of the mTOR
pathway and reduced protein synthesis. The phenotype of p38g/d / mice is reverted
by overactivation of mTOR with amino acids, shRNA-mediated knockdown of Deptor,
or cardiomyocyte overexpression of active p38g and p38d. Moreover, in WT mice,
heart weight is reduced by cardiac overexpression of DEPTOR. Our results demonstrate
that p38g/d control heart growth by modulating mTOR pathway through DEPTOR
phosphorylation and subsequent degradation.
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ardiac growth is tightly regulated to ensure that the heart
reaches its appropriate size. Cardiomyocytes rapidly
proliferate during fetal life, but soon after birth differ-
entiated cardiomyocytes enter a postmitotic state and the ability
to proliferate is lost. Postnatal cardiac growth is therefore
mainly achieved through increases in cell size (physiological
hypertrophy) associated with increased protein synthesis1
together with the expansion of non-myocyte populations2.
Hypertrophic growth is also the adaptive response of
cardiomyocytes to stress stimuli, including cardiac pressure or
volume overload, cytoskeletal abnormalities and intrinsic
contractility defects. Although cardiomyocyte hypertrophy
initially enhances cardiac output in stress situations, prolonged
hypertrophy, known as pathological hypertrophy, is associated
with an increased risk of morbidity and mortality due to
cardiovascular diseases such as diastolic and systolic heart
failure and arrhythmia3. Understanding the mechanism of
cardiac growth thus has important clinical implications. The
key unanswered questions are how cells perceive extracellular
hypertrophic stimuli and convert them into intracellular signals,
and how these signals lead to cardiac hypertrophy4.
Several studies identiﬁed mammalian TOR (mTOR) as a key
regulator of cardiac hypertrophy; for example, the mTOR
inhibitor rapamycin prevents heart-weight gain in an overload
model of hypertrophy5 and blocks cardiomyocyte size increases
induced by AngII6 and phenylephrine7, likely by inhibiting protein
synthesis7. mTOR is a conserved serine/threonine kinase with a
key regulatory function in cardiovascular physiology and
pathology8. mTOR integrates signals from growth factors,
nutrients and stresses to regulate multiple processes, including
translation, cell cycle progression, autophagy and cell survival9.
mTOR function is regulated by the formation of two multi-protein
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). mTORC1 is composed of the mTOR catalytic subunit
and ﬁve associated proteins: Raptor, PRAS40, mLST8/GbL,
DEPTOR and Tti1/Tel2. In mTORC2, the mTOR catalytic
subunit is associated with six proteins: mLST8/GbL, DEPTOR,
Tti1/Tel2 (in common with mTORC1) and Rictor, mSin1 and
Protor10. The activities of the mTORC1 and mTORC2 pathways
are regulated by the common inhibitory component DEPTOR11.
Stress-inducing stimuli in the heart activate several mitogen-
activated protein kinases (MAPK), which are known to
participate in hypertrophy, remodelling, contractility and heart
failure12,13. MAPKs are key regulators of cell stress responses,
including cell proliferation, differentiation and apoptosis14,15. The
MAPK family consists of the extracellular signal-regulated
protein kinases (ERK), the c-Jun NH2-terminal protein kinases
(JNK) and the p38 MAP kinases16. Several studies have proposed
that ERK cascade is involved in the hypertrophic response17.
The p38 MAPKs are activated in response to proinﬂammatory
cytokines, hormones and stress signals. Four p38 MAPK isoforms
have been identiﬁed, and can be grouped into two subsets based
on sequence homology, substrate speciﬁcity and sensitivity to
chemical inhibitors: p38a and p38b, and p38g and p38d (ref. 15).
MKK3 and MKK6, the kinases acting upstream of p38
MAPKs, appear to play a role in cardiac hypertrophy18, and
susceptibility to cardiac hypertrophy is promoted by cardiac-
speciﬁc overexpression of dominant-negative p38a (ref. 19).
However, ﬁndings in mice lacking p38a in cardiomyocytes
indicate that this effect is p38a independent20, whereas heart
development requires endogenous p38b (ref. 21). Although the
p38g isoform is highly abundant in the heart22 and p38d is also
expressed in cardiomyocytes23, little is known about the role of
these isoforms in cardiac hypertrophy24.
Here, we report that p38g and the closely related kinase p38d
are activated by pathological and physiological hypertrophic
stimuli and are required for cardiac physiological and patholo-
gical hypertrophy. Using p38g/d null mice, we show that p38g
and p38d interact with and phosphorylate the inhibitory mTOR
complex component DEPTOR, inducing its degradation and thus
promoting cell growth.
Results
p38c and p38dmodulate postnatal cardiac hypertrophic growth.
Stress stimuli in the heart activate several MAPKs, which have
been implicated in mechanisms of cardiomyocyte hypertrophy
and survival13. p38g is abundant in heart tissue, and the closely
related isoform p38d is also well expressed23. Stress-induced
hypertrophy appears to modulate the levels of both kinases23, but
their function and activation in the heart remain unsolved.
Analysis of wild-type (WT) mice showed that expression of both
kinases increases during postnatal growth and that they become
activated, p38g activity peaking on postnatal week 2 coinciding
with the transition to hypertrophic growth25, and p38d activity
peaking on postnatal week 6 (Fig. 1a). To assess the role of p38g
and p38d in cardiac growth, we used knockout mice lacking p38g,
p38d or both kinases, conﬁrming the deletion of these kinases in
the heart by western blot (Supplementary Fig. 1a). Ventricular
mass between postnatal weeks 4 and 11 was monitored relative to
tibia length in WT mice and mice lacking one or both of the
kinases. Ventricular mass was notably lower in p38g / ,
p38d / and p38g/d / mice (Fig. 1b). Lower heart mass
in the knockout animals correlated with the presence of
cardiomyocytes of below-normal size, determined from cell
cross-sectional area on histological sections, suggesting a defect
in postnatal hypertrophic growth (Fig. 1c,d). Similar analysis
conducted at postnatal day 1 showed no differences between
genotypes in heart or body size (Supplementary Fig. 1b,c),
indicating that p38g/d kinases modulate hypertrophic heart
growth in the postnatal period, and not in the fetus.
Echocardiography of 9-week-old mice revealed a thinner
diastolic inter-ventricular septum (IVS) and telediastolic left
ventricular posterior wall (LVPW;d) in p38g / , p38d / and
p38g/d / mice than in age-matched WT mice, and this
correlated with a below-normal corrected left ventricular mass
(Fig. 1e). However, the knockout models had normal systolic
function, with no observed differences from WT in ejection
fraction or fractional shortening (Fig. 1e). Moreover, haematox-
ylin and eosin and Picrosirius red staining revealed no differences
in ﬁbrosis or cardiac morphology (Supplementary Fig. 1d,e).
p38c and p38d control pathological hypertrophy. The
involvement of p38g and p38d in physiological postnatal hyper-
trophic heart growth prompted us to examine whether these
kinases are activated by angiotensin (Ang) II, a stress stimulus
that induces hypertrophy in the adult heart26,27. AngII induced
phosphorylation and activation of p38g and p38d kinases in the
heart (Fig. 2a). Osmotic minipump administration of AngII over
28 days increased systolic arterial pressure in WT and all the
three knockout models (Supplementary Fig. 2a), but only WT
mice showed above-baseline increases in LV mass and IVS
thickness (Fig. 2b and Supplementary Fig. 2b,c). In WT mice,
heart mass (measured as the ventricular-weight-to-tibia-length
ratio) increased almost 2-fold after 28 days of AngII infusion,
whereas p38g/d / mice showed no hypertrophic growth
(Fig. 2c and Supplementary Fig. 2d). Analysis of heart sections
showed that AngII increased cardiomyocyte cross-sectional area
in WT mice by around 50%; in contrast, cardiomyocyte
cross-sectional area in AngII-treated p38g/d / , p38g /
and p38d / mice did not differ from that observed in saline-
treated mice (Fig. 2d,e and Supplementary Fig. 2e). AngII
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treatment did not affect ejection fraction in WT or single or
double KO mice, indicating preserved systolic ventricular
function (Fig. 2f and Supplementary Fig. 2f), and the extent of
ﬁbrosis was similar in all genotypes (Supplementary Fig. 2g).
Impaired mTOR activation in hearts of p38c or p38d null mice.
The size of mammalian cells is controlled by the mTOR
pathway28. To assess whether mTOR signalling is altered in mice
lacking p38g and p38d (Supplementary Fig. 3a), we analysed
heart protein extracts by immunoblot. We found that cardiac
activation of mTORC1 and mTORC2 was impaired in p38g/d / ,
p38g / and p38d / mice, as assessed by the phosphorylation
of the mTOR targets p70S6K, S6 and FOXO1/3a and by mTOR
autophosphorylation on Ser 2481 (Fig. 3a, Supplementary
Fig. 3b,c); in contrast, no changes were detected in the
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staining with FITC-WGA (green) in hearts from 9-week-old WT, p38g / , p38d / and p38g/d / mice. (e) Echocardiography results for 9-week-old
WT, p38g / , p38d / and p38g/d / mice. IVS;d (inter-ventricular septum in diastole); LVPW;d (left ventricle posterior wall in diastole);
LV (left ventricle). Data are means±s.e.m. (n¼ 5–13). *Po0.05; **Po0.01; ***Po0.001 (one-way ANOVA coupled to Bonferroni post tests).
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expression or activation of p38a (Supplementary Fig. 3d).
A major function of mTORC1 is the promotion of protein
synthesis8, an essential driver of hypertrophic cardiomyocyte
growth. Immunoblot analysis of translation initiation/elongation
factors in the hearts of p38g/d / mice revealed weak
phosphorylation of EIF4E, EIF4G and EIF4B and strong
phosphorylation of EF2 (Fig. 3b), indicating that cardiac
protein synthesis is impaired in these mice. To conﬁrm this
ﬁnding, we injected puromycin into WT and p38g/d /
mice 30min before heart extraction and measured its
incorporation into newly synthesized proteins29. p38g/d /
hearts contained fewer puromycin-labelled peptides than WT
hearts, indicating a lower rate of protein synthesis (Fig. 3c). The
p38g/d pathway thus appears to support growth induction in the
heart by promoting the activation of mTOR-regulated protein
synthesis.
p38c and p38d interact with mTOR through DEPTOR.
We next investigated whether p38g/d isoforms interact with
components of the mTOR complexes. Immunoblot analysis of
immunoprecipitated p38g from mouse embryonic ﬁbroblasts
(MEFs) surprisingly detected co-immunoprecipitation of several
components of both mTORC1 and mTORC2 (Fig. 4a). To hone
the search for speciﬁc interactions, we focused on mTOR and
DEPTOR, components common to the mTORC1 and mTORC2
complexes. DEPTOR has an inhibitory action on the mTOR
pathway and contains a PDZ domain11, which has the potential
to interact with the C-terminal of p38g, as occurs with
other PDZ-containing proteins30,31. To test DEPTOR–p38g
interaction, we transfected HEK-293 cells with HA-tagged p38g,
Flag-tagged DEPTOR and myc-tagged mTOR, alone and in
combination. p38g co-immunoprecipitated with DEPTOR
regardless of whether the cells co-expressed mTOR (Fig. 4b);
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in contrast, p38g only co-immunoprecipitated with mTOR when
it was expressed together with DEPTOR (Fig. 4c), thus indicating
that p38g is a DEPTOR-interacting protein. To determine which
DEPTOR domain interacts with p38g, we transfected HEK-293
cells with HA-tagged p38g and Flag-tagged DEPTOR domains
(the DEP domain or PDZ domain). p38g interacted with the PDZ
domain and not the DEP binding site (Supplementary Fig. 4b).
To determine whether DEPTOR also interacts with p38d,
we transfected HEK-293 cells with Flag-DEPTOR and
either HA-p38g or HA-p38d. Although both kinases
co-immunoprecipitated with DEPTOR, the interaction with
HA-p38g appeared to be stronger (Fig. 4d). However in MEF,
we detected co-immunoprecipitation of DEPTOR with p38d
(Supplementary Fig. 4a). Moreover, in vitro analysis indicated
direct interaction of p38g and p38d with DEPTOR
(Supplementary Fig. 4d). Surprisingly neither the PDZ nor DEP
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domains are sufﬁcient for this interaction, because while p38d
interacted with whole DEPTOR, it did not bind the individual
DEP or PDZ domains (Supplementary Fig. 4c). Moreover,
HA-p38d co-immunoprecipitated with endogenous p38g, indicating
that p38g and p38d form part of the same complex (Fig. 4e).
p38c and p38d modulate DEPTOR protein levels. DEPTOR
contains several potential MAPK phosphorylation sites (S/T-P),
located outside the PDZ domain. An in vitro kinase assay showed
p38g-mediated phosphorylation of DEPTOR at four residues
(Ser145, Ser244, 265 and Ser293) and p38d-mediated phosphor-
ylation at two (Ser265 and Thr321); no phosphorylation by p38a
was detected (Fig. 5a, Supplementary Fig. 5a). DEPTOR
phosphorylation on (S/T-P) residues in live cells was conﬁrmed
by immunoprecipitation/immunoblot analysis of HEK-293 cells
transfected with DEPTOR or DEPTOR (13xS/T-A) mutant
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together with constitutively active p38g or p38d mutants (Fig. 5b)
and was conﬁrmed by mass spectrometry to selected peptides
(Supplementary Table 1 and Supplementary Fig. 5a,b).
DEPTOR levels increase in response to serum deprivation,
resulting in mTOR inhibition, whereas serum stimulation leads
to phosphorylation-dependent degradation of DEPTOR and
enhanced mTOR activity11,32. To investigate whether p38g
or p38d promote mTOR activity by triggering DEPTOR
degradation, we blocked translation of new protein with
cycloheximide in HEK 293 cells transfected with DEPTOR and
the active p38 mutants. Active p38g or p38d reduced DEPTOR
protein levels to a similar extent as serum stimulation (Fig. 5c,
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Supplementary Fig. 6a), and the effect was stronger in cells
co-transfected with both kinases (Fig. 5c). Similar results were
obtained for endogenous DEPTOR in HeLa cells (Fig. 5d,
Supplementary Fig. 6b). Moreover, the DEPTOR (13xS/T-A)
mutant was not degraded, conﬁrming that DEPTOR degradation
was phosphorylation-dependent (Supplementary Fig. 6c). We
next determined which phosphorylation sites in DEPTOR are
necessary for its degradation by generating single-point DEPTOR
mutants through the substitution of serine/threonine with alanine
in codons 145, 244, 265, 293 or 321 (Supplementary Table 2). The
protein half-life of two mutants (S293A and T321A) was
extended to the same level as that of the mutated DEPTOR
(13xS/T-A) mutant (Fig. 5e and Supplementary Fig. 6d),
whereas a more moderate half-life extension was observed
for S244A and S265A mutants (Fig. 5e and Supplementary
Fig. 6d). These data indicate that p38g- and p38d-mediated
phosphorylation of key residues targets DEPTOR for degradation.
DEPTOR is a substrate of SCF E3 ubiquitin ligase33, and
DEPTOR poly-ubiquitination is dependant on DEPTOR
phosphorylation33. Then we assayed whether phosphorylation
in vitro of DEPTOR by p38g or p38d promote ubiquitination of
DEPTOR. Our results indicate that DEPTOR presented higher
ubiquitination after in vitro phosphorylation by p38g and p38d
(Supplementary Fig. 6e). Moreover, we observed that in HEK293,
active p38g or p38d signiﬁcantly enhanced poly-ubiquitination of
native DEPTOR but not the non-phosphorylatable DEPTOR
(13xS/T-A) mutant (Supplementary Figs 6f and 7a).
To determine whether p38g is involved in DEPTOR degrada-
tion after serum stimulation, we ﬁrst veriﬁed the activation of the
kinase in this setting (Supplementary Fig. 7b). MEFs lacking
p38g/d had above-normal levels of DEPTOR and were resistant
to DEPTOR degradation after serum stimulation (Fig. 6a).
No changes were found in the mTOR complex components
Raptor or Sin1 (Supplementary Fig. 7c). The above-normal and
serum-independent DEPTOR content in p38g/d / cells
correlated with impaired mTOR activation, measured by
below-normal phosphorylation of p70S6K and its target S6
(Supplementary Fig. 7c). Moreover, the serum-independent
DEPTOR content in these cells correlated with increased binding
to mTOR (Supplementary Fig. 7d). Consistent with impaired
mTOR pathway activation (Supplementary Fig. 7e), p38g/d /
MEFs had lower protein synthesis activity and were smaller than
WT counterparts (Fig. 6b,c).
To conﬁrm whether p38g/d isoforms trigger DEPTOR
degradation through a posttranscriptional mechanism, we treated
MEFs with the protein synthesis inhibitor cycloheximide (CHX).
DEPTOR levels in WT MEFs declined after 12 h exposure to
CHX, whereas high DEPTOR levels were sustained in p38g/d null
MEFs after 24 h (Supplementary Fig. 7f). Consistent with these
results, DEPTOR levels in HeLa cells were reduced by expression
of the constitutively active p38g and p38d mutants, and this effect
was blocked by the proteasome inhibitor MG132 (ref. 34; Fig. 6d).
As expected, shRNA-mediated suppression of DEPTOR in WT
cells resulted in greater mTOR activation, protein synthesis and
in consequence increased cell size (Supplementary Fig. 8a–c).
Interestingly, treatment with DEPTOR shRNA in p38g/d /
cells restored WT mTOR activity, protein synthesis and cell size
(Fig. 6e,f, Supplementary Fig. 8d). These results thus suggest that
p38g/d isoforms are key regulators of DEPTOR degradation by
the proteasome, thereby promoting mTOR-dependent protein
synthesis and cell growth.
p38c/d regulation of mTOR activity controls heart hypertrophy.
To determine whether p38g and p38d interact with cardiac
mTOR complexes in vivo, we immunoprecipitated p38g and p38d
from heart extracts. The immunoprecipitates contained several
mTORC1 and mTORC2 components, including DEPTOR
(Fig. 7a,b Supplementary Fig. 9a,b). Moreover, p38g immuno-
precipitates contained p38d and vice versa, conﬁrming that the
two kinases form part of the same complex in vivo
(Supplementary Fig. 9c,d). Further analysis in heart extracts of
p38g / and p38d / mice revealed that each kinase is needed
for the interaction of the other in the mTOR complexes
(Supplementary Fig. 9c), providing a probable explanation for the
shared phenotype of p38g and p38d null mice.
The control of heart size by p38g/d-induced DEPTOR
degradation in cardiomyocytes predicts that hearts from p38g
and p38d null mice will present higher protein levels of DEPTOR,
and this was conﬁrmed by immunoblot analysis of hearts from
9-week-old animals (Fig. 7c). Interestingly, DEPTOR mRNA
levels were below normal in p38g and p38d null hearts, indicating
that the increased DEPTOR protein expression is not owing
to higher DEPTOR transcription (Supplementary Fig. 9e).
Moreover, DEPTOR levels were strongly reduced from P1 to 2
weeks in WT hearts, a period in which the heart switches from
proliferation to hypertrophic growth. This correlated with
maximal activation of p38g and p38d, and with the activation
of mTOR (Fig. 7d). Moreover, DEPTOR phosphorylation and
ubiquitination in WT mice were increased during this period,
whereas phosphorylation and ubiquitination were reduced in
p38g and p38d null mice (Fig. 7e). In WT mice, angiotensin II,
which activates p38g and p38d (Fig. 2a), also correlated with
DEPTOR degradation and mTOR activation (Fig. 7f). These
results suggest that p38g and p38d modulate heart growth in vivo
by controlling DEPTOR degradation and in consequence mTOR
activity.
To determine whether the impaired heart growth in the
p38g/d / animals results from an autonomous effect on
postnatal cardiomyocyte growth, we generated mice lacking p38d
in striated muscle by crossing mice carrying loxP-ﬂanked p38d
with MCK Cre mice (p38dMckKO), which reach peak Cre
expression on postnatal day 10 (ref. 35). The cardiac phenotype of
mice lacking p38d speciﬁcally in striated muscle resembled that of
p38d / mice, suggesting that p38d-mediated control of heart
growth is cell autonomous (Fig. 7g–j and Supplementary
Fig. 10a). To further conﬁrm that the phenotype is cardiac
speciﬁc, we treated p38g/d / mice with cardiac-speciﬁc
adeno-associated viruses expressing p38g/d active mutants
under the troponin T promoter (AAV-TnT-p38g/dact).
Cardiac-speciﬁc expression of p38g/d-active mutant reduced
DEPTOR levels in p38g/d / heart to the levels of WT mice and
increased mTOR activation (Fig. 8a). In consequence, reduction
of heart growth was reverted in p38g/d / mice treated with
AAV-TnT-p38g/dact and cardiomyocyte cross-sectional area
increased to WT levels (Fig. 8b,c).
To conﬁrm whether p38-mediated modulation of the mTOR
pathway is responsible for normal postnatal heart growth, we
treated MCK-cre and p38dMck-KO mice with the mTOR inhibitor
rapamycin from weeks 4 to 9 after birth. Rapamycin treatment
reduced the heart weight and cardiomyocyte size only in control
mice (MCK-cre), equalizing with heart weight in p38dMck-KO
mice (Fig. 8e,f). Moreover, echocardiographic studies showed that
rapamycin reduced diastolic IVS, LVPW and LV mass in MCK-
Cre mice but not p38dMck-KO mice (Fig. 8g), without between-
genotype differences in ejection fraction (Fig. 8g). Thus the small
hearts in p38dMck-KO and p38g/d KO mice appear to result from
the inhibition of mTOR activation in these mice.
To test whether decreased mTOR signalling could account for
the weak heart growth in p38g/d / mice, we hyperactivated
mTOR with aminoacids (aa) to restore heart growth in p38g/d
KO mice. As expected, daily aa injection activated the mTOR
pathway in p38g/d / hearts (Supplementary Fig. 10b).
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Compared with saline treatment, aa supplementation signiﬁcantly
increased heart size, LV mass and cardiomyocite cross-sectional
area (Supplementary Fig. 10c–f). Consistently, cardiac-speciﬁc
overexpression of DEPTOR in WT mice resulted in reduced
mTOR activation and lower heart mass, correlating with the
presence of cardiomyocytes of below-normal size, determined
from cell cross-sectional area on histological sections (Fig. 9a–d).
To conﬁrm that decreased DEPTOR degradation in cardio-
myocytes contributes to the phenotype of p38g/d KO mice, we
used DEPTOR-targeted shRNA under the promoter of cardiac
troponin T (AAV-TnT-shDEPTOR). Cardiac-speciﬁc reduction
of DEPTOR expression in p38g/d / mice was conﬁrmed by
western blot and was sufﬁcient to restore mTOR activation
(Fig. 9e). Furthermore, these animals showed re-established
cardiac growth and increased cardiomyocyte cross-sectional
area (Fig. 9f–h). Moreover, a control, AAV-Tnt or AAV-TnT-
shDEPTOR did not affect cardiac growth in WT mice
(Supplementary Figs 11 and 12). These results conﬁrm that
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reduction of heart growth observed in p38g/d / mice is driven
by the accumulation of DEPTOR caused by the absence of
DEPTOR phosphorylation and degradation. DEPTOR accumula-
tion inhibits mTOR pathway and consequently growth.
Discussion
In this study, we provide evidence that two stress kinases, p38g
and p38d, promote the activity of mTOR, a critical sensor of
metabolic and nutrient stresses, by targeting the mTOR inhibitory
partner DEPTOR for proteasome degradation. The ﬁnding that
DEPTOR is a physiological p38g/d substrate is, to our knowledge,
the ﬁrst demonstration of DEPTOR interaction with a non-
mTOR complex protein. Moreover, our results show that p38g or
p38d are both able to phosphorylate DEPTOR and induce its
subsequent proteasomal degradation, contrary to the proposal
that DEPTOR phosphorylation was only mTOR dependent11.
IP p38γ:
IP Total Supernatant
EB WT EB WT EB WT
75
250
37
150
150
37
37
SIN1
mTOR
GBL
Rictor
Raptor
DEPTOR
p38γ
Heart lysates
EB IP p38δ
48
48
48
48T
L
DEPTOR
DEPTOR
p38δ
p38δ
WT p38γ/δ–/–
48
100
DEPTOR
Vinculin
2.5 *
2.0
1.5
1.0
0.5
0.0A
rb
itr
ar
y 
un
its
(re
lat
ive
 to
 vi
nc
uli
n) DEPTOR WTp38γ/δ–/–
35
48
48
48
48
48
P-S6
DEPTOR
P-p38γ
p38γ
P-p38δ
p38δ
P1 2 weeks
EB WT p38γ/δ–/–
93
72
57
48
48
48
48
100
DEPTOR
P-Ser-Pro
P-Thr-Pro
Anti-Ub
DEPTOR
Vinculin
IP
(U
b)n
IP
 F
la
g
TL
48
35
100
WT WT ANGll
DEPTOR
P-S6
Vinculin
HW/TI
Mck-Cre p38δMck-KO
8
7
6
5
4
m
g 
m
in
–
1 ***
Mck-Cre
p38δMck-ko
9 Weeks old
Cross-sectional area
Mck-Cre
p38δMCK-KO
***
600
400
200
0
9 Weeks old
μm
2  
pe
r c
el
l MCK-Cre
p38δ MCK-KO
48
35
100
Deptor
P-S6 235
Vinculin
1.5
1.0
0.5
0.0Re
la
tiv
e 
am
ou
nt
to
 v
in
cu
lln
DEPTOR
**
MCK-Cre
p38δMCK-KO
a b
c d
e
f
h
g
i j
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10477
10 NATURE COMMUNICATIONS | 7:10477 |DOI: 10.1038/ncomms10477 | www.nature.com/naturecommunications
148
The p38g/d-mTOR signalling pathway controls protein synthesis
and cell growth, and molecular and functional evidence indicates
that this pathway plays an important physiological role in the
regulation of ventricular cardiac hypertrophy.
Our conclusion is supported by several lines of evidence:
(1) mTOR activity is below-normal in hearts and cells from mice
deﬁcient in p38g and p38d; (2) low mTOR activation in cells
lacking p38g and p38d leads to reduced cell size and protein
synthesis; (3) p38g and p38d co-immunoprecipitate with
mTORC1 and mTORC2 complexes; (4) p38g and p38d bind to
DEPTOR; (5) DEPTOR is phosphorylated by p38g and p38d;
(6) DEPTOR protein half-life is shortened by active p38g and
p38d mutants, but extended by knockout of p38g and p38d;
(7) DEPTOR levels are elevated in hearts lacking p38d or p38g/d;
(8) reduction of DEPTOR levels correlates with p38g and p38d
activation; (9) silencing of DEPTOR in cells lacking p38g and
p38d increases their protein content and size; (10) rapamycin
treatment in the postnatal period equalizes heart size in WT
and KO animals; (11) mTOR activation by aa injection into
p38g/d / mice results in heart growth; (12) cardiac-speciﬁc
overexpression of active p38g/d reduces DEPTOR levels, in-
creasing mTOR activity and cardiomyocyte growth; (13) cardiac
overexpression of DEPTOR phenocopies the p38g/d /
phenotype; (14) cardiac-speciﬁc silencing DEPTOR in p38g/d /
mice increases their heart size and cardiomyocyte growth.
Despite the physiological and pathological importance of cell-
size regulation, our understanding of the underlying mechanisms
remains very limited. In the heart, the regulation of cell size is a
key process that modulates the organ’s response to external
stimuli. Identifying molecular mechanisms through which
hypertrophy can be suppressed without provoking circulatory
insufﬁciency is a major challenge. Our data strongly indicate that
lack of p38g and p38d reduces the capacity for cardiomyocyte
growth without having functional implications: cardiac function
remained normal in these mice even in the presence of AngII-
induced hypertrophy, and they showed no increase in ﬁbrosis
with respect to WT mice.
Surprisingly, although mTOR is necessary for embryonic
cardiovascular development and for the postnatal maintenance
of cardiac function8, inhibition of mTOR as a result of the lack of
p38g and p38d does not have a deleterious effect on heart
physiology in basal condition. This is likely because p38g and
p38d act through the mTOR modulator DEPTOR, so that the
lack of p38g and p38d results only in partial inhibition of mTOR
activity. This ﬁnding is of great interest because other models in
which the heart is incapable of growing display signs of cardiac
pathology such as cardiac dilation or heart failure36,37. The fact
that the modulation of these kinases results in reduced heart
hypertrophy without obvious secondary effects makes p38g and
p38d potential targets for therapeutic intervention. However,
it would be interesting to further study whether modulation of
these kinases could have functional implication after a stronger
challenge such as myocardial infarction.
Our ﬁndings provide deﬁnition of the previously uncharacter-
ized role of p38g and p38d in cardiac hypertrophy38,
demonstrating that p38g and p38d are activated during
postnatal growth and by stress stimuli in the heart. This
activation correlates with DEPTOR phosphorylation,
ubiquitination and degradation, modulating cardiac growth in
tissue culture and animal models. Mice deﬁcient in these kinases
presented reduced DEPTOR phosphorylation and degradation,
correlating with impaired postnatal and pathologically induced
cardiac hypertrophy.
The ﬁnding that lack of just one of these kinases produces the
defect is quite surprising because each normally compensates the
loss of the other in other biological processes. The non-
redundancy of these isoforms in the induction of cardiac
hypertrophy is likely explained by their interaction in vivo. Both
kinases cooperate in the binding to the mTOR complex and in the
modulation of its activity through the phosphorylation and
subsequent ubiquitination and proteasomal degradation of
DEPTOR. Although p38g interacts with DEPTOR through the
PDZ domain, the exact interaction between DEPTOR and p38d
remains unclear. Moreover, our experiments with single-point
mutants indicated that both kinases are needed to induce
DEPTOR degradation. Lack of phosphorylation on S293 or
T321, residues respectively phosphorylated by p38g and p38d,
are sufﬁcient to abolish DEPTOR degradation, indicating a
requirement for cooperation between both kinases to induce
DEPTOR degradation. Moreover, mTOR induces DEPTOR
phosphorylation on other residues, which are also necessary for
DEPTOR ubiquitination and degradation11,32,33. Additional
studies will be needed to clarify how these kinases cooperate to
phosphorylate DEPTOR and to determine whether p38 g and d
act as a heterodimer. Moreover it would be interesting to study
whether this mechanism acts in other tissues and in response to
other stimuli.
Cell autonomous control of cell hypertrophy by p38g and p38d
was validated by several independent approaches, including the
use of mice lacking p38d in myocytes, and immortalized
ﬁbroblasts from p38g/d / mice. Furthermore, hearts from
p38g/d null animals are able to grow after AAV-mediated
Figure 7 | Cardiac p38c/d activation correlates negatively with DEPTOR levels. (a) Endogenous cardiac Sin-1, mTOR, GbL, Rictor, Raptor and DEPTOR
co-immunoprecipitate with endogenous p38g. p38g immunoprecipitates (IP), total lysates and Co-IP supernatants from WT heart lysates were analysed
by SDS–PAGE. EB: beads with IgG control. (b) Endogenous cardiac DEPTOR co-immunoprecipitates with p38d. Immunoblot analysis of p38d
immunoprecipitates (IP) and total lysates (TL) from the hearts of 9-week-old p38g/d / mice infected with AAV-TnT-p38gact and AAV-TnT-p38dact.
(c) p38g/d / hearts express above-normal levels of DEPTOR protein. Immunoblot analysis of heart lysates from WTand p38g/d / mice starved for
4 h and re-fed for 2h (n¼ 3–4). (d) Cardiac DEPTOR levels during postnatal development correlate negatively with p38g and p38d activation and mTOR
pathway activation. Heart lysates from WT p1 and 2-week-old mice were analysed by immunoblot (n¼6). (e) Levels of DEPTOR phosphorylation and
ubiquitination in vivo are reduced in p38g/d / hearts. Upper panel: poly-ubiquitinated proteins were IP from WT and p38g/d / heart lysates
and immunoprecipitates were immunoblotted with anti-DEPTOR antibody. Lower panels: WT and p38g/d / mice were intravenously injected with
AAV-TNT-Flag-DEPTOR and hearts harvested at the age of 2 weeks. Flag-DEPTOR was immunoprecipitated from heart lysates, and immunoprecipitates
were analysed by immunoblotting with the indicated antibodies. (n¼ 5). (f) Angiotensin II (ANGII) treatment induces a reduction in DEPTOR levels in WT
hearts. WTmice were treated with ANGII or saline for 21 days. Heart lysates were analysed by immunoblotting. (n¼ 3). (g–i) MCKdelta KO mice have
small hearts. (f) Heart-weight-to-tibia-length ratios in WTand MCKdelta KO (p38dMCKKO) mice killed at 9 weeks. (g) Top: representative haematoxylin
and eosin staining of transverse heart sections from 9-week-old WT and MCKdelta KO mice. Bottom: representative staining with FITC-WGA (green) in
hearts from 9-week-old WTand MCKdelta KO mice. (h) Cardiomyocyte cross-sectional area quantiﬁed fromWGA-stained hearts. (j) MCKdelta KO hearts
have higher protein levels of DEPTOR. MCK-Cre control mice and MCKdelta KO (p38dMCKKO) mice were starved for 4 h before being killed and tissue
was collected. Heart lysates were analysed by immunoblotting; the bar chart shows quantiﬁcation of vinculin-normalized band intensities (ImageJ; n¼4).
Data are means±s.e.m. (n¼ 5). **Po0.01; ***Po0.001 (t-test).
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Figure 8 | Cardiac p38c/d control heart growth by modulating mTOR activity. (a–d) Cardiac-speciﬁc expression of active p38g and p38d mutant
forms in p38g/d / hearts restores normal heart size. p38g/d / mice were intravenously injected at 4 weeks of age with AAV-TnT-p38gact and
AAV-TnT-p38dact, and hearts were harvested from 9-week-old WT, p38g/d / and p38g/d / AAV-TnT-p38g/dact mice. (a) Immunoblot analysis of
heart lysates. (b) Top: representative haematoxylin and eosin (H&E) staining of transverse heart sections. Bottom: representative staining with FITC-WGA
(green). (c) Cardiomyocyte cross-sectional area quantiﬁed from WGA-stained hearts. (d) Heart-weight-to-tibia-length ratio. (e–g) Rapamycin treatment
preserves normal heart size in MCKdelta KO hearts. MCK-Cre (control) and MCKdelta KO (p38dMCKKO) mice were intraperitoneally injected daily with
rapamycin (2mg kg 1 per day) from 4 to 9 weeks of age. (e) Heart-weight-to-tibia-length ratio. (f) Top: representative H&E stained transverse heart
sections from 9-week-old MCK-Cre and MCKdelta KO mice after rapamycin treatment. Bottom: representative FITC-WGA staining (green) in hearts from
9-week-old MCK-Cre and MCKdelta KO mice after rapamycin treatment. (g) Echocardiography analysis of 9-week-old MCK-Cre and MCKdelta KO mice
treated with rapamycin or vehicle. IVS;d (interventricular septum in diastole); LVPW;d (left ventricle posterior wall in diastole); LV Mass (left ventricle)
and ejection fraction. Data are means±s.e.m. (n¼ 5). *Po0.05; **Po0.01; ***Po0.001 (one-way analysis of variance coupled to Bonferroni post test).
NS, not signiﬁcant.
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cardiomyocyte overexpression of p38g and p38d, and
AAV-mediated DEPTOR overexpression in WT hearts reduces
cardiomyocyte size. Finally, reduction of DEPTOR levels in
cardiomyocytes from p38g/d null animals increased heart growth
to the level seen in WT mice, indicating that the phenotype found
in p38g/d null animals is mediated by DEPTOR.
Our results identify p38g and p38d signalling as a key regulator
of mTOR activity, promoting protein synthesis and cell
hypertrophy by phosphorylating the mTOR inhibitor DEPTOR
and inducing its ubiquitination and degradation. p38g/d
signalling through mTOR complexes is an important mediator
of cardiac hypertrophy, and this pathway may also be important
in other physiological processes mediated by mTOR, such as
cancer and autophagy. These results reveal a new avenue in the
control of mTOR activation and open a route to the development
of new treatment strategies for disease.
Methods
Mice. Mice deﬁcient for p38g (B6.129-Mapk12tm1) and p38d (B6.129-
Mapk13tm1) were backcrossed for 10 generations to the C57BL/6J background
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Figure 9 | Deptor cardiac speciﬁc expression reduces heart size. (a–d) Cardiac-speciﬁc expression of Flag-DEPTOR in WT hearts reduces heart size. WT
mice were intravenously injected at 4 weeks of age with AAV-TnT-Flag-DEPTOR and hearts harvested at 9 weeks of age. (a) Immunoblot analysis of heart
lysates. (b) Heart-weight-to-tibia-length ratio (c) Top: representative haematoxylin and eosin (H&E) staining of transverse heart sections from untreated
(WT) and AAV-TnT-Flag-DEPTOR-injected mice. Bottom: representative staining with FITC-WGA (green). (d) Cardiomyocyte cross-sectional area
quantiﬁed from WGA-stained heart. (n¼ 5–9). Data are means±s.e.m. (n¼ 5). *Po0.05; **Po0.01 (t-test). (e–h) Cardiac-speciﬁc DEPTOR silencing in
p38g/d / mice restores normal heart size. Hearts from WT, p38g/d / and p38g/d / mice intravenously injected at birth with AAV-TnT-shDeptor
were harvested at 9 weeks of age. (e) Immunoblot analysis of heart lysates. (f) Heart-weight-to-tibia-length ratio (g) Top: representative H&E staining of
transverse heart sections from untreated WT and p38g/d / and from AAV-TnT-shDeptor injected p38g/d / mice. Bottom: representative staining
with FITC-WGA (green). (h) Cardiomyocyte cross-sectional area quantiﬁed from WGA-stained hearts. (n¼ 5–7). Data are means±s.e.m. (n¼ 5).
*Po0.05; **Po0.01; ***Po0.001 (one-way analysis of variance coupled to Bonferroni post test). NS, not signiﬁcant.
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(Jackson Laboratory). To generate mice lacking p38d in striated muscle, p38d
(B6.129-Mapk13tm1) mice were crossed with the FVB-Tg(Ckmm-cre)5Khn/J line
on the C57BL/6J background (Jackson Laboratory). Genotype was conﬁrmed by
PCR analysis of genomic DNA. For signalling studies, animals were killed by
cervical dislocation. For AngII experiments, 9-week-old male mice were treated
with AngII (1mg kg 1 per minute, 28 days) via subcutaneously implanted
mini-osmotic pumps (Alzet); saline was administered as a control. For
rapamycin treatment, mice were daily injected intraperitoneally with rapamycin
(LC Laboratories, R-5000) (2mg kg 1 per day) or vehicle (0.25% polyethylene
glycol (Sigma), 0.25% Tween-20 (Sigma) in PBS); injections started at 4 weeks
of age and continued until 9 weeks of age, when heart size was analysed by
echocardiography and mice were killed. Amino acid (aa) supplementation was
achieved by daily intraperitoneal injections, starting at the day of birth, of aa
solution at a dose of 0.1ml g 1 body weight, with a maximal dose of 2ml per
day39. All aa were purchased from Sigma-Aldrich. The solution contained the
following aa concentrations: 6.0 g l 1 isoleucine, 12.0 g l 1 leucine, 7.2 g l 1
valine, and 6.04 g l 1 arginine (pH 7.4; Sigma). PBS (pH 7.4) was used as a control.
Four-week-old mice were intravenously injected with 1 1012 viral particles
encoding human p38g and p38d active mutants or wild-type human Flag-
DEPTOR under the TnT promoter. Hearts were harvested from 9-week-old mice.
Day-old mice were intravenously injected with 0.5 1012 viral particles encoding
wild-type human Flag-DEPTOR under the TnT promoter and hearts were
harvested for analysis of DEPTOR phosphorylarion/ubiquitination at 2 weeks of
age. To avoid DEPTOR degradation, mice were injected the proteasome inhibitor
MG132 (Shelleckchem; 0.1mg kg 1 per day intraperitoneally) on the 2 days before
harvesting the hearts. In the cardiac-speciﬁc DEPTOR silencing experiment,
1-day-old mice were intravenously injected with 0.5 1012 viral particles encoding
shDEPTOR and the cardiac phenotype was studied at 8 weeks of age. All animal
procedures conformed to EU Directive 86/609/EEC and Recommendation
2007/526/EC regarding the protection of animals used for experimental and other
scientiﬁc purposes, enacted under Spanish law 1201/2005.
Histology. Tissue samples were ﬁxed in 10% formalin for 48 h, dehydrated and
embedded in parafﬁn. Sections (8 mm) were cut and stained with haematoxylin and
eosin (American Master Tech Scientiﬁc). Fibrosis was assessed with Picrosirius red
staining (Sigma). For wheatgerm agglutinin (WGA) immunoﬂuorescence, 8 mm
heart sections were prepared, washed in PBS, incubated for 2 h in WGA-Alexa 488
lectin (Invitrogen, Carlsbad, CA, USA), and washed and mounted in anti-fade
reagent. Four images ( 20) were taken from each heart, and the diameter and
areas of 100–200 cross-sectionally oriented myocytes were measured and analysed
with Image J software.
Echocardiography. Mice were anaesthetized by inhalation of isoﬂurane and
oxygen (1.25% and 98.75%, respectively), and echocardiography was performed
with a 30-MHz transthoracic echocardiography probe. Images were obtained with
the Vevo 2100 micro-ultrasound imaging system (VisualSonics, Toronto, Canada).
Short-axis, long-axis, B-mode and two-dimensional M-mode views were obtained.
In summary, scans were conducted by two experienced researchers blinded to the
mouse genotype. Measurements of left parasternal long and short axes and
M-mode (left parasternal short axis) images were obtained at a heart rate of
500–550 b.p.m. LV end-diastolic diameter (LVEDD), LV end-systolic diameter
(LVESD) and wall thickness were measured from M-mode tracings, and the
average of three consecutive cardiac cycles is reported. The LV fractional short-
ening percentage was calculated as ([LVEDD LVESD]/LVEDD) 100 MRI of
lung was performed with a 7-T Agilent scanner (Agilent, Santa Clara, CA, USA)
equipped with a DD2 console and an actively shielded gradient set (205/120 insert
of maximum 130mTm 1 gradient strength). For image acquisition, we used a
combination of volume coil/surface coil coil to enhance signal-to-noise ratio
formed by a 72-mm inner diameter quadrature birdcage TX coil (Rapid Biomedical
GmBH, Germany) and an actively detuning 30-mm ﬂexible customized surface RX
coil (Neos Biotec, Pamplona, Spain). Following a tripilot gradient-echo image,
a gradient-echo sequence without gating was used to acquire oblique coronal
slices (one to two slices) and axial slices (7–10 slices covering the entire lung, 72-s
acquisition time per slice) using the following parameters: TR/TE¼ 6.7/2.2ms, ﬂip
angle¼ 10 degree, bandwidth¼ 100 kHz, ﬁeld of view¼ 3 3 cm, matrix¼ 256
 128, slice thickness¼ 1mm (ref. 40). From these images, interventricular septum
and left ventricle posterior wall thicknesses and left ventricle corrected mass were
determined; the short-axis M-mode quantiﬁcation was chosen as the most
representative. Function was estimated from the ejection fraction and fractional
shortening obtained from M-mode views by a blinded echocardiography expert.
For ejection fraction measurements, a long- or short-axis view of the heart was
selected to obtain an M-mode registration in a line perpendicular to the left
ventricular septum and posterior wall at the level of the mitral chordae tendinea.
Immunoblot analysis. Tissue extracts were prepared in Triton lysis buffer
(20mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137mM NaCl, 2mM
EDTA, 25mM b-glycerophosphate, 1mM sodium orthovanadate, 1mM
phenylmethylsulfonyl ﬂuoride, and 10 mgml 1 of aprotinin and leupeptin), and
for co-immunoprecipitation experiments, lysis buffer was supplemented with 0.3%
Chaps. Extracts (20–50 mg protein) and immunoprecipitates (prepared from
2–10mg protein) were examined by immunoblot. For the immunoprecipitation
assay, heart extracts were incubated with 4 mg of a speciﬁc antibody coupled to
protein-G-Sepharose. After incubation overnight at 4 C with agitation, the
captured proteins were centrifuged at 10,000g, the supernatants collected, and the
beads washed four times in lysis buffer. Beads were boiled for 5min 95 C in 10ml
sample buffer. Extracts and immunoprecipitates were examined by SDS–PAGE and
blotted with antibodies to the following targets: p38g and p38d (refs 41,42) at
1 mgml 1; vinculin and Flag (Sigma); puromycin (Millipore clone 12D10); HA
and Myc (Bethyl Laboratories, Inc.); ubiquitin (ThermoFisher); and phospho-p38,
phospho-mTOR (Ser2481), mTOR, Myc-Tag, phospho-p70S6 kinase, p70S6
kinase, phospho-S6 (Ser 235/236), phospho-S6 (Ser 240/244), S6 ribosomal
protein, phospho-FOXO1/3a, phospho-eEF2, eEF2, phospho-EIF4E, EIF4E,
phospho-EIF4G, EIF4G, phospho-EIF4B, EIF4B, DEPTOR, phospho-MAPK/CDK
substrate (PXSP or SPXR/K) (34B2), phospho-Threonine-Proline, Raptor, Rictor,
Sin1, GbL, phospho-4EBP1, 4EBP1, phospho-AKT (Ser473) and AKT (Cell
Signaling) all were used at 1:1,000. Immunocomplexes were detected by enhanced
chemiluminescence (GE Healthcare Lifesciences). Full scans of all blots and gels are
available as Supplementary Fig. 13.
Cell lines and cell culture. HeLa and HEK-293T (American Type Culture
Collection (ATCC), USA) cells and mouse embryonic ﬁbroblasts (MEF) were
cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Sigma), glutamine (2mM) and penicillin/streptomycin (100 mgml 1).
Lentivirus vector production and cell infection. Lentiviruses were produced by
transient calcium phosphate co-transfection of HEK-293T cells was done with the
pLKO mouse shRNA 1 DEPTOR (plasmid #21337 Addgene), pLKO mouse shRNA
2 DEPTOR (plasmid #21338 Addgene), together with pD8.9 and pVSV-G.
Supernatants containing the LV particles were collected 48 and 72 h after removal
of the calcium phosphate precipitate and were centrifuged at 700g at 4 C for
10min and ﬁltered through 0.45-mm ﬁlter units (Corning). Once ﬁltered, the
virus-containing medium was added (1:1 volume) to MEF culture medium.
After incubation for 24 h at 37 C and 5% CO2, the medium was changed, and
puromycin selection (3 mgml 1 puromycin) was initiated 48 h after infection. The
selection medium was changed every 2 days during 1 week, and the cells were
subsequently used for experiments.
Adeno-associated virus vector production and cell infection. The AAV shuttle
and helper plasmids were transfected into HEK 293A cells by calcium-phosphate
co-precipitation. A total of 840 mg plasmid DNA (mixed in an equimolar ratio)
was used per Hyperﬂask (Corning) seeded with 1.2 108 cells the day before.
Seventy-two hours after transfection, the cells were collected by centrifugation and
the cell pellet was resuspended in TMS (50mM Tris HCl, 150mM NaCl, 2mM
MgCl2) on ice before digestion with DNase I and RNaseA (0.1mgml 1 each;
Roche) at 37 C for 60min. Clariﬁed supernatant containing the viral particles was
obtained by iodixanol gradient centrifugation44. Gradient fractions containing
virus were concentrated using Amicon UltraCel columns (Millipore) and stored at
 70 C (ref. 43).
AAV plasmids were cloned and propagated in the Stbl3 E. coli strain (Life
Technologies). pRK5 FLAG human DEPTOR (plasmid #21334, Addgene), pCEFL
Flag p38g D129A, pCMV Flag p38d F324S and pGIPZ mouse shRNA DEPTOR
clone 1 (V3LMM_485571) were cloned into the pAcTnT AAV plasmid to generate
pAAV-TnT-GFP-Luc, pAAV-TnT-p38gact, pAAV-TnT-p38dact, pAAV-TnT-Flag-
DEPTOR and pAAV-TnT-shDeptor. These AAV plasmids were packaged into
AAV-9 capsids with the use of pAdDF6 helper plasmids (providing the three
adenoviral helper genes) and pAAV2/9 (providing rep and cap viral genes),
obtained from PennVector. Shuttle vectors were generated by direct cloning
(GeneScript) of synthesized NheI-SalI fragments into pAcTnT cut with the same
restriction enzymes.
The AAV shuttle and helper plasmids were transfected into HEK 293A cells by
calcium-phosphate co-precipitation. A total of 840 mg plasmid DNA (mixed in an
equimolar ratio) was used per Hyperﬂask (Corning) seeded with 1.2 108 cells the
day before. Seventy-two hours after transfection, the cells were collected by
centrifugation and the cell pellet was resuspended in TMS (50mM Tris HCl,
150mM NaCl, 2mM MgCl2) on ice before digestion with DNase I and RNaseA
(0.1mgml 1 each; Roche) at 37 C for 60min. Clariﬁed supernatant containing
the viral particles was obtained by iodixanol gradient centrifugation44. Gradient
fractions containing virus were concentrated using Amicon UltraCel columns
(Millipore) and stored at  70 C.
Standard curves were constructed using known copy numbers (105–108)
of the respective plasmid (pAAV-TnT-GFP-Luc, pAAV-TnT-p38gact, pAAV-TnT-
p38dact, pAAV-TNT-Flag-DEPTOR and pAAV-TNT-shDeptor) carrying the
appropriate complementary DNA.
In vivo protein synthesis assay. For all in vivo measurements of protein
synthesis, mice were injected intraperitoneally with 0.040 mmol g 1 puromycin
dissolved in 100 ml PBS. Exactly 30min after injection, tissues were extracted and
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frozen in liquid N2 for subsequent immunoblot analysis of protein-incorporated
puromycin.
Measurement of in vitro protein synthesis by SUnSET assay. All the
experiments were performed following the protocol described in ref. 45 with some
modiﬁcations. MEFs were seeded in six-well plates with 106 cells per well in 1ml
complete DEMEM, and treated with 1 mgml 1 puromycin solution (Sigma) for
10min at 37 C and 5% CO2 (¼ pulse). The cells were washed twice with
pre-warmed complete medium, resuspended in 1ml of the same medium and
incubated for 50min at 37 C and 5% CO2 (¼ chase). The cells were washed twice
with cold PBS, and harvested. They were then washed once more by centrifugation
at 4 C in cold PBS/0.1% BSA, and pellets were incubated in 30 ml of staining mix
(mouse IgG2 anti-puromycin antibody (12D10) diluted 1/50 in PBS/BSA) for
30min. The cells were washed twice with PBS/BSA and incubated in 30 ml of
PE-labelled anti-mouse IgG (Invitrogen) diluted 1/100 in PBS/BSA. The cells
were washed and resuspended in 200 ml PBS/BSA and analysed by FACS
(ﬂuorescence-activated cell sorting).
cDNA transfection-based experiments. Cells were plated at 60% conﬂuence in
DMEM/10%FBS 12–15 h before transfection. The cells were transfected using the
calcium phosphate method30 with the pRK5-based cDNA expression plasmids
indicated in the ﬁgures. The culture medium was replaced 12 h after transfection
with fresh complete medium, and cells were collected 48 h later. For DEPTOR
degradation experiments in HEK 293T or HELA cells, the medium was changed
after 24 h for medium lacking serum, and after a further 24 h, the cells were
incubated in medium with 10% FBS or no FBS together with 10 mM cycloheximide.
At the times indicated, the cells were collected and analysed by western blot. To
block DEPTOR degradation induced by the constitutionally active p38g/d mutants,
cells were preincubated with the proteasome inhibitor MG132 (Shelleckchem) at a
ﬁnal concentration of 10 mM.
The plasmids used in the different experiments were pRK5 myc Rat mTOR
(plasmid #1861, Addgene); pRK5 FLAG human DEPTOR (plasmid #21334,
Addgene); pRK5 FLAG human DEPTOR (13xS/T-A; plasmid #21702, Addgene);
pRK5 FLAG DEPTOR (PDZ domain; plasmid #21701, Addgene); pRK5 FLAG
DEPTOR (DEP domains; plasmid #21700, Addgene); pcDNA3-myc3-CUL1
(plasmid #19896, Addgene); pcDNA3-myc3-bTrCP (plasmid #20718, Addgene);
HA-Ubiquitin (plasmid #18712); pcDNA3 HA human p38g and pcDNA3 HA
human p38d, kindly provided by Roger Davis (University of Massachusetts
Medical School, Worcester, USA); and pCEFL Flag p38gD129A and pCMV Flag
p38dF324S, kindly provided by David Engelberg (The Hebrew University of
Jerusalem, Israel).
In vitro kinase assay. One microgram of human GST-DEPTOR protein
(H00064798, Novus Biologicals) was incubated for 30min with 1 mg of
active recombinant p38g, p38g or p38a kinases (provided by MRC Protein
Phosphorylation and Ubiquitylation Unit, Dundee, UK) in the presence of 200 mM
cold ATP. The reaction was stopped by adding SDS-containing sample buffer, and
proteins were resolved by SDS–PAGE and visualized by staining with colloidal
Coomassie Blue. The band containing GST-DEPTOR was excised and treated with
DTT to reduce disulﬁde bonds and with iodoacetamide to derivatize cysteine
residues. The protein was in-gel digested with trypsin, and the resulting peptides
were extracted from the gel and analysed by nanoscale-microcapillary reversed
phase liquid chromatography tandem mass spectrometry46,47.
Flow cytometry cell size analysis. MEFs were trypsinized, washed and analysed
by FACS to determine cell size based on the mean forward scattered light intensity.
Blood pressure measurement. Blood pressure in mice was measured using the
noninvasive tail-cuff method48.
Statistical analysis. Differences between groups were examined for statistical
signiﬁcance by two-tailed Student’s t-test, one-way or two-way analysis of variance
coupled to the Bonferroni post test.
The rest of the materials and methods are found in the Supplementary
Methods.
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SUPPLEMENTARY INFORMATION	
 
Supplementary Figure 1. p38γ and δ  deficiency results in small hearts without fibrosis 
development. 
155
(a) WT, p38γ/δ-/-, p38γ-/-, p38δ-/- mice were sacrificed at 9 weeks of age and cardiac p38γ and 
p38δ expression was analysed in heat lysates. 
(b & c) Wild type (WT) and p38γ/δ-/- male mice were sacrificed at postnatal day one and body 
weight (b) and heart weight:tibia length ratio (c) were  measured (n=8-9). Data are means ± 
SEM (n=5-13). Ns, P>0.05 (t-test). 
(d) Representative H&E heart micrographs from 9-week-old WT, p38γ-/-, p38δ-/- and p38γ/δ-/- 
mice. Scale bar, 50.2µm (n=8-10). 
(e) Representative picrosirius red stained transverse heart sections from 9-week-old WT, p38γ-/-, 
p38δ-/- and p38γ/δ-/- mice. Scale bar, 1mm, (n=8-10).  
Data are means ± SEM. (t-test).  
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Supplementary Figure 2. p38γ and δ are involved in angiotensin-II -induced hypertrophy 
in vivo. 
157
WT, p38γ-/-, p38δ-/- and p38γ/δ-/- mice were treated for 28 days with angiotensin II (AngII) 
(1µg/kg/min) or saline, delivered by subcutaneously implanted osmotic minipumps. 
(a, b, c & d) p38γ-/-, p38δ-/- and p38γ/δ-/- are protected against angiotensin II-induced cardiac 
hypertrophy. (a) WT, p38γ-/-, p38δ-/- and p38γ/δ-/- mice treated for 28 days with AngII or Saline 
show no differences in systolic blood pressure development. (b & c) Echocardiography 
evaluation of LV Mass and IVS;d after AngII or Saline treatment. (d)  Heart weight to tibia 
length ratios for WT, p38γ-/-, p38δ-/- and p38γ/δ-/- after 28 days of Ang II or saline treatment. 
(n=4-7). (e) Cardiomyocyte cross-sectional area quantified in WGA-stained hearts. (f) 
Echocardiography evaluation of systolic cardiac function after AngII or Saline treatment. IVS;d 
(inter-ventricular septum in diastole); LV (left ventricle). 
 (g) WT, p38γ-/-, p38δ-/- and p38γ/δ-/- mice treated for 28 days with AngII show no differences in 
fibrosis development. Representative picrosirius red stained transverse heart sections from 9-
week-old WT, p38γ-/-, p38δ-/- and p38γ/δ-/- mice treated for 28 days with AngII. Scale bar, 1mm 
(n=6-12). 
Data are means ± SEM. *P<0.05; **P<0.01; ***P<0.001 (1-way ANOVA coupled to 
Bonferroni’s post test).  
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 Supplementary Figure 3. Hearts of p38γ-/- or p38δ-/- mice show below-normal mTOR 
activation. 
(a) p38γ or p38δ were immunoprecipited from WT and p38γ/δ-/- heart lysates and analyzed by 
immunoblot. (n=4) 
159
(b & c) WT and p38γ-/- or p38δ-/- heart lysates from 9-week-old male mice were analyzed by 
immunoblot for mTOR signalling pathway components. (n=4). 
(d) WT and p38γ/δ-/- heart lysates from 9-week-old male mice were analyzed by immunoblot 
for p38 alpha activation and protein levels. (n=4). 
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Supplementary Figure 4. p38γ directly interacts with DEPTOR through its PDZ domain. 
(a) p38γ interacts with DEPTOR through its PDZ domain. Full length Flag-DEPTOR, Flag-
DEP DOM and Flag-PDZ DOM were expressed in HEK-293T cells together with HA-p38γ or 
HA-p38γ alone. Anti-Flag co- immunoprecipitates or total lysates were analyzed by SDS-
PAGE. 
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(b) p38δ interacts with DEPTOR through un unkown domain. Full length Flag-DEPTOR, Flag-
DEP DOM and Flag-PDZ DOM were expressed in HEK-293T cells together with HA-p38δ or 
HA-p38δ alone. Anti-Flag co- immunoprecipitates or total lysates were analyzed by SDS-
PAGE. 
(c) p38γ and p38δ directly interact with DEPTOR. GST Pull down experiment. GST-DEPTOR 
was used to precipitate untagged p38γ and p38δ	recombinant proteins.   
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 Supplementary Figure 5. DEPTOR is specifically phosphorylated by p38γ and p38δ in 
vitro and in vivo. 
(a) ESI-MS analysis of DEPTOR phosphorylation by constitutively active p38γ or p38δ 
mutants. In an in vitro kinase assay, recombinant human DEPTOR protein (1µg) was incubated 
163
alone or in the presence of p38γ or p38δ kinases (1µg) and 0.2mM of cold ATP. 
(b-c) ESI-MS analysis of DEPTOR phosphorylation by constitutively active p38γ or p38δ 
mutants. In an in vivo kinase assay, human Flag-DEPTOR was expressed in HEK-293T cells 
alone or together with constitutively active p38γ or p38δ mutants. HEK-293T cells starved for 
30h. DEPTOR phosphorylation was analyzed from Flag immunoprecipitates by mass 
spectrometry. After trypsin digestion, phosphopeptides previously detected in the in vitro 
experiments and their non-phosphorylated counterparts were monitored using the parallel 
reaction monitoring (PRM) mode in a Q Exactive hybrid quadrupole-orbitrap mass spectrometer 
(Thermo Scientific). (b) Extracted ion chromatogram traces (XIC) of the fragments indicated 
with a red triangle in (c). The relative intensity of DEPTOR-derived phosphopeptides in each 
experiment is expressed as percentage, taking the intensity of the corresponding unmodified 
peptide as a reference. (c) MS/MS spectra interpreted using Scaffold at the peak apex of each 
phosphorylated peptide. Note that the MS/MS spectra confirm peptide phosphorylation at Ser 
and Thr residues in the consensus sequences SP and TP, respectively.  For peptide 
(K)STSFMSVsPSK(E), treatment with MG132 was necessary to prevent their proteolysis. 
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Supplementary Figure 6. DEPTOR degradation is dependent of p38γ  and p38δ  
phosphorylation.  
165
(a) Flag-DEPTOR was expressed in HEK-293T cells, which were serum starved for 30 hr. 
Fresh serum-free or 10% FBS medium was then added together with 10µM cycloheximide 
(CHX) for the times indicated. Flag-DEPTOR levels were analyzed by immunoblotting with the 
indicated antibodies. 
(b) HeLa cells were serum starved for 30 hr and fresh serum-free or 10% FBS medium was then 
added together with 10µM cycloheximide (CHX) for the times indicated. Endogenous DEPTOR 
levels were then analyzed by immunoblotting with the indicated antibodies.		
(c) Constitutively active p38γ and p38δ  mutants induce DEPTOR degradation but not 
13xS/T!A DEPTOR mutant degradation.  Blots were quantified with ImageJ relative to 
vinculin levels. Data are means ± SEM. *P<0.05 (t-test). 
(d) Quantification of DEPTOR protein levels from immunoblot assay. DEPTOR 
phosphorylation mutants were expressed in HEK-293T alone or together with constitutively 
active p38γ and p38δ  mutants. Fresh media without serum was added together with 10µM 
cycloheximide (CHX) and cells harvested at the times indicated. DEPTOR degradation was 
analyzed by immunoblot. 
(e) SCF E3 was prepared by FLAG beads IP using 293 cells transfected with βTrCP. 
Recombinant GST-DEPTOR was in vitro phosphorylated or not with active p38γ and p38δ. 
SCF E3, and DEPTOR as the substrate, were added into a reaction mixture containing ATP, 
ubiquitin, E1 and E2, followed by constant mixing for 60 min. The reaction mixture was then 
loaded onto PAGE gel for IB with the indicated antibodies. 
(f) Constitutively active p38γ and p38δ  mutants induce ubiquitination of DEPTOR but not the 
13xS/T!A DEPTOR mutant. Flag-DEPTOR or Flag- 13xS/T!A DEPTOR was expressed in 
HEK-293T cells alone or together with constitutively active p38γ and p38δ mutants. HEK-293T 
cells starved for 30 hr and were incubated for 12 hr with 10µM MG132. DEPTOR was 
inmunoprecipitated using anti-Flag antibody. Inmunoprecipitates and cell lysates were analyzed 
by immunoblotting with the indicated antibodies. 
Data are means ± SEM (n=3). *P<0.05 (t-test). 
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 Supplementary Figure 7. p38γ  and p38δ  control mTOR pathway through the regulation 
of DEPTOR degradation.  
(a) Constitutively active p38γ and p38δ  mutants induce ubiquitination of DEPTOR but not the 
13xS/T!A DEPTOR mutant. Flag-DEPTOR or Flag- 13xS/T!A DEPTOR was expressed in 
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HEK-293T cells alone or together with constitutively active p38γ and p38δ mutants and HA-
Ub. Cells were serum starved and incubated for 12 hr with 10µM MG132. Poly-Ubiquitinated 
proteins were IP from cell lysates with bead-conjugated anti-HA Ab and immunoprecipitates 
were analyzed by immunoblotting with the indicated antibodies. 
(b) p38γ is activated upon serum stimulation. MEF cells were stimulated with 10% FBS during 
30 min. Then cells were harvested and p38γ immunoprecipitated. Total lysates (TL) and p38γ 
immunoprecipitates analyzed by immunoblot.  
(c) p38γ/δ-/- MEFs have below-normal serum-induced mTOR activation. WT and p38γ/δ-/- MEFs 
were serum-starved for 30 hr, followed by serum addition. Cells were harvested at the indicated 
time points for immunoblotting with the indicated antibodies. 
(d) p38γ/δ-/- MEFs have below-normal activation of the mTOR pathway in starvation 
conditions. Confluent WT and p38γ/δ-/- MEFs were serum-starved for 16 hr and harvested for 
immunoblotting with the indicated antibodies. 
(e) Higher amounts of endogenous DEPTOR co-immunoprecipitate with mTOR in p38γ/δ-/- 
MEFs. Endogenous mTOR was immunoprecipitated from WT and p38γ/δ-/- MEFs and 
immunoprecipitates were analyzed by SDS-PAGE. 
(f) DEPTOR degradation is impaired in p38γ/δ-/- MEF cells. WT and p38γ/δ-/- MEFs were 
treated with 10µM cycloheximide (CHX), harvested at the times indicated, and endogenous 
DEPTOR levels were analyzed by immunoblotting. Western blot was quantified. 
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Supplementary Figure 8. Deptor silencing leads to mTOR pathway hyperactivation and 
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reverts p38γ/δ-/-  reduced  cell size.  
(a, b & c) Silencing DEPTOR in WT MEFs results in mTOR hyperactivation and a slight 
increase in protein syinthesis. MEFs were singly or doubly infected with two different DEPTOR 
lentiviral shRNA constructs for 24 hr. Uninfected cells were eliminated by selection with 3 
µg/ml puromycin for 1 week. (a) The resulting cell lines were then serum-starved for 24 hr 
before harvesting. Equal amounts of whole cell lysates were immunoblotted with the indicated 
antibodies. (c) Cell size was measured by flow cytometry (forward scatter). Left: Representative 
histogram. Right: Quantification graph of the forward scatter mean fluourescence intensity 
(FSC-A MFI) relative to WT.  (c) In the resulting cell lines the protein concentration per cell 
was measured by Bradford method. (n=4-6) 
 (d) Silencing DEPTOR in p38γ/δ-/- MEFs rescues normal cell size. MEFs were infected with 
two DEPTOR lentiviral shRNA constructs alone or in combination for 24 hr. Uninfected cells 
were eliminated by selection with 3 µg/ml puromycin for 1 week. In the resulting cell lines cell 
size was measured by flow cytometry (forward scatter). Top: Representative histogram. Bottom: 
Quantification of forward scatter mean fluorescence intensity (FSC-A MIF) relative to WT 
cells. (n=4) 
Data are means ± SEM (n=6). **P<0.01; ***P<0.001 (1-way ANOVA coupled to Bonferroni’s 
post test).  
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Supplementary Figure 9. p38γ and δ are mutually necessary for their interaction with 
mTOR complexes in heart tissue. 
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(a) Endogenous cardiac mTOR, GβL, Raptor, Rictor and Sin-1 co-immunoprecipitate with 
endogenous p38γ.  p38γ immunoprecipitates (IP), total lysates (Total) and supernatants from 
WT and p38γ/δ-/- heart lysates were analyzed by SDS-PAGE. 
 (b) Endogenous cardiac mTOR, GβL, Raptor, Rictor and Sin-1 co-immunoprecipitate with 
endogenous p38δ. p38δ immunoprecipitates (IP), total lysates and Co-IP supernatants from WT 
and p38γ/δ-/- heart lysates were analyzed by SDS-PAGE.  
(c) Endogenous cardiac mTOR, Raptor, Rictor, Sin-1 and p38δ co-immunoprecipitate with 
endogenous p38γ only when both p38γ and p38δ are present. p38γ immunoprecipitates (IP), 
total lysates and Co-IP supernatants from WT, p38γ-/- and p38δ-/- heart lysates were analyzed by 
SDS-PAGE. 
(d) Endogenous p38γ co-immunoprecipitates with endogenous p38δ in heart lysates. p38δ 
immunoprecipitates (IP) and total lysates (TL) from WT and p38γ/δ-/- heart lysates were 
analyzed by SDS-PAGE. 
(e) p38γ/δ-/- hearts present reduced DEPTOR mRNA levels. DEPTOR mRNA was measured by 
qRT-PCR and normalized to GADPH mRNA levels. (n=7-11). 
Data are means ± SEM (n=7-10). **P<0.01 (t-test). 
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Supplementary Figure 10. Amino acid induced mTOR activation in mice deficient in p38γ 
and δ is sufficient to revert its small heart phenotype. 
(a) Echocardiography results for 9-week-old MCK-Cre and MCK p38δ KO (p38δMCK-KO) mice. 
IVS;d (inter-ventricular septum in diastole); LVPW;d (left ventricle posterior wall in diastole); 
LV (left ventricle). (n=5). 
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(b, c,  d & e) Amino acids (aa) treatment reverts reduced heart size in p38γ/δ-/- mice. WT and 
p38γ/δ-/-  mice were injected daily with a mixture of amino acids  i.p  or Saline until  9 weeks of 
age. (b) Amino acid treatment activated mTOR pathway in p38γ/δ-/- 9 weeks old hearts.  Heart 
lysates were analyzed by immunoblot for mTOR pathway activation. (c) Heart weight to tibia 
length ratio. (g) Echocardiography analysis LV Mass at 9 weeks of age in saline or amino acid 
treated mice. (e) Top: Representative H&E stained transverse heart sections from 9-week-old 
WT and p38γ/δ-/- mice after amino acid or saline treatment. Scale bar, 1mm. Bottom: 
Representative FITC-WGA staining (green) in hearts from 9-week-old 9-week-old WT and 
p38γ/δ-/- mice after amino acid or saline treatment. (f) Cardiomyocyte cross-sectional area 
quantification from the FITC-WGA staining (green) in hearts from 9-week-old 
Data are means ± SEM (n=5). *P<0.05; **P<0.01; ***P<0.001 (2-way ANOVA coupled to 
Bonferroni’s post test or t-test). 
Supplementary Figure 11. Adeno-associated control virus injection does not affect cardiac 
growth. 
(a, b & c) Adeno-associated serotype 9-virus control injection does not affect cardiac growth. 
WT mice were injected or not at 4 weeks old with AAV-cTnT-GFP-Luc virus and heart 
phenotype analyzed at 9 weeks of age. (a) Heart weight to tibia length ratio. (b) Top: 
Representative H&E stained transverse heart sections from WT and AAV-cTnT-GFP-Luc 
injected mice. Scale bar, 1mm. Bottom: Representative WGA (red) and dapi (blue) staining in 
hearts from WT and AAV-cTnT-GFP-Luc injected mice. (c) Cardiomyocyte cross-sectional 
area quantification from the WGA staining (red) in heart sections. 
Data are means ± SEM (n=5), (t-test). 
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 Supplementary Figure 12. Adeno-associated shDEPTOR virus injection in WT mice does 
not affect cardiac growth. 
(a, b & c) Adeno-associated serotype 9-virus shDEPTOR was injected to 4 weeks-old mice and 
heart phenotype analyzed at 8 weeks-old. (a) Heart weight to tibia length ratio. (b) Top: 
Representative H&E stained transverse heart sections from 8-week-old WT and AAV-cTnT-
shDEPTOR injected mice. Scale bar, 1mm. Bottom: Representative FITC-WGA staining 
(green) in hearts from 8-weeks-old WT and AAV-cTnT-shDEPTOR injected mice. (c) 
Cardiomyocyte cross-sectional area quantification from the FITC-WGA staining (green) in 
hearts from 8-week-old. 
Data are means ± SEM (n=5), (t-test). 
 
Supplementary Figure 13. Western blots full scans.  
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Supplementary table 1. Peptides selected in this study for the in vitro and in vivo analysis 
of p38γ and p38δ phosphorylation of human DEPTOR by PRM 
Monoisotopic masses for singly (m/z), doubly (MH+2) or triply (MH+3) charged ions from 
trypsin-digested peptides of human DEPTOR (Uniprot entry Q8TB45 - DPTOR_HUMAN), 
containing SP or TP consensus phosphorylation motifs of p38γ and p38δ, and their unmodified 
or Met-oxidized counterparts. In red, selected masses for each sequence. Parent and fragment 
masses for later analyses were generated using the ProteinProspector Tools 
(http://prospector.ucsf.edu/prospector/mshome.htm). 
	 	
m/z$(mi)$ MH+2(mi)$ MH+3(mi)$ Mods$ Start$ End$ Miss$ Sequence$ length$
1494.7022$ 747.8547$ 498.9056$ 1Oxidation$1Phospho$ 143$ 154$ 0$ (K)LMSPENTLLQPR(E)$ 12$
1398.741$ 699.8741$ 466.9185$
$
143$ 154$ 0$ (K)LMSPENTLLQPR(E)$ 12$
1414.7359$ 707.8716$ 472.2501$ 1Oxidation$ 143$ 154$ 0$ (K)LMSPENTLLQPR(E)$ 12$
1478.7073$ 739.8573$ 493.5739$ 1Phospho$ 143$ 154$ 0$ (K)LMSPENTLLQPR(E)$ 12$
2070.0536$ 1035.5304$ 690.6894$
$
143$ 160$ 1$ (K)LMSPENTLLQPREEEGVK(Y)$ 18$
2086.0485$ 1043.5279$ 696.021$ 1Oxidation$ 143$ 160$ 1$ (K)LMSPENTLLQPREEEGVK(Y)$ 18$
2166.0148$ 1083.5111$ 722.6765$ 1Oxidation$1Phospho$ 143$ 160$ 1$ (K)LMSPENTLLQPREEEGVK(Y)$ 18$
2150.0199$ 1075.5136$ 717.3448$ 1Phospho$ 143$ 160$ 1$ (K)LMSPENTLLQPREEEGVK(Y)$ 18$
1936.9528$ 968.98$ 646.3225$ 1Phospho$ 312$ 328$ 0$ (K)RPVTSEELLTPGAPYAR(K)$ 17$
1856.9865$ 928.9969$ 619.667$
$
312$ 328$ 0$ (K)RPVTSEELLTPGAPYAR(K)$ 17$
2065.0478$ 1033.0275$ 689.0208$ 1Phospho$ 312$ 329$ 1$ (K)RPVTSEELLTPGAPYARK(T)$ 18$
1985.0815$ 993.0444$ 662.3653$
$
312$ 329$ 1$ (K)RPVTSEELLTPGAPYARK(T)$ 18$
1157.5507$ 579.279$ 386.5218$
$
258$ 268$ 0$ (K)STSFMSVSPSK(E)$ 11$
1253.5119$ 627.2596$ 418.5088$ 1Oxidation$1Phospho$ 258$ 268$ 0$ (K)STSFMSVSPSK(E)$ 11$
1173.5456$ 587.2764$ 391.8534$ 1Oxidation$ 258$ 268$ 0$ (K)STSFMSVSPSK(E)$ 11$
1237.517$ 619.2622$ 413.1772$ 1Phospho$ 258$ 268$ 0$ (K)STSFMSVSPSK(E)$ 11$
1527.7723$ 764.3898$ 509.929$
$
258$ 271$ 1$ (K)STSFMSVSPSKEIK(I)$ 14$
1623.7336$ 812.3704$ 541.916$ 1Oxidation$1Phospho$ 258$ 271$ 1$ (K)STSFMSVSPSKEIK(I)$ 14$
1543.7672$ 772.3873$ 515.2606$ 1Oxidation$ 258$ 271$ 1$ (K)STSFMSVSPSKEIK(I)$ 14$
1607.7387$ 804.373$ 536.5844$ 1Phospho$ 258$ 271$ 1$ (K)STSFMSVSPSKEIK(I)$ 14$
2364.2323$ 1182.6198$ 788.7489$ 1Phospho$ 308$ 328$ 1$ (K)SVLKRPVTSEELLTPGAPYAR(K)$ 21$
2284.266$ 1142.6366$ 762.0935$
$
308$ 328$ 1$ (K)SVLKRPVTSEELLTPGAPYAR(K)$ 21$
1285.6457$ 643.3265$ 429.2201$
$
257$ 268$ 1$ (R)KSTSFMSVSPSK(E)$ 12$
1381.6069$ 691.3071$ 461.2072$ 1Oxidation$1Phospho$ 257$ 268$ 1$ (R)KSTSFMSVSPSK(E)$ 12$
1301.6406$ 651.3239$ 434.5517$ 1Oxidation$ 257$ 268$ 1$ (R)KSTSFMSVSPSK(E)$ 12$
1365.612$ 683.3096$ 455.8755$ 1Phospho$ 257$ 268$ 1$ (R)KSTSFMSVSPSK(E)$ 12$
2011.9922$ 1006.4998$ 671.3356$ 1Phospho$ 139$ 154$ 1$ (R)LYEKLMSPENTLLQPR(E)$ 16$
2027.9872$ 1014.4972$ 676.6672$ 1Oxidation$1Phospho$ 139$ 154$ 1$ (R)LYEKLMSPENTLLQPR(E)$ 16$
1932.0259$ 966.5166$ 644.6802$
$
139$ 154$ 1$ (R)LYEKLMSPENTLLQPR(E)$ 16$
1948.0208$ 974.5141$ 650.0118$ 1Oxidation$ 139$ 154$ 1$ (R)LYEKLMSPENTLLQPR(E)$ 16$
$
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	Gene	 Primer		 Sequence	
Deptor	 Fw	 ATAGACGGCACCATCTCAA 
Rev	 GTCGGCTAATTTCTGCATG 
S145A	
mutation	
Fw	 GGCTATATGAAAAGCTGATGGCCCCTGAAAACACACTCCTGC 
Rev	 GCAGGAGTGTGTTTTCAGGGGCCATCAGCTTTTCATATAGCC 
S244A	
mutation	
Fw	 CCAGGAAACTCATGACGCTCCCTTCTGCCTGAGG 
Rev	 CCTCAGGCAGAAGGGAGCGTCATGAGTTTCCTGG 
S265A	
mutation	
Fw	 CCAGCTTTATGTCAGTGGCCCCCAGCAAGGAGATC 
Rev	 GATCTCCTTGCTGGGGGCCACTGACATAAAGCTGG 
S293A	
mutation	
Fw	 GCTACTTCAGCAGCGCCCCCACCCTCAGC 
Rev	 GCTGAGGGTGGGGGCGCTGCTGAAGTAGC 
T321A	
mutation	
Fw	 CCTCTGAGGAACTCCTTGCTCCCGGGGCTCCG 
Rev	 CGGAGCCCCGGGAGCAAGGAGTTCCTCAGAGG 
  
Supplementary Table 2. Primers sequences. 
 
 
 
SUPPLEMENTARY METHODS 
Detection of DEPTOR Phosphorylation Sites In Vivo 
HEK-293T cells were transfected with FLAG-DEPTOR using the calcium phosphate 
method. At 30 hr post-transfection, 293T cells were treated with 10 µM MG132 for 16 
hr to block the 26S proteasome pathway prior to collecting the whole cell lysates for 
FLAG-immunoprecipitation. After extensive washing with PBS 1x buffer, 10µl of 
sample buffer was added to FLAG-immunoprecipitates, which were boiled for 5 
minutes at 95ºC. The samples were reduced, alkylated, digested with trypsin, and 
desalted on C18 reverse phase microcolumns as before 1,2. Analyses were performed on 
a nano HPLC system coupled with a hybrid quadrupole orbitrap mass spectrometer 
(QExactive, Thermo Scientific). For LC analysis, each sample was loaded in Buffer A 
(0.1% formic acid) and on-line desalted on a 2 cm packed pre-column (Thermo Acclaim 
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PepMap 100). Analytical separation was performed over a 50 cm column (Thermo 
Acclaim PepMap 100, 75 µm ID x 500 mm)  at 200 nL/min with a 180 min gradient 
from 8 to 31% of Buffer B (0.1% formic acid / 90 % acetonitrile) using an EASY-nLC 
1000 HPLC (Thermo Scientific). Samples were analysed randomly with an extensive 
column wash between each sample to minimize carry-over. Phosphorylated peptides 
detected in the in vitro experiments, and their non-phosphorylated counterparts, were 
monitored using the parallel reaction monitoring (PRM) mode. In all experiments, a full 
mass spectrum with 2 microscans at 140.000 resolution relative to m/z 200 (AGC target 
1 × 106, 20 ms maximum injection time, m/z 400–1200) was followed by PRM scans at 
17.500 resolution (AGC target 2 × 105, 120 ms maximum injection time, isolation width 
of ±2 Th) and triggered by a scheduled inclusion list of the selected peptide ions 
(Supplementary Table 1). Fragmentation was performed in the HCD collision cell using 
anormalized collision energy of 27%. Quantification was carried out post-acquisition 
using the extracted ion chromatograms (XICs) using a ±3 ppm mass tolerance, unless 
otherwise noted. Detection of the targeted peptide was based on the presence of the 
intact monoisotopic precursor signal, mass error within ±3 ppm, and manual verification 
of the MS/MS spectra. Proteome Discoverer 1.4.0.288 (Thermo Scientific) was also 
used together with Scaffold (version Scaffold_4.4.1, Proteome Software Inc., Portland, 
OR) to validate MS/MS based peptide identifications and fragment assignments. 
Site-Directed Mutagenesis 
The DEPTOR cDNA in pRK5 (plasmid #21334, Addgene) was mutagenized with the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). The primers 
used are specified in the Supplementary table 2. 
qRT-PCR 
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The expression of mRNA was examined by qRT-PCR using a 7900 Fast Real Time 
thermocycler and FAST SYBR GREEN assays (Applied Biosystems). Relative mRNA 
expression was normalized to Gapdh mRNA measured in each sample. Deptor was 
amplified using the primers shown in Supplemental Table 2. 
In vitro ubiquitin assay 
Cullin-βTrCP E3 complex was precipitated from 293 cells overexpressing both proteins 
with myc. GST-DEPTOR protein (H00064798, Novus biologicals) was incubated ofor 
30 minutes with 1 µg of active recombinant p38g and p38d or without kinases (provided 
by MRC Protein Phosphorylation and Ubiquitylation Unit, Dundee, UK) in the presence 
of 200 µM cold ATP followed by incubation with Cullin-βTrCP E3 complex in the 
presence of E1 and E2 in a ubiquitin reaction buffer (Abcam). Polyubiquitinated 
DEPTOR was resolved by SDS-PAGE and detected by IB with anti-DEPTOR Ab and 
antiubiquitin. 
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RESUMEN 
La muerte súbita es una muerte inesperada que resulta de una enfermedad cardíaca cuya 
presencia es conocida o desconocida. Aunque se trata de un evento poco frecuente en 
los deportistas jóvenes, tiene un gran impacto en la sociedad actual. Numerosos estudios 
se han realizado para conocer cómo prevenir la muerte súbita y poder detectar los 
sujetos con mayor susceptibilidad. No obstante, el diagnóstico diferencial entre 
hipertrófia fisiológica o “corazón de atleta” y la cardiomiopatía hipertrófica aún no se 
ha podido establecer con claridad. Además, poco se conoce sobre las mutaciones 
genéticas y vías de señalización asociadas a un mayor riesgo de sufrir muerte súbita 
cardiaca. Previamente p38γ y p38δ han sido involucradas en el crecimiento hiperttrófico 
cardiaco. En este estudio mostramos que MKK3 es el principal activador de p38γ y 
p38δ en el corazón, mientras que MKK6 regula la actividad de p38α. De esta forma, la 
falta de activación de la vía MKK6-p38α lleva a la hiperactivación de MKK3-p38γ/δ y a 
una actividad aumentada de la vía de señalización de mTOR que deriva en el desarrollo 
de hipertrófia cardiaca fisiológica. Sin embargo, cuando los ratones deficientes en 
MKK6 son sometidos a un entrenamiento crónico de ejercicio de resistencia, su función 
sistólica cardiaca disminuye, muestran un mayor prolongamiento del intervalo QT y 
presentan susceptibilidad incrementada de muerte súbita. Este estudio identifica que 
alteraciones en la vía de señalización MKK3/6-p38γ/δ pueden llevar al desarrollo de 
hipertrófia fisiológica pero con un mayor riesgo de desarrollo de un intervalo QT 
prolongado y de muerte súbita asociada al ejercicio. 
 
Aportación Personal al trabajo: He participado tanto en el diseño experimental, como 
en la realización de los experimentos y en la escritura del artículo. 
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ABSTRACT 
Sudden cardiac deaths are rare events in athletics but are highly visible with substantial 
impact on our society. Many attempts have been made to detect those at risk for sudden 
cardiac death, but the differential diagnosis between physiological hypertrophy and 
hypertrophic cardiomyopathy is not yet clearly established. Moreover little is known 
about the genetic traits and signaling pathways associated to an increase risk of sudden 
cardiac death. Mitogen activated protein Kinases Kinases 3 and 6 (MKK) have been 
suggested to be implicated in the control of cardiac growth, however, the cardiac 
phenotype of animals lacking these kinases remains to be explored. Moreover it is not 
clear how these kinases control the activation of the different p38MAPK isoforms in 
cardiomyocytes. Here we show that, in the heart, MKK3 is the main activator of p38γ 
and p38δ while MKK6 activates cardiac p38α. Furthermore, the deficiency in MKK3 
causes decreased postnatal cardiac growth due to reduced p38γ and p38δ activation. 
Likewise, the lack of MKK6-p38α activation, leads to MKK3-p38γ/δ hyperactivation, 
increased mTOR signaling and causes physiological cardiac hypertrophy. However, 
when MKK6 deficient mice are challenged with chronic endurance training, the QT 
interval is prolonged in these mice and show increase risk of sudden cardiac death. The 
cardiac hypertrophy observed in Mkk6-/- mice can be reverted by knocking out either 
p38γ or p38δ, as well as inhibiting mTOR pathway with Rapamycin. In conclusion, we 
have identified that alterations in MKK3/6-p38γ/δ pathway in cardiomyocytes are 
associated with physiological cardiac hypertrophy and predispose to Long QT 
development and sudden cardiac death. 
184
  
INTRODUCTION 
An enormous amount of research has been generated during the past 10 years evaluating 
the causes and events surrounding sudden cardiac death (SCD) and potential screening 
mechanisms for identifying those at risk. Although there is not a universally accepted 
definition, SCD can be considered a non-traumatic, non-violent, unexpected death due 
to cardiac causes within 1 hour of the onset of symptoms [16]. 
Intensive endurance training is able to cause a distinct pattern of functional and 
structural changes within normal myocardial tissue [18]. During intense aerobic 
exercise, the oxygen consumption of muscle tissue increases markedly, and cardiac 
output must rise to meet the demands. Over time, endurance training, leads to the 
development of physiological cardiac hypertrophy called “athlete’s heart”, which is 
characterized by a proportional increased in left ventricular mass, with wall thicknesses 
under 15 mm and a moderated dilated left ventricle, increased heart rate during exercise 
and decreased resting heart rate, increased ventricular stroke volume, and increased 
cardiac output, without fibrosis development [13]. However, there is an overlap 
between this type of physiologic cardiac hypertrophy and mild forms of hypertrophic 
cardiomyopathy (HCM), the most common genetic disorder of the cardiovascular 
system. HCM is commonly characterized by asymmetric left ventricular hypertrophy 
with a reduced LV-diameter and fibrosis development. Hypertrophic cardiomyopathy is 
a common cause of sudden deaths among athletes, therefore differentiating this 
condition from the non-pathological “athlete’s heart” presents an important challenge. 
Several mutations have been associated to HCM, the most common and better 
characterized are mutations of genes encoding critical contractile myofilament proteins. 
Besides, with a low frequency of occurrence, mutations in genes encoding calcium-
sensitive and calcium-handling proteins have been recently implicated in the 
pathogenesis of HCM. However, a 50% of patients diagnosed with HCM worldwide do 
not host known gene mutations, highlighting the need to identify novel genes 
responsible for HCM [19]. 
 Long QT Syndrome has been also associated with cardiac sudden death. It is associated 
with specific mutations in genes that encode cardiac ion channels. Besides, cardiac 
hypertrophy is a risk factor for QT-prolongation and cardiac sudden death. Recent 
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studies in human patients and animal models have demonstrated that cardiac 
hypertrophy significantly affects myocardial electrotonic cell-to-cell coupling, leading 
to disturbance in action potential duration and potential malignant arrhythmia and 
cardiac sudden death [12, 17, 38]. 
In response to hemodynamic overload, cardiac myocytes are subjected to mechanical 
stretch, and autocrine and paracrine humoral factors are released. These factors bind to 
different receptors on cardiomyocytes, and activate intracellular signaling pathways that 
lead to cell growth. A great number of signaling cascades and proteins are involved in 
the regulation of cardiac growth and hypertrophy. Besides, it is now clear that several 
signaling molecules play unique roles in the regulation of pathological and 
physiological cardiac hypertrophy [24]. The production of cardiac IGF1 and activation 
of the PI3K pathway has been described during postnatal development and upon 
exercise training in humans and animal models [28, 32]. In contrast, pressure overload 
and heart failure is associated with elevated levels of angiotensin-II, catecholamines and 
ET-1 and the activation of GPCR specific receptors [1, 28, 31, 33, 42, 43]. 
However, it has been shown, that some pathways that were believed to promote 
physiologic hypertrophic growth, are involved in pathological hypertrophy as well. IGF 
transgenic mice, present proportionally enlarge hearts with normal cardiac function, but 
when prolonged on time, it progresses to pathological hypertrophy with decreased 
cardiac function [25]. An essential feature of both physiological and pathological 
hypertrophy is increased protein synthesis. mTOR pathway is the critical regulator of 
protein synthesis mainly through the phosphorylation of its downstream substrates. 
Activation of mTOR pathway is increased during postnatal cardiac development [14], 
also in hearts from transgenic mouse models of physiological hypertrophy (IGF-PI3K 
pathway) [25, 26, 34, 35]. Moreover, rapamycin, a specific mTOR inhibitor, attenuated 
and regressed pathological hypertrophy induced by cardiac overload. [35]. Likewise, 
p38γ and p38δ MAPKs, have been recently involved in the control of postnatal cardiac 
hypertrophic growth as well as Angiotensin-II induced cardiac hypertrophy, through the 
control of mTOR pathway activation [14]. This suggests that physiological 
hypertrophied hearts, due to genetic causes or endurance training, depending on the 
type, duration and potency of the environmental signals could progress into pathological 
conditions.  
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 The p38-MAPK signaling pathway is an important mediator of numerous biological 
functions including cell growth, cell proliferation, cell cycle and cell death, and is 
considered a critical component of stress response pathways [9, 15, 22]. In the heart, the 
four p38 MAPKs (p38α/β/γ/δ) are expressed, but p38α and p38γ gamma protein levels 
are higher. p38α and p38β play redundant roles in the regulation of cardiac proliferation 
during embryonic development, and their deficiency leads to septal defects [10]. 
However, mice lacking p38α or p38β alone in the heart, display a normal cardiac 
structure and function in basal condition. In response to cardiac overload, p38α MAPK 
has been implicated in the regulation of myocyte apoptosis [29], whereas p38β has a 
predominant role in the regulation of the hypertrophic response [2, 4, 20, 30, 40]. 
Additionally, we have previously reported that mice deficient in p38γ and p38δ present 
reduced postnatal hypertrophic growth associated to a decreased activation of the 
mTOR pathway. Besides, p38γ and p38δ deficiency protects against cardiac overload 
induced pathological hypertrophy [14]. 
MKK3 and MKK6, the main up-stream activators of the p38 isoforms, are highly 
selective for p38 MAPKs and do not activate JNKs or ERK1/2 [7, 8, 11]. Mice lacking 
both MKK3 and MKK6 are not viable, dying in mid-gestation with defects in the 
placenta and the development of the embryonic vasculature [3]. This observation 
indicates that MKK3 and MKK6 have partial redundant roles, because loss of either 
gene alone yields healthy mice [21, 37, 41]. Both MKKs are expressed in cardiac tissue 
and have been previously involved in cardiac hypertrophy. Nevertheless, all the studies 
have been performed by overexpressing the dominant negatives or by constitutively 
active mutants of MKK3 and MKK6, non-physiological models that could account for 
artefactual phenotypes associated [4, 27]. Moreover, is not known which is the major 
MKK required for the activation of the different p38 MAPK isoforms in the regulation 
of heart growth during postnatal cardiac development nor upon other hypertrophic 
stimuli. Thus, further experiments are needed taking advantage of MKK single 
knockout mice and cardiac-specific conditional knockouts. 
The purpose of the study reported here was to examine the role of the MAPK Kinases 
MKK3 and MKK6 in the activation of the different p38 MAPK isoforms in the heart, 
and their implication in the regulation of physiological and pathological cardiac 
hypertrophy. Here we show that MKK3 is the main activator of p38γ and p38δ 
isoforms, whereas MKK6 activates p38α in the heart. Furthermore MKK6 exerts a 
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feedback loop upstream the signaling pathway, and its deficiency leads to MKK3-
p38γ/δ hyperactivation, and an enhance physiological-type of cardiac hypertrophic 
growth. Accordingly, mice lacking MKK3 present reduced postnatal cardiac 
hypertrophy. Mkk6-/- physiological hypertrophy progresses into pathological 
hypertrophy when mice undergo chronic endurance training, with prolong QT interval 
and increase risk of sudden death. 
RESULTS 
Several studies have been done to address the role of p38 MAPK pathway in the cardiac 
homeostasis and disease. The four p38 isoforms are expressed in the heart and have 
been involved in the regulation of cardiac growth at different levels and stages during 
development [10, 14], as well as in the pathogenesis of cardiac diseases [40]. However, 
it is not yet clear the importance of the p38 up-stream kinases, MKK3 and MKK6, in 
this context. To study the role of MKK3 and MKK6, in the heart, we used mice 
deficient in either of the MKKs. At First, we studied the cardiac phenotype of Mkk6-/- 
mice during the postnatal stages of cardiac development. MKK6 deficient hearts were 
proportionally bigger than control hearts at 9 weeks of age (Figure 1A). Ventricular 
mass between postnatal weeks 4 and 15 was monitored in WT and Mkk6-/- mice. At 4 
weeks after birth, heart size was similar between genotypes, but from this moment 
onwards, an enhanced cardiac growth was observed (Figure 1B). The cardiac increase in 
size can be due to proliferation or hypertrophy. Therefore, we studied the 
cardiomyocyte cross-sectional area at the same time points. Surprisingly, at 4 weeks 
cardiomyocytes from MKK6 deficient hearts showed reduced cardiomyocyte area 
compared to control mice, although their heart size at this time was similar to control 
hearts (Figure 1C). This suggets that Mkk6-/- hearts present an increased number of 
cardiomyocytes at this developmental stage, which could be indicative of enhance 
cardiomyocyte proliferation. Accordingly, Mkk6-/- hearts showed a strong reduction in 
p21 and Rb expression at 4 weeks (Supplementary Figure 1A), two important tumor 
suppressors involved in maintaining cell cycle arrest in adult cardiomyocytes [39], and 
increased levels of Ki67 stainning (Supplementary Figure 1B). Nevertheless, the latter 
augmentation in heart size observed in Mkk6-/- mice correlates with a greater increase in 
cardiomyocyte cross-sectional area compared to WT cardiomyocytes, indicative of an 
enhance hypertrophic growth (Figure 1D). Hypertension is one of the main causes of 
cardiac hypertrophy. To rule out this possibility, systolic blood pressure was measured 
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 at different time points during postnatal cardiac development. Contrary, systolic blood 
pressure was lower in Mkk6-/- mice indicating that differences in blood pressure could 
not explain the cardiac hypertrophy observed in these mice (Supplementary Figure 1C). 
There are two types of cardiac hypertrophic growth, the physiological hypertrophy that 
occurs during cardiac postnatal development or in trained athletes, and the pathological 
hypertrophy associated to pressure load in a disease setting (hypertension, aortic 
constriction, etc.) or to cardiomyopathy (familial, viral, toxic or metabolic). 
Physiological cardiac hypertrophy is characterized by a proportional increased heart 
size, without fibrosis development that leads to normal or enhanced cardiac function, 
without re-expression of fetal genes. Whereas pathological hypertrophy leads to fibrosis 
development with the up-regulation of fetal genes, reduced cardiac function and is 
associated with increased mortality [24]. Analysis of these parameters was performed in 
order to distinguish the type of hypertrophy observed in Mkk6-/- mice. Echocardiography 
of 9-week-old mice reinforced the outcome that Mkk6-/- mice have significantly bigger 
hearts, measured as an increased left ventricle corrected mass. Moreover, Mkk6-/- hearts 
showed thicker diastolic interventricular septum (IVS; d) and telediastolic left ventricle 
posterior wall (LVPW; d), together with a wider left ventricle internal diameter in 
diastole compared to WT mice (Figure 1D). This indicated a proportional increase in 
heart size in mice lacking MKK6. The cardiac systolic function was normal in mice 
deficient in MKK6, but the E/A ratio, a diastolic function parameter; the stroke volume 
and cardiac output were increased in these mice (Figure 1E). 
Moreover, the level of cardiac fibrosis in 9-week-old hearts was measured by picrosirius 
red staining and its posterior quantification, showed no differences in fibrosis levels 
between genotypes (Supplementary Figure 1C). In correlation, the expression levels of 
different genes markers of fibrosis were similar in WT and Mkk6-/- hearts during 
postnatal cardiac development and in adulthood (Supplementary Figure 1D). Another 
parameter used to distinguish between the two types of cardiac hypertrophy is the re-
expression of fetal genes in the pathological one. Several cardiac stress gene markers 
were analyzed between postnatal weeks 4 and 9 and showed that although there was a 
cardiac stress-like expression pattern at 4 weeks of age in Mkk6-/- hearts, this stress 
seemed to be compensated because from there on, no changes in the fetal gene 
expression levels were observed (Supplementary Figure 1E). Altogether this data 
indicates that Mkk6-/- mice are developing physiological cardiac hypertrophy. 
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MKK6 is one of the main up-stream activators of p38 MAPKs, however, it is not well 
established the specificity of this MAPK kinase towards the different p38 isoforms in 
the heart. Therefore we analyzed the p38s phosphorylation levels in heart lysates from 
WT and MKK6 deficient hearts. Surprisingly, immunoprecipitation assays for p38γ and 
p38δ showed that these two alternative p38 isoforms were hyperphosphorylated in 
Mkk6-/- hearts (Figure 2A&B). In contrast, p38α activation was strongly reduced 
compared to control hearts (Figure 2C). Therefore, other MKK may be responsible of 
the increased p38γ and p38δ phosphorylation. Being MKK3 the other main p38 up-
stream activator, its phosphorylation levels were analyzed by immunoblot. MKK3 
phosphorylation was strongly increased in cardiac lysates from Mkk6-/- mice (Figure 
2D). This suggested that while cardiac p38α activation was mainly mediated by MKK6, 
cardiac p38γ and p38δ hyperphosphorylation was probably mediated by MKK3. 
Accordingly, the phosphorylation of the cardiac p38γ and p38δ was strongly decreased 
in mice deficient in MKK3, without affecting p38α activation (Figure 2 E). These 
results indicate that in the heart, in homeostatic conditions, MKK3 is the dominant 
activator of p38γ and p38δ isoforms, whereas MKK6 is the main p38α activator. We 
have previously reported that p38γ and p38δ control postnatal cardiac hypertrophic 
growth. Consequently, the reduced activation of p38γ and p38δ in Mkk3-/- hearts 
correlated with a reduction in postnatal cardiac growth (Figure 2F). In the same way, the 
hyperactivation of p38γ and p38δ in Mkk6-/- hearts was associated with the development 
of physiological cardiac hypertrophy.  
p38γ and p38δ promote cardiac hypertrophic growth through the activation of mTOR 
pathway. Correspondingly, mice deficient in MKK6 presented an increase activation of 
the cardiac mTOR pathway, addressed by the augmented phosphorylation of its down-
stream targets (Figure 3A). It is well established that mTOR is a key regulator of protein 
synthesis and that protein synthesis is an essential factor in cardiomyocyte hypertrophic 
growth. Thus, the activation of different eukaryotic initiation/elongation translation 
factors in heart lysates was analyzed. Immunoblot assays showed an increase activation 
of translation signaling in hearts lacking MKK6 compared to WT hearts (Figure 3B). To 
corroborate whether protein synthesis was enhanced in Mkk6-/- hearts, puromycin was 
injected in WT and Mkk6-/- mice and, 30 minutes after the injection, hearts were 
harvested and puromycin incorporation into newly synthesized peptides was studied. 
Mkk6-/- hearts showed an increase in puromycin-labelled peptides compared to control 
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 mice, indicating an enhance protein synthesis in vivo in hearts lacking MKK6 (Figure 
3C).  
To understand whether the specificity observed in the activation of the different p38 
isoforms by the MKKs also occurs in other cell types, the p38γ phosphorylation was 
studied in MEFs WT, Mkk3-/- and Mkk6-/-. In agreement with the outcomes observed in 
cardiac lysates, MKK6 deficiency led to p38γ hyperphosphorylation and subsequently, 
increase mTOR pathway activation and bigger cell size. Besides, Mkk3-/- MEFs 
presented reduced mTOR pathway activation and smaller cell size associated to the 
reduction in p38γ phosphorylation (Supplementary Figure 2).  
To determine whether the enhance heart growth of Mkk6-/- was due to an autonomous 
effect in postnatal cardiomyocyte development, we generated mice carrying loxP-
flanked gene Mkk6LoxP/LoxP (Figure 4A). To deplete Mkk6 in striated muscle, these mice 
were crossed with MCK Cre mice (MKK6 MCK−KO), which reach peak Cre expression 
on postnatal day 10 [5]. Specific deletion of Mkk6 was achieved in these mice in muscle 
and heart (Figure 4A, B and Supplementary Figure 2D). The cardiac phenotype of 
MKK6 MCK−KO at 9 weeks of age resembled the one observed in MKK6 whole-body 
knockout mice. This suggests that MKK6 controls heart growth in a cell-autonomous 
manner (Figure 4C-F). To further corroborate that is MKK6 in cardiomyocytes the 
responsible of the increased hypertrophic growth; mice lacking MKK6 specifically in 
cardiomyocytes were used. With that aim Mkk6LoxP/LoxP mice were crossed with MHC 
Cre mice (MKK6 αMHC−KO), which starts to be expressed at embryonic day E10.5 [23]. 
Cardiac specific deletion of Mkk6 rendered a phenotype very similar to the Mkk6-/- full 
knockout and MKK6 MCK−KO mice, corroborating that MKK6-mediated control of heart 
growth is cell autonomous (Figure 5 A-E). 
Then, we confirmed that the MKK6-mediated modulation of p38γ/δ activation is 
responsible for the enhanced postnatal cardiac hypertrophic growth using different 
mouse models. Mkk6-/- mice were crossed with mice lacking p38γ in the whole body and 
mice with the double deficiency in Mkk6-/- Mapk12-/- were generated, and their cardiac 
phenotypes studied at 9 weeks after birth. p38γ deletion reverted the enhanced cardiac 
growth to the WT levels, rendering similar heart size and cardiomyocyte cross-sectional 
area to control mice (Figure 6). Besides, the cardiac phenotype of Mkk6-/- p38δMCK−KO 
was analyzed, showing that the deletion of p38δ specifically in striated muscle in Mkk6-
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/- mice reduced the MKK6 enhance hypertrophy to the p38δMCK−KO heart size, which is 
smaller that control hearts, indicating that p38δ is downstream MKK6 in the regulation 
of cardiac growth (Figure 7). Altogether this data demonstrates that MKK6 enhanced 
cardiac hypertrophic growth is mediated by the hyperactivation of the MKK3-p38γ/δ 
pathway in the striated muscle. 
To test whether increased mTOR signaling could account for the enhanced heart growth 
in Mkk6-/- mice, we inhibited mTOR activation by a daily injection of Rapamycin, a 
specific mTOR inhibitor, from 3 weeks until 9 weeks after birth. mTOR inhibition was 
enough to reduce the heart size of WT and Mkk6-/- mice to the same level, with a strong 
reduction in their cardiomyocyte cross-sectional area. Thus, the Mkk6-/- bigger hearts 
appear to result from the hyperactivation of mTOR pathway in these mice (Figure 8). 
Physiological cardiac hypertrophy is understood an adaptive response that causes an 
increased ventricle mass but with normal or enhanced cardiac function with no increase 
mortality risk [18]. However, several studies suggest that physiological hypertrophy 
could progress into pathological, which is strongly associated with sudden cardiac 
death. Therefore we decided to challenge adult MKK6 deficient mice that already have 
developed a physiological hypertrophy with exercise training, a stimulus that changes 
the cardiac functional load and triggers a hypertrophic response to counterbalance the 
increase in wall stress. 
After 3 weeks of swimming training, a significant increase in ventricular mass was 
observed in both genotypes. Wheat germ agglutinin (WGA) immunostaining indicated 
that it was due to an enlargement in the cardiomyocyte cross-sectional area (Figure 9A-
C). Echocardiography studies reinforce the outcome that swimming training increased 
heart size in both genotypes. After 3 weeks of endurance exercise training, the systolic 
function did not change in control mice, but it was significantly reduced in mice lacking 
MKK6 to the level of the WT mice (Figure 9D). No fibrosis development was observed 
at the end of the training. Interestingly, swimming reduced fibrosis levels in both 
genotypes (Supplementary Figure 3). Although the cardiac function was similar in the 
swimming-trained Mkk6-/- and WT mice, the Mkk6-/- mice mortality due to chronic 
endurance training was increased. All mice died suddenly in the swimming training or 
just after the exercise (Figure 9E). 
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 In order to understand the increased predisposition to sudden cardiac death observed in 
Mkk6-/- mice, an RNASeq was perform comparing WT and Mkk6-/- cardiac gene 
expression at 9 weeks of age. The principal Top Tox Function identified was Cardiac 
Arrhythmia, and within Cardiac Arrhythmia, Long QT syndrome was the most 
significant (Figure 10A&B). Moreover Long QT Syndrome has been associated with 
increased predisposition to sudden cardiac death and is known to be cause by mutations 
in cardiac ion channels [18]. Then, we confirmed that the mRNA expression of several 
cardiac ion channels involved in Long QT Syndrome was altered in Mkk6-/- hearts 
compared with control hearts in basal condition (Figure 10C). ECG studies showed no 
differences between genotypes in basal condition. After the endurance exercise training, 
a similar increase in the PR segment length was observed in WT and Mkk6-/- trained 
mice. However, the interbeat in terval and QT interval were significantly longer in mice 
lacking MKK6 compared to control mice after the 3 weeks of swimming training 
(Figure 11). This indicates that MKK6 deficiency leads to bradichardia and predisposes 
to the prolongation of the Long QT interval and cardiac sudden death upon endurance 
exercise training. 
DISCUSION 
A proper heart size is critical to maintain body homeostasis, therefore, derangements in 
cardiac growth can lead to the development of different cardiomyopathies. The heart 
needs to grow during development to meet the demand of blood flow to the growing 
body, and this growth is achieved through proliferation during the fetal stages. But soon 
after birth, cardiomyocytes withdraw from cell cycle and the rest of the postnatal 
cardiac increase in size is through cardiomyocyte hypertrophy. Furthermore, cardiac 
hypertrophy is also an adaptive response that occurs throughout life in response to 
changes in blood pressure and circulatory resistance. However, when the hypertrophic 
stimuli are sustained in time, it can become pathological. Chronic hypertension 
associated to cardiovascular diseases can lead to pathological hypertrophy and heart 
failure. On the other hand, exercise training is the only chronic stimulus that in most 
cases leads to physiological hypertrophy characterized by normal or increased cardiac 
function. However, a low percentage of athletes that undergo high-intensity exercise 
training, progress into heart disease or suffer sudden cardiac death. 
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The present study provides several independent lines of evidence to support a critical 
role of the MKK3/6–p38γ/δ signaling pathway in the development of physiological 
cardiac hypertrophy with increased predisposition to sudden cardiac death upon 
endurance exercise training. As documented via using different knockout mouse 
models, in the absence of MKK6 the MKK3- p38γ/δ kinases become hyperactivated, 
which induce enhanced postnatal hypertrophic growth through the mTOR pathway. The 
hypertrophy developed is physiological, with normal or even increased cardiac function 
in basal condition, but associated to altered expression of cardiac ion channels. Under 
stress conditions such as endurance exercise training, these mice develop long QT 
syndrome and show increased sudden cardiac death. Moreover, we have described that 
the two main p38 up-stream activators present a strong specificity towards the 
activation of the different p38 MAPK isoforms in the heart, being p38γ/δ mainly 
regulated by MKK3, and p38α by MKK6 at least in homeostatic conditions. 
The p38 MAPK pathway has been previously associated with the regulation of cardiac 
hypertrophic growth. While p38α and p38β have been involved in pathological cardiac 
hypertrophy in different disease models, p38γ and p38δ seem to be involved in the 
regulation of physiological cardiac growth during development but also pathological 
hypertrophy in response to angiotensin-II treatment. However, how the activation of the 
different p38 MAPK isoforms is regulated in this context has not been previously 
addressed. Likewise, the involvement of MKK3 and MKK6 in cardiac hypertrophy was 
still controversial. On the one hand, several studies reported that the overexpression of 
the constitutive active form of MKK3 and MKK6 in cardiomyocytes in vitro leads to 
hypertrophic growth [36, 44]. On the other hand, it has been also shown that the 
overexpression of the MKK3 and MKK6 dominant negatives drives cardiac 
hypertrophy [4]. Our data agrees with the idea that MKK3 promotes hypertrophic 
growth. We show that the hyperactivation of MKK3 leads to cardiac hypertrophy, and 
its deficiency alters the hypertrophic growth process. Furthermore, our studies also 
support the fact that both, the hyperactivation and deficiency of MKK6 in 
cardiomyocytes, could lead to cardiac hypertrophy. This can be explained by the 
involvement of MKK6 in the promotion of cardiac hypertrophy at the same time that 
exerts a negative feedback up-stream the signaling pathway. The negative feedback 
could be done directly by MKK6, or by p38α, whose phosphorylation levels are 
strongly decreased in Mkk6-/- hearts. Negative regulation of the MAP3K TAK1 by p38α	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 has been reported in other cell types, but the fact that cardiac-specific p38α conditional 
mice do not have cardiac basal phenotype does not support this hypothesis [29]. The 
negative feedback would also explain why in the absence of MKK6, MKK3 becomes 
hyperphosphorylated. Although this hypothesis could explain as well how the dnMKK6 
overexpression causes cardiac hypertrophy, it does not clarify the reasons why 
dnMKK3 causes hypertrophy. It is true that the overexpression of dominant negative 
forms does not inhibit the scaffold functions of the kinase. Besides, it is an indirect form 
to inhibit the endogenous kinase function that could affect other signaling molecules. 
The activation of the different p38 MAPK cardiac isoforms has not been characterized 
in these models, and no studies have been performed to this date in the specificity of the 
MKK3 and MKK6 towards the p38 MAPKs in the heart. We show that MKK3 
preferentially regulates p38γ and p38δ activation, while MKK6 is responsible for p38α 
regulation.  
MKK6 mice present hyperactive p38γ/δ and reduced p38α activation, therefore any of 
these isoforms could be involved in the phenotype observed. It has been shown that 
p38α cardiac-specific knockout mice do not present a basal cardiac phenotype. 
Furthermore, p38α has been involved in the regulation of apoptosis, but does not control 
hypertrophy in an aortic constriction model [29]. We demonstrate that 
hyperphosphorylated MKK3 promotes cardiac hypertrophic growth through the 
activation p38γ and p38δ, which in turn increase mTOR signaling in the heart. This 
agrees with the previous reports from our group that point out an essential role of p38γ 
and p38δ in the promotion of physiological and pathological cardiac hypertrophy, 
through the mTOR pathway [14]. We further corroborate this conclusion, firstly by 
showing that the double deficiency in MKK6 and p38γ or p38δ in the heart reverts the 
cardiac hypertrophy observed in MKK6 deficient mice. Secondly, the treatment with 
Rapamycin, an mTOR specific inhibitor, in MKK6 mice during the early postnatal 
cardiac development leads to a strong reduction in heart size to the same level that 
control hearts. In correlation, MKK3 deficient mice show decreased p38γ and p38δ 
activation and reduced postnatal hypertrophic growth.  
p38γ and p38δ control of cardiac hypertrophy during postnatal cardiac development is 
cell autonomous [14]. Accordingly, the lack of MKK6 in skeletal striated muscle or in 
cardiomyocytes renders a similar phenotype to the full knockout mice. Furthermore, the 
lack of p38δ specifically in the striated muscle is sufficient to revert the enhanced 
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cardiac hypertrophic growth to the same size as the p38δMCK-KO mice, indicating that 
cardiac p38δ is downstream MKK6 in the signaling pathway controlling the 
hypertrophic growth. Notably, p38δ reversion of MKK6 phenotype is stronger than the 
reversion achieved with p38γ. This agrees with the already reported dominant role of 
p38δ in the regulation of cardiac hypertrophic growth [14]. 
The hypertrophic response can broadly be classified as either physiological or 
pathological. The Mkk6-/- hearts develop a physiological hypertrophy based on the 
distinctive characteristics of both types of hypertrophic growth. The increase in heart 
size is proportional, left ventricle walls are thicker, but at the same time the left 
ventricle internal diameter is wider, therefore the normal cardiac structure is maintained. 
Moreover, the cardiac function is normal with increased cardiac output and stroke 
volume. Finally, no fibrosis development or fetal gene up-regulation is observed. 
Although the expression level of several cardiac ion channels is altered in Mkk6-/-  
hearts, in basal condition the ECG in these mice is normal and no arrhythmias are 
detected. However, after endurance exercise training during 3 weeks, Mkk6-/- mice 
develop long QT syndrome and show increased sudden cardiac death. It is known that 
pathologic cardiac hypertrophy alters ion channel coupling and is a risk factor for QT-
prolongation and cardiac sudden death [12, 17, 38], however it is thought that 
physiological hypertrophy is benign and is not associated with increased mortality. 
Although is not frequent, a small percentage of elite athletes die from cardiac sudden 
death. Some of them suffered from mild congenital hypertrophic cardiomyopathies that 
are wrongly diagnosed as Athlete’s heart. It would be of interest to study whether there 
is an association in athletes between the initial physiologic heart size, and the 
probability to die from sudden cardiac death when they have already become athletes 
and whether they carry mutations in the MKK3/6-p38γ/δ pathway. 
Our results identified the MKK3/6- p38γ/δ as new genetic pathway involved in 
physiological cardiac hypertrophy. However, the cardiac hyperactivation of MKK3 and 
p38γ and p38δ is associated with an increased risk to develop long QT syndrome and to 
suffer sudden cardiac death upon chronic exercise training. 
 
MATERIALS AND METHODS 
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 Mice 
Mkk3–/– (B6.129-Map2k3tm1Flv) [21, 41] and Mkk6–/– (B6.129-Map2k6tm1Flv) mice [37] 
were as previously described [3]. Mice with a germ-line mutation in the Map2k6 gene 
with LoxP elements inserted into two different introns (Map2k6LoxP) were constructed 
by using homologous recombination in ES cells. ES cells were electroporated with this 
vector (Figure 4A) and selected with 200 µg/ml G418 and 2 µM gangcyclovir. Several 
correctly targeted ES cell clones were identified by Southern blot analysis and PCR 
analysis. These ES cell clones were injected into C57BL/6J blastocysts to create 
chimeric mice that transmitted the mutated Map2k6 allele through the germ line. The 
Flp NeoR cassette was excised by crossing these mice with ACTB:FLPe B6;SJL that 
expresses a FLP1 recombinase gene under the direction of the human ACTB promoter. 
The Map2k6LoxP mice were maintained on a C57BL/6J mouse strain background (back-
crossed 10 generations). To generate mice lacking MKK6 or p38δ in striated muscle, 
Map2k6LoxP or p38δ (B6.129-Mapk13tm1) mice were crossed with the FVB-Tg(Ckmm-
cre)5Khn/J line on the C57BL/6J background (Jackson Laboratory). Mice lacking 
MKK6 in cardiomyocytes were generated by crossing Map2k6LoxP mice with the 
Tg(Myh6-cre)2182Mds line on the C57BL/6J background (Jackson Laboratory). p38γ 
(B6.129-Mapk12tm1) line was crossed with the Mkk6–/– (B6.129-Map2k6tm1Flv) line to 
generate double knockout mice. Likewise, mice lacking p38δ in striated muscle were 
crossed with the Mkk6–/– (B6.129-Map2k6tm1Flv) line. Genotype was confirmed by PCR 
analysis of genomic DNA. For signaling studies, animals were killed by cervical 
dislocation. For rapamycin treatment, mice were daily injected intraperitoneally with 
rapamycin (LC Laboratories, R-5000) (2  mg  kg−1 per day) or vehicle (0.25% 
polyethylene glycol (Sigma), 0.25% Tween-20 (Sigma) in PBS); injections started at 4 
weeks of age and continued until 9 weeks of age, when heart size was analyzed by 
echocardiography and mice were killed. All animal procedures conformed to EU 
Directive 86/609/EEC and Recommendation 2007/526/EC regarding the protection of 
animals used for experimental and other scientific purposes, enacted under Spanish law 
1201/2005. 
Histology 
Tissue samples were fixed in 10% formalin for 48  h, dehydrated and embedded in 
paraffin. Sections (8  µm) were cut and stained with haematoxylin and eosin (American 
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Master Tech Scientific). Fibrosis was assessed with Picrosirius red staining (Sigma). 
For wheat germ agglutinin (WGA) immunofluorescence, 8  µm heart sections were 
prepared, washed in PBS, incubated over-night in WGA-Alexa 488 lectin (Invitrogen, 
Carlsbad, CA, USA), and washed and mounted in anti-fade reagent. Four images (× 20) 
were taken from each heart, and the diameter and areas of 100–200 cross-sectionally 
oriented myocytes were measured and analysed with Image J software. 
Echocardiography 
Mice were anaesthetized by inhalation of isoflurane and oxygen (1.25% and 98.75%, 
respectively), and echocardiography was performed with a 30-MHz transthoracic 
echocardiography probe. Images were obtained with the Vevo 2100 micro-ultrasound 
imaging system (VisualSonics, Toronto, Canada). Short-axis, long-axis, B-mode and 
two-dimensional M-mode views were obtained. In summary, scans were conducted by 
two experienced researchers blinded to the mouse genotype. Measurements of left 
parasternal long and short axes and M-mode (left parasternal short axis) images were 
obtained at a heart rate of 500–550  b.p.m. LV end-diastolic diameter (LVEDD), LV 
end-systolic diameter (LVESD) and wall thickness were measured from M-mode 
tracings, and the average of three consecutive cardiac cycles is reported. The LV 
fractional shortening percentage was calculated as ([LVEDD−LVESD]/LVEDD) × 100 
MRI of lung was performed with a 7-T Agilent scanner (Agilent, Santa Clara, CA, 
USA) equipped with a DD2 console and an actively shielded gradient set (205/120 
insert of maximum 130  mT  m−1 gradient strength). For image acquisition, we used a 
combination of volume coil/surface coil coil to enhance signal-to-noise ratio formed by 
a 72-mm inner diameter quadrature birdcage TX coil (Rapid Biomedical GmBH, 
Germany) and an actively detuning 30-mm flexible customized surface RX coil (Neos 
Biotec, Pamplona, Spain). Following a tripilot gradient-echo image, a gradient-echo 
sequence without gating was used to acquire oblique coronal slices (one to two slices) 
and axial slices (7–10 slices covering the entire lung, 72-s acquisition time per slice) 
using the following parameters: TR/TE=6.7/2.2  ms, flip angle=10 degree, 
bandwidth=100  kHz, field of view=3 ×  3  cm, matrix=256 ×  128, slice thickness=1  mm 
(ref. 40). From these images, interventricular septum and left ventricle posterior wall 
thicknesses and left ventricle corrected mass were determined; the short-axis M-mode 
quantification was chosen as the most representative. Function was estimated from the 
ejection fraction and fractional shortening obtained from M-mode views by a blinded 
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 echocardiography expert. For ejection fraction measurements, a long- or short-axis view 
of the heart was selected to obtain an M-mode registration in a line perpendicular to the 
left ventricular septum and posterior wall at the level of the mitral chordae tendinea. 
Immunoblot analysis 
Tissue extracts were prepared in Triton lysis buffer (20  mM Tris (pH 7.4), 1% Triton X-
100, 10% glycerol, 137  mM NaCl, 2  mM EDTA, 25  mM β -glycerophosphate, 1  mM 
sodium orthovanadate, 1  mM phenylmethylsulfonyl fluoride, and 10  µg  ml−1 of 
aprotinin and leupeptin). Extracts (20–50  µg protein) and immunoprecipitates (prepared 
from 0,5-2mg) were examined by immunoblot. For the immunoprecipitation assay, 
heart extracts were incubated with 4  µg of a specific antibody coupled to protein-G-
Sepharose. After incubation overnight at 4  °C with agitation, the captured proteins were 
centrifuged at 10,000g, the supernatants collected, and the beads washed four times in 
lysis buffer. Beads were boiled for 5  min 95  °C in 10  µl sample buffer. Extracts and 
immunoprecipitates were examined by SDS–PAGE and blotted with antibodies to the 
following targets: p38γ and p38δ (refs 41, 42) at 1  µg  ml−1; vinculin (Sigma); 
puromycin (Millipore clone 12D10); and phospho-MKK3/6, MKK3, MKK6, phospho-
p38, phospho-mTOR (Ser2481), mTOR, phospho-p70S6 kinase, p70S6 kinase, 
phospho-S6 (Ser 235/236), phospho-S6 (Ser 240/244), S6 ribosomal protein, phospho-
FOXO1/3a, phospho-eEF2, eEF2, phospho-EIF4E, EIF4E, phospho-EIF4G, EIF4G, 
phospho-EIF4B, EIF4B, phospho-4EBP1, 4EBP1 (Cell Signaling) all were used at 
1:1,000. Immunocomplexes were detected by enhanced chemiluminescence (GE 
Healthcare Lifesciences).  
Cell lines and cell culture 
Immortalized mouse embryonic fibroblasts from WT mice, Mkk3-/- and Mkk6-/- mice 
(were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Sigma), glutamine (2  mM) and penicillin/streptomycin (100  µg  ml−1). 
In vivo protein synthesis assay 
For all in vivo measurements of protein synthesis, mice were injected intraperitoneally 
with 0.040  µmol  g−1 puromycin dissolved in 100  µl PBS. Exactly 30  min after injection, 
tissues were extracted and frozen in liquid nitrogen for subsequent immunoblot analysis 
of protein-incorporated puromycin. 
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Blood pressure measurement 
Blood pressure in mice was measured using the non-invasive tail-cuff method48. 
qRT-PCR 
The expression of mRNA was examined by qRT-PCR using a 7900 Fast Real Time 
thermocycler and FAST SYBR GREEN assays (Applied Biosystems). Relative mRNA 
expression was normalized to Gapdh mRNA measured in each sample. p21 Fw: 
CCTGGTGATGTCCGACCTG, Rev: CCATGAGCGCATCGCAATC , Rb Fw: 
TGCATCTTTATCGCAGCAGTT, Rev: GTTCACACGTCCGTTCTAATTTG Fn1 
Fw: ATGTGGACCCCTCCTGATAGT, Rev: GCCCAGTGATTTCAGCAAAGG;, 
Col1a1 Fw: GCTCCTCTTAGGGGCCACT, Rev: CCACGTCTCACCATTGGGG;, 
Col3a1 Fw: CTGTAACATGGAAACTGGGGAAA, Rev: 
CCATAGCTGAACTGAAAACCACC;, Nppa Fw: GCTTCCAGGCCATATTGGAG, 
Rev: GGGGGCATGACCTCATCTT , Nppb Fw: GAGGTCACTCCTATCCTCTGG, 
Rev: GCCATTTCCTCCGACTTTTCTC, Acta-2 Fw: 
CCCAAAGCTAACCGGGAGAAG, Rev: CCAGAATCCAACACGATGCC;, Myh7 
Fw: ACTGTCAACACTAAGAGGGTCA, Rev: TTGGATGATTTGATCTTCCAGGG; 
, Kcnh2 Fw: GTGCTGCCTGAGTATAAGCTG; Rev: 
CCGAGTACGGTGTGAAGACT; Scn5a Fw: ATGGCAAACTTCCTGTTACCTC, 
Rev: CCACGGGCTTGTTTTTCAGC;  Ank2 Fw: 
AGATTACTGTGCAGCATAACAGG, Rev: TGGTTGTAAAGGAAACACACTCA;, 
Cav3 Fw: GGATCTGGAAGCTCGGATCAT, Rev: 
TCCGCAATCACGTCTTCAAAAT; Kcnj2 Fw: ATGGGCAGTGTGAGAACCAAC, 
Rev: TGGACTTTACTCTTGCCATTCC. 
Endurance exercise training 
Swimming training was performed as previously described [6] with some modifications. 
Mice swam in water at a depth of 25 cm in a glass container (60×30×45 cm) at 30 to 
32ºC. The animals were progressively familiarized with swimming during the first 2 
weeks by increasing each swimming session time by 10 min per day, and held at 90 min 
per session until the end of the training. The first swimming session started at 12.30 pm 
and four hours of rest were left between sessions. Mice were allowed to swim at their 
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 own pace, and the water was gently bubbled to ensure that mice swam rather than 
floating. 
 
 
Week 
1 
Time  
 
10’+10’ 
(min) 
 
20’+20’ 
 
 
30’+30’ 
 
 
40’+40’ 
 
 
50’+50’ 
 
 
0 
 
 
0 
Week 
2 
60’+60’ 70’+70’ 80’+80’ 90’+90’ 90’+90’ 90’+90’ 90’+90’ 
Week 
3 
90’+90’ 90’+90’ 90’+90’ 90’+90’ 90’+90’ 90’+90’ 90’+90’ 
Week 
4 
90’+90’ 90 90 90 90 90’+90’ 90’+90’ 
Week 
5 
90 90 90 90’+90’ END   
 
Electrocardiographic Recordings 
Mice were lightly anaesthetized using 1.5% isoflurane in 95% oxygen. Baseline ECG 
was recorded for 5 min and at the end of the endurance training protocol. Response to 
toe-pinch reflex was examined to ensure the proper level of anesthesia. 
Statistical analysis 
Differences between groups were examined for statistical significance by two-tailed 
Student’s t-test, one-way or two-way analysis of variance coupled to the Bonferroni 
post-test. Survival was analyzed with Kruskal-Wallis test. 
201
   
 
ACKNOWLEDGEMENTS 
We thank S. Bartlett for English editing, F. Cruz and J.A. Bernal for their help with 
swimming training protocol, A. Molina for histological analysis. We are grateful to R.J. 
Davis for critical reading of the manuscript. We thank the staff at the CNIC Genomics 
and Bioinformatics units for technical support and help with data analysis. G.S. is an 
investigator of the Ramón y Cajal Program. B.G.T. is a fellow of FPI Severo Ochoa 
CNIC Program (SVP-­‐2013-­‐067639). This work was funded by the following grants to 
G.S.: ERC 260464, EFSD 2030, MICINN SAF2010-­‐19347, and Comunidad de Madrid 
S2010/BMD-­‐2326. The CNIC is supported by the Ministerio de Economía y 
Competitividad and the Pro-­‐CNIC Foundation. 
 
FIGURE LEDGENDS 
Figure 1. Mkk6-/-  hearts are hypertrophic. 
Cardiac phenotype from WT and Mkk6-/- was studied at 9 weeks. (a) Hearts and 
hematoxylin and eosin-stained cardiac longitudinal sections of wild-type (WT) and 
Mkk6-/- mice. (b) Heart-weight-to-tibia-length ratio at the indicated time points. (c) 
Bottom. Hematoxylin and eosin-stained sections from 9 weeks-old WT and Mkk6-/- 
mice. Top: Cardiomyocyte cross-sectional area quantified in FITC wheat germ 
agglutinin (FITC-WGA)-stained hearts. (d) Echocardiography results for 9-week-old 
WT and MKK6-/- mice. LV Mass (Left ventricle mass), LVID;d (Left ventricle internal 
diameter in diastole), LVPW;d (left ventricle posterior wall in diastole); IVS;d (inter-
ventricular septum in diastole). (e) Cardiac function measured by echocardiography. 
Data are means±s.e.m. (n=5–13). *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA 
coupled to Bonferroni post tests or t-test). 
Figure 2. MKK6 is necessary for p38α activation and MKK3 for p38γ and p38δ in 
the heart. 
(a-d) p38 MAPK signaling pathway in WT and Mkk6-/- heart lisates was analyzed at 9 
weeks. (a, b) Immunoprecipitation analysis of the phosphorylation and protein levels of 
p38γ and δ isoforms respectively in heart extracts. (c) Immunoblot analysis of the p38α 
phosphorylation and protein levels. (d) Phosphorylation and protein levels of MKK3 
and MKK6 in cardiac lysates. (e) Heart-weight-to-tibia-length ratio at the indicated time 
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 points from WT and Mkk3-/- mice. (f) Immunoprecipitation analysis of the 
phosphorylation and protein levels of p38α, p38γ and p38δ isoforms in heart extracts 
from 9 week-old WT and Mkk3-/- Data are means±s.e.m. (n=4–6). *P<0.05; (one-way 
ANOVA coupled to Bonferroni post tests). 
Figure 3. Hearts from Mkk6-/- mice show increased mTOR activation.  
(a,b) Immunoblot analysis of mTOR signaling pathway activity (a) and the activation 
status of translation factors (b) in heart lysates of 9-week-old WT and Mkk6-/- mice. (c) 
Protein content from WT and Mkk6-/- hearts measured as the protein-DNA ratio. (d) In 
vivo measurement of protein synthesis. Mice were injected intraperitoneally with 
0.040  µmol  g−1 puromycin dissolved in 100  µl PBS. Exactly 30  min after injection, 
tissues were extracted and frozen in liquid nitrogen for immunoblot analysis with anti-
puromycin antibody (n=3-4). 
Figure 4. Striated Muscle MKK6 controls postnatal heart growth. 
The cardiac phenotype from MCK-Cre and MKK6MCK-KO mice was studied at 9 weeks. 
(a) Schematic view of the generation of the MKK6MCK-KO conditional knockout mice.  
(b) Deletion of MKK6 in tissue lysates from MCK-Cre and MKK6MCK-KO (K) mice in  
quadriceps (Q), gastronemius (G), Soleus (S) and Heart (H). (c) Heart-weight-to-tibia-
length ratio. (d) Hematoxylin and eosin-stained cardiac transversal sections of wild-type 
(WT) and MKK6-/- mice. (e) Cardiomyocyte cross-sectional area quantified in FITC 
wheat germ agglutinin (FITC-WGA)-stained hearts. (f) Fibrosis development analyzed 
with picrosirius red staining. Data are means±s.e.m. (n=4-8). *P<0.05 (t-test). 
Figure 5. Cardiomyocyte MKK6 controls postnatal heart growth. 
The cardiac phenotype from αMHC-Cre and MKK6αMHC-KO mice was studied at 9 
weeks. (a) Specific deletion of MKK6 in tissue lysates from αMHC-Cre (C) and 
MKK6αMHC-KO (K) mice in heart (H), muscle (M), kidney (K), spleen (S), brain (B), 
liver (L), white fat (WF) and brown fat (BF). (b) Heart-weight-to-tibia-length ratio. (c) 
Hematoxylin and eosin-stained cardiac transversal sections. (d) Cardiomyocyte cross-
sectional area quantified in FITC wheat germ agglutinin (FITC-WGA)-stained hearts. 
(e) Fibrosis development analyzed with picrosirius red staining. Data are means±s.e.m. 
(n=3-7). *P<0.05 (t-test). 
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Figure 6. p38γ is downstream MKK6 in the regulation of cardiac hypertrophy. 
The cardiac phenotype from WT and Mkk6-/- p38γ-/- mice was studied at 9 weeks. (a) 
Heart-weight-to-tibia-length ratio from WT, Mkk6-/- and Mkk6-/- p38γ-/- mice. (b) 
Hematoxylin and eosin-stained cardiac transversal sections. (c) Cardiomyocyte cross-
sectional area quantified in FITC wheat germ agglutinin (FITC-WGA)-stained hearts. 
Data are means±s.e.m. (n=5-10). **P<0.01 (t-test). 
Figure 7. p38δ is downstream MKK6 in the regulation of cardiac hypertrophy. 
The cardiac phenotype from MCK-Cre and Mkk6-/-, p38δMCK-KO and Mkk6-/- p38δMCK-
KO mice was studied at 9 weeks. (a) Heart-weight-to-tibia-length ratio. (b) Hematoxylin 
and eosin-stained cardiac transversal sections. (c) Cardiomyocyte cross-sectional area 
quantified in FITC wheat germ agglutinin (FITC-WGA)-stained hearts. Data are 
means±s.e.m. (n=5-10). *P<0.05; ***P<0.001 (one-way ANOVA coupled to 
Bonferroni post tests). 
Figure 8. Mkk6-/- control heart growth by modulating mTOR activity. 
(a-c) WT and Mkk6-/- mice were intraperitoneally injected daily with rapamycin 
(2  mg  kg−1 per day) or vehicle from 4 to 9 weeks of age. (a) Heart-weight-to-tibia-length 
ratio. (b) Representative H&E stained transverse heart sections after treatment. (c) 
Cardiomyocyte cross-sectional area quantified in FITC wheat germ agglutinin (FITC-
WGA)-stained hearts. Data are means±s.e.m. (n=5). *P<0.05; **P<0.01; ***P<0.001 
(one-way analysis of variance coupled to Bonferroni post test). 
Figure 9. Mkk6-/- mice show increased susceptibility to sudden cardiac death upon 
endurance training. 
WT and Mkk6-/- mice were swimming trained during 3 weeks and a sedentary group 
was used as control. (a) Heart-weight-to-tibia-length ratio. (b) Representative H&E 
stained transverse heart sections after treatment. (c) Cardiomyocyte cross-sectional area 
quantified in FITC wheat germ agglutinin (FITC-WGA)-stained hearts. (d) 
Echocardiography results for 9-week-old WT and Mkk6-/- after the training program. LV 
Mass (Left ventricle mass). (e) Percentage of survival during the training program. Data 
are means±s.e.m. (n=5). *P<0.05; **P<0.01; ***P<0.001 (one-way analysis of 
variance coupled to Bonferroni post test or Kapplan-Meier survival analysis). 
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 Figure 10. Mkk6-/- mice resent altered cardiac ions channels expression associated 
with Long QT Syndrome. 
(a-b) Genes differentially expressed between WT and Mkk6-/- -9 week-old mice 
involved in (a) Top Tox Functions, and specifically in (b) Arrythmia. (c) Cardiac Ion 
Channel gene expression from WT and Mkk6-/- -9 week-old mice. Data are 
means±s.e.m. (n=4).  *P<0.05; **P<0.01; ***P<0.001 (t-test analysis). 
Figure 11. Endurance training caused a greater increase in the QT interval from 
Mkk6-/- mice. 
Electrocardiograms were recorded from WT and Mkk6-/- sedentary and trained groups 
after the training program was completed. Data are means±s.e.m. (n=8-5). **P<0.01; 
(one-way analysis of variance coupled to Bonferroni post test). 
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SUPPLEMENTARY INFORMATION 
 
Supplemetary Figure 1. Mkk6-/- mice develop physiological hypertrophy. 
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(a) p21 and Rb expression levels in hearts from WT and Mkk6-/- mice at the indicated 
time points. (b) Ki67 staining of cardiac sections at 6 weeks from WT and Mkk6-/- mice. 
(c) Systolic blood pleasure measured from WT and Mkk6-/- mice. (d) Fibrosis 
quantification from picrosirius red staining of WT and Mkk6-/- hearts.  (e-f) Gene 
expression of different markers of (e) fibrosis and (f) cardiac stress, from WT and Mkk6-
/- hearts at the indicated time points. 
 
Supplementary Figure 2. MKK3/6-p38 pathway regulates mTOR activation and 
cell size in MEF cells. 
222
 (a) Analysis of p38γ activation and expression by immunoprecipitation in WT, Mkk3-/- 
and Mkk6-/- MEF cells. (b) Immunoblot analysis of mTOR signaling in WT, Mkk3-/- and 
Mkk6-/- MEF cells. (c) Micrographs from WT, Mkk3-/- and Mkk6-/- MEF cells. (d) 
MKK6 deletion specificity from MCK-Cre (C) and MKK6αMHC-KO (K) in brain (B), 
kidney (K), brown fat (BF), white fat (WF), liver (L) and spleen (S) (n=3). 
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Supplementary Figure 3. Mkk6-/- mice were swimming trained. 
(a) Immunoblot analysis of mTOR inhibition by Rapamycin in heart lysates from WT 
and Mkk6-/- mice. (b) Echocardiography results for 9-week-old WT and Mkk6-/- mice. 
LV Mass (Left ventricle mass), LVID;d (Left ventricle internal diameter in diastole), 
LVPW;d (left ventricle posterior wall in diastole); IVS;d (inter-ventricular septum in 
diastole). (c) Systolic blood pleasure measured from WT and Mkk6-/- mice at the end of 
the endurance training. (d) Electrocardiogram detection in mice. Data are means±s.e.m. 
(n=5–12). *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA coupled to Bonferroni 
post tests or t-test). 
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DISCUSION 
To preserve the homeostasis and health of the organism, cells are constantly responding 
to changes in the physical and chemical properties of the environment by altering many 
of their cellular functions. The p38 MAPK pathway belongs to the Mitogen Activated 
Protein Kinases (MAPKs) family and is involved in the transduction of most 
extracellular signals, specifically stress signals. While the p38 MAPK family has been 
implicated in a wide variety of biological processes, a specific role for p38γ and p38δ 
MAPKs in cellular signaling and its contribution to both physiological and pathological 
conditions are presently lacking. In this thesis, we outline a role for p38γ and p38δ 
MAPK in important cellular processes such as in acute and chronic inflammatory 
responses and cardiac growth, as well as in pathological conditions such as 
inflammatory disease, steatosis, diabetes and cardiac hypertrophy. 
The p38 MAPK pathway has been involved in the regulation of inflammatory responses 
since its discovery. p38α MAPK was first identified as the primary target of anti-
inflammatory pyridinyl imidazole drugs that inhibit endotoxin-stimulated production of 
TNFα [105]. Thanks to the availability of specific inhibitors for p38α and p38β 
isoforms, nowadays we have great understanding of the essential role of p38α in 
inflammation and in numerous TLR4-triggered responses in macrophages and dendritic 
cells [62]. Furthermore, studies using whole body knockout and conditional tissue-
specific knockouts of p38α and p38β allowed dissecting the contribution of each of 
these isoforms revealing a dominant role of p38α in the regulation of cytokine 
production and inflammatory responses. In contrast, p38β appears to be required neither 
for the acute, nor chronic inflammatory responses [13, 124]. However, the contributions 
of p38γ and p38δ to inflammatory responses were largely unexplored until two years 
ago that our group and others showed that these two kinases are key elements in the 
control of inflammation. Several studies have reinforced the importance of p38γ and 
p38δ in inflammatory responses and in diseases with a strong inflammatory component 
such as psoriasis, arthritis and colon cancer [35, 45, 194]. A role of the alternative p38 
isoforms in inflammation was suggested first by the similarities in the activation of p38 
family members. Specifically, MKK6 activates all p38 isoforms, and when 
overexpressed by cell transfection, each p38 can be activated in cells treated with IL-1β 
and TNF-α [54, 84, 90, 110, 170]. 
Besides, while p38α is expressed in all inflammatory cell lineages and its expression 
levels does not seem to change during cell differentiation or upon stimulation, in this 
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 DISCUSION 
thesis work we have shown that p38γ and p38δ present a very distinct expression 
pattern in the different myeloid cell lineages. p38γ and p38δ are expressed in 
macrophages and monocytes, however, kupffer cells express high protein levels of p38γ 
isoform, but very low levels of p38δ, and on the other hand, neutrophils express high 
levels of p38δ but almost no p38γ. A similar expression pattern has been reported by 
other groups [73, 81]. The activation pattern of the p38 isoforms also differs in myeloid 
cell lineages. In macrophages activation of p38α and p38δ has been detected upon LPS 
stimulation [73], however, p38γ is the only isoform activated in Kuppfer cells, and p38α 
the one activated in neutrophils by LPS. All this particularities in the expression and 
activation of p38γ and p38δ in myeloid cells indicate that both may be regulating 
important processes in inflammatory responses and that their functions might be non 
redundant with p38α, or between each other. 
In 1994 C. Manthey’s lab, found that SB202190 inhibits maximally 65% of LPS-
induced TNF-α production by macrophages [73]. Since SB202190 does not inhibit p38δ 
[84, 170] they speculated that p38δ might mediate the 35% of TNF-α production that is 
insensitive to SB202190 [115]. This observation correlates with our finding that p38δ, 
together with p38γ, phosphorylates in macrophages the eEF2K to regulate TNFα 
production in a model of LPS-induced acute hepatitis. In the same year, Risco et al. 
reported that p38γ and p38δ regulate TNFα production through the regulation of ERK 
activation. [138]. Nevertheless, we didn’t detect changes in ERK activation upon LPS 
stimulation neither in bone marrow derived macrophages (BMDM) from Mkk3-/-Mkk6+/- 
full body knockout mice or from mice lacking specifically p38γ and p38δ in myeloid 
cells. Although they also use LPS treatment of bone marrow derived macrophages 
(BMDM) the difference in LPS dosage or in mouse models (they obtain the BMDM 
from p38γ and p38δ full body knockout mice, whereas we isolated them from myeloid-
specific conditional mice) could be responsible for the different outcome. Firstly, the 
lack of these kinases in other tissues could affect the bone marrow cells in an 
independent manner from the autonomous p38γ and p38δ deficiency. Secondly, the 
moment in which the deletion occurs during the mouse development and the 
effectiveness of the deletion may be different in both models.  
Likewise, p38γ and p38δ have an essential role in chronic inflammatory responses. In 
this thesis we have shown that myeloid p38γ and p38δ contribute to the pathogenesis of 
non-alcoholic fatty liver disease (NAFLD), which refers to a wide spectrum of liver 
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damage, from steatosis to inflammation, fibrosis and cirrhosis. NALFD is strongly 
associated with obesity and type-2-diabetes and predisposes to hepatocellular 
carcinoma.  
Lack of p38γ and p38δ specifically in myeloid cells conferred protection against three 
different models of steatosis: methionine-coline deficient diet (MCD), high fat diet (HF) 
and high fat and fructose diet (HFF), indicating that the protection observed is 
independent of the model used to induce the disease. This reduced liver damage and 
steatosis development is due to an impaired migration and infiltration of neutrophils 
lacking p38γ and p38δ into the liver. The defects in neutrophil migration are consistent 
with previous reports using global and myeloid-restricted p38δ deletion in an acute lung 
injury model [81]. Surprisingly, the lack of p38δ alone in the whole body is insufficient 
to protect against liver steatosis in our MCD model. However, the deletion of p38 
specifically in neutrophils is enough to confer protection against liver neutrophil 
infiltration and steatosis development. Although p38γ is only expressed at very low 
levels, in non-stimulated or LPS-stimulated neutrophils, one possibility we did not rule 
out is whether in Mapk13-/- neutrophils, p38γ activation or expression is increased as a 
compensatory mechanism. These kind of compensatory behaviors have been previously 
described inside the p38 MAPK pathway [143, 145]. Another possibility is that p38γ 
contributes in other cell type to the regulation of liver neutrophil infiltration and 
steatosis progression. The fact that p38δ deficiency specifically in neutrophils confers a 
greater protection against steatosis development than its deletion in myeloid cells (not 
shown) or the whole body p38δ knockout mice might indicate that p38δ has an opposite 
role in other tissue.  
Our studies have shed some light in the pathophisiology of LPS-induced acute liver 
damage and of NAFLD development. In both disease models, myeloid cells play an 
essential role in liver inflammation and damage, however, TNFα production by 
macrophages and monocytes but not neutrophil liver infiltration is determinant for LPS- 
hepatitis, but in NALFD pathogenesis neutrophils are the key players. Although more 
experiments should be done to elucidate whether there is a primary defect in neutrophil 
migration and liver infiltration in the LPS-induced acute hepatitis, or if the reduced liver 
neutrophil population it is secondary to the reduced TNFα production and reduced liver 
inflammation, our data indicate that neutrophils do not play a dominant role LPS–
stimulated hepatic damage. Moreover, the neutrophil competitive migration experiment 
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demonstrates that the defective neutrophil migration in diet-induced steatosis is not 
secondary to a defective production of TNFα or other chemokines.  
Several studies have suggested redundant functions among the p38 MAPK isoforms and 
its upstream activators MKK3 and MKK6 [19, 129]. Sabio G. et al (2005) clearly 
demonstrated that the different p38 present overlapping functions by the use of cells 
from knockout mice lacking multiple family members in combination with the use of 
specific inhibitors for the different kinases. Such redundancy may account for the 
failure on finding a phenotype in the different p38 knockout mice and point to the need 
to generate knock-in mice expressing inactive p38MAPK and mice with tissue-specific 
inactivation of the individual p38MAPK family members [143]. In our studies we have 
observed that p38γ/δLyz-KO mice present a stronger phenotype than either of the single 
conditional knockouts, indicating partial redundant roles for p38γ and p38δ in myeloid 
cells. Nevertheless, a dominant role of p38δ could be appreciated, indicating that their 
functions are not overlapping completely and some of them are only partially 
compensated by the other isoform. In the LPS-induced acute hepatitis model, p38γ and 
p38δ have opposite roles in the regulation of IL-10 levels in BMDM. While the lack of 
p38γ leads to an increase IL-10 production, the deficiency in p38δ increases its levels in 
response to LPS. Besides, double knockout BMDM show IL-10 levels comparable to 
WT cells. On the other hand, p38δ seems to be the main isoform in the regulation of IL-
6 production; p38γ deficiency does not affect it. However, both are involved in the 
control of TNFα levels in response to LPS, although, p38δ seems to have a predominant 
role. This explains why in p38δLyz-KO show a stronger protection against LPS-induced 
liver damage than p38γLyz-KO.  
This redundancy is also observed between the p38s up stream kinases, MKK3 and 
MKK6. Whereas mice lacking both MKK3 and MKK6 are not viable, dying at mid-
gestation with defects in the placenta and the development of the embryonic vasculature 
[19], loss of either gene alone yields healthy mice [113, 160, 179]. Likewise, in our 
acute hepatitis model the single deficiency in MKK3 or MKK6 partially protects against 
LPS-induced liver damage, but this protection is not enough to reduce the mortality. In 
this acute inflammatory model, MKK6 seems to have a dominant role in the regulation 
of hepatic apoptosis, necrosis and neutrophil infiltration. Although TNFα production by 
liver monocytes/macrophages is reduced in single knockout mice, BMDM deficient in 
either of the MKKs produce normal levels of cytokines in response to LPS. This may 
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reflect important differences in between the two myeloid cell populations. Moreover, it 
is possible as well, that the lack of MKK3 and MKK6 in other cell types could be 
affecting the liver monocytes/macrophages. Furthermore, the fact that only MKK6 
deficient mice present reduced hepatic apoptosis and necrosis, while both single 
knockout mice show reduced TNFα production by liver myeloid cells, suggests that 
MKK6 may be playing a role in other cell type such as hepatocytes that explains the 
protection observed. To address this possibility, further experiments should be 
performed using liver-specific conditional knockout mice. 
But this redundancy does not always occur, Romeo Ricci has reported specific roles of 
p38δ in insulin secretion and neutrophil migration that cannot be compensated by other 
p38 isoforms [81, 156], and the same occurs for the role in p38α in placental 
development. Along with this idea, we have shown that the expression of both 
alternative p38 MAPKs is essential in the heart for a normal postnatal cardiac growth. 
Several studies have implicated the p38 MAPK pathway in cardiomyocyte proliferation 
and hypertrophy [20, 44, 111, 171]. It has been shown that p38α and p38β play 
redundant roles in the regulation of embryonic heart development. Double knockout 
mice die during embryonic development with septal defects associated to 
cardiomyocyte-reduced proliferation [44]. However, Yibin Wang et al. proposed that 
these kinases also have divergent roles in the heart, p38α seems to regulate 
cardyomyocyte apoptosis and p38β the hypertrophic response induced by the 
overexpression of MKK3 constitutive active mutant [171]. In contrast, no studies had 
been performed before in the cardiac role of p38γ and p38δ in vivo, despite of the fact 
that the four p38 isoforms are expressed in the heart, and p38γ together with p38α is one 
of the predominant isoforms. In this thesis work we show that the alternative p38 
MAPKs cooperate to regulate postnatal cardiac hypertrophic growth, through the 
regulation of mTOR pathway activation in a non-redundant manner. Although, it has 
been described that p38δ is highly expressed in the ventricles during embryonic 
development [139], the cardiac size and structure of mice lacking p38γ and p38δ is 
normal at birth. At this moment, the expression levels of both kinases are very low, but 
protein levels and activation increase during the early postnatal cardiac development. 
Single knockout and double knockout mice present a similar reduction in heart size due 
to a decreased cardiomyocyte hypertrophic growth. This indicates that p38γ and p38δ 
cooperate in the regulation of cardiomyocyte growth and that the deficiency in one of 
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these isoforms cannot be compensated by other p38 MAPKs. Interestingly, p38γ and 
p38δ interact in the heart and this interaction seems to be necessary for the regulation of 
Deptor degradation. This explains why the loss of only one of these kinases produces 
the defect in cardiac growth. We have shown that p38γ interaction with Deptor occurs 
through its PDZ domain, but we do not know how p38δ interacts with Deptor. 
Something surprising is the stronger phenotype observed in p38δ deficient mice 
compared to those that lack p38γ, despite the fact p38γ interaction with Deptor is 
stronger, and both isoforms phosphorylate key residues involved in Deptor degradation. 
This could be due to the regulation of an additional substrate for p38δ involved in 
cardiac growth different from Deptor, or due to a role of p38δ in other cell types that 
contribute to regulate cardiomyocyte hypertrophy. To rule out this possibility the 
postnatal cardiac phenotype should be studied in cardiomyocyte-specific conditional 
knockout mice for p38γ and p38δ. Although p38α homodimers have been described, to 
date this is the first report of interaction in between different p38 isoforms to cooperate 
in substrate phosphorylation. It remains to be clarified whether p38γ and p38δ are acting 
in the heart as a heterodimer and whether this interaction occurs in other tissues. 
In contrast with the MKK3 and MKK6 partial redundancy observed in the LPS-induced 
acute inflammatory model, in the cardiac tissue these MKKs have divergent roles in the 
control of heart growth. On the one hand MKK6 deficiency leads to the hyperactivation 
of MKK3 and the subsequent p38γ and p38δ hyperphosphorylation. However, p38α 
phosphorylation was strongly reduced. On the other hand, MKK3 deficiency leads to a 
reduction in p38γ and p38δ phosphorylation, but p38α phosphorylation is not affected. 
Besides, in agreement with the role of p38γ and p38δ in the promotion of hypertrophic 
growth, Mkk3-/- mice have a reduced heart size and Mkk6-/- hearts are bigger than 
control hearts. This suggests that MKK6 mainly activates cardiac p38α, whereas MKK3 
is the main activator of cardiac p38γ and p38δ in postnatal cardiac homeostasis. 
Besides, the presence of a negative feedback from MKK6 to up-stream activators or to 
MKK3, could explain the hyperactivation of MKK3 observed in the absence of MKK6. 
Although the cardiac specific conditional knockout for p38α does not develop a 
hypertrophic heart as the Mkk6-/- mouse model, there is the possibility that in Mkk6-/- 
hearts the reduction of p38α activation could account for the MKK3 hyperactivation. 
This negative feedback it has been described before at the level of TAK1 activation 
[30]. The absence of a hypertrophic phenotype in p38α conditional mice could be due to 
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compensatory changes in the expression/activation of other p38 isoforms. More 
experiments need to be done to clarify this question. 
The heart is one of the organs whose size is essential to maintain body homeostasis. A 
proper cardiac growth is necessary during development to meet the demand of blood 
flow to the growing body and organs, but also throughout life to be able to respond to 
changes in the patterns of blood pressure and circulatory resistance. Cardiomyocytes 
withdraw from the cell cycle soon after birth and postnatal cardiac increase in size in 
through hypertrophic growth. There are physiological hypertrophy and pathological 
hypertrophy of the heart. The physiological hypertrophy is considered as an adaptive 
response, which is accompanied by an adjustment of the cardiac function with an 
increased demand of cardiac output. Such an adaptive hypertrophy is observed in the 
increase in cardiac mass after birth and in response to exercise. It is characterized by the 
absence of fibrosis and leads to enhance contractility and cardiac output. In response to 
pathological stresses (toxins, hypertension, etc.), the heart also often increases its mass, 
which was viewed in the past as an adaptive response as well. However, cumulative 
evidence obtained from studies using more advanced technologies in human patients 
and animal models suggests that cardiac hypertrophy is a maladaptive process of the 
heart in response to intrinsic and extrinsic stresses. Although toxic stress-induced 
hypertrophy can normalize wall tension, it is a risk factor for malignant arrhythmia and 
cardiac sudden death. The lack of p38γ and p38δ leads to decrease hypertrophic growth 
during postnatal development, but also in response to hypertension caused by 
angiotensin-II treatment due to reduced mTOR activation, indicating that these kinases 
are involved in the control of physiologic and pathologic cardiac hypertrophy. This 
correlates with the finding that the PI3K pathway, which also controls mTOR activation 
through AKT, is also activated in both physiological and pathological hypertrophy. 
Furthermore, the insulin-like growth factor (IGF) that signals through PI3K, is involved 
in the growth of the heart after birth [152] and its overexpression induces cardiac 
hypertrophy [46]. IGF-I expression is sufficient to initially induce an analog of 
physiological cardiac hypertrophy; however, this hypertrophy progresses to a 
pathological condition characterized by decreased systolic performance and increased 
fibrosis. Likewise, the hyperactivation of endogenous p38γ and p38δ in MKK6 
deficient hearts leads to the development of physiological cardiac hypertrophy, with 
increased cardiac output and no fibrosis development. However, when challenged with 
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endurance exercise training, these mice show increase sudden death probably associated 
to the prolongation of the QT interval and increase arrhythmias. Alterations in the 
function of cardiac channels or “cardiac channelopathies” occur at the cellular level in 
cardiac hypertrophy [88]. In correlation with this observation, MKK6 deficient mice 
present at baseline alter expression of different ion channels that have been previously 
associated with prolongation of the QT interval. However, the long QT and the 
arrhythmias do only appear after the heart is challenged. At baseline these alterations 
are no pathological, whereas with endurance training, Mkk6-/- hearts become even more 
hypertrophic but without fibrosis development leading to an increase rate of sudden 
death in these mice. Suggesting that the increase susceptibility to arrhythmias and the 
prolongation of the QT interval is not due to fibrosis development, but maybe due to the 
further increase in cardiac mass. The increase in cardiac mass induced by endurance 
training is very similar in both genotypes, which could indicate that endurance training 
is activating signaling pathways independent of p38γ and p38δ activation. It would be 
of interest to treat Mkk6-/- mice with stimuli that induce pathological hypertrophy, such 
as angiotensin-II, to study whether their hearts become further hypertrophic and if it 
also leads to increased sudden cardiac death susceptibility. Likewise, challenging mice 
deficient in p38γ and p38δ with endurance training could add significant knowledge to 
the signaling pathways involved in cadiac hypertrophy. 
In general, these outcomes suggest that even a hypertrophic heart that seems to be 
physiological and with improve cardiac function could present a higher predisposition 
for malignant arrhythmia and cardiac sudden death when challenged. It could be 
hypothesized that those people who have an increased heart mass with better cardiac 
function due to genetic causes, could be predispose to become elite athletes. It would be 
of interest to study whether mutations in the MKK3/6-p38γ and p38δ pathway are 
enriched in this population, and whether they are associated with increased risk of 
arrhythmias and sudden death. 
A distinction between adaptive and maladaptive hypertrophy is whether the hypertrophy 
is necessary for the compensatory function of the heart under physiological and 
pathological stress conditions. Several studies and our own work agree with the idea 
that cardiac hypertrophy is neither required nor necessarily compensatory in response to 
pathological stimuli. Mice lacking p38γ and p38δ do not develop cardiac hypertrophy in 
response to the hypertension induced by angiotensin-II treatment. The elimination of 
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hypertrophy in these animals did not cause compromised hemodynamic changes 
through an observation of over a period of several weeks. Similar results were obtained 
by forced expression of a dominant negative calcineurin mutant or by calcineurin 
suppression in an aortic constriction model [80, 193]. Interestingly, the absence of a 
hypertrophic cardiac response to aortic banding in a transgenic mouse model was 
accompanied by a significant slower pace of deterioration of systolic function [56]. All 
this suggests that cardiac hypertrophy in response to extrinsic and intrinsic stresses is 
not a compensatory response. It would be interesting to study whether the lack of p38γ 
and p38δ abolishes the hypertrophic growth induced by endurance training as well as if 
the lack of this hypertrophic response leads to cardiac failure. Furthermore, it remains to 
be addressed whether the cardiac phenotype observed in MKK6 deficient mice is only 
due to the lack of this kinase in cardiomyocytes or is also mediated by other cell types. 
Mice deficient in MKK6 specifically in striated muscle or in cardiomyocytes develop 
cardiac hypertrophy, although the hypertrophy is milder that the one observed in the 
whole body knockout mice. Moreover, the depletion of p38δ in striated muscle is 
enough to revert Mkk6-/- hypertrophic phenotype. Altogether suggests that at least part 
of the phenotype is cell autonomous. Nevertheless, the endurance training experiment 
should be performed in the cardiac-specific MKK6 conditional knockout to verify that 
the increased sudden death is due to the lack of this kinase in the heart. 
Although hypertrophic growth is very important in cardiomyocytes, it also occurs in 
other cell types. Interestingly, immortalized mouse embryonic fibroblasts (MEFs) from 
Mkk3-/- mice or Mapk12-/- and Mapk13-/- mice are significantly smaller than control 
MEFs, whereas the deficiency in MKK6 leads to a bigger cell size. This seems to 
correlate with the activation status of p38γ and p38δ and mTOR pathway, indicating 
that p38γ and p38δ may be regulating hypertrophic growth through the regulation of 
mTOR pathway activation in other cell types different from cardiomyocytes. 
With the increased understanding of the p38 MAPK pathway, its potential as 
therapeutic targets for different diseases is growing very fast during the last years. For a 
long time it has been known that p38α is a key component in the regulation of 
inflammatory mediators such as TNFα, IL-1b, IL-6 or IL-8, which are commonly 
implicated in the detrimental inflammatory pathogenesis of different disease models. 
Furthermore, in cardiovascular diseases, inflammation constitutes a key factor involved 
in the pathogenesis of the disease. In addition, p38α is activated in the heart upon 
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ischemia/ reperfusion injury and its inhibition in animal models reduces the infraction 
size. Several promising p38α inhibitors have progressed into clinical trials for the 
treatment of rheumatoid arthritis, psoriasis, Chron’s disease, cancer, COPD, multiple 
myeloma and cardiovascular disease. However, a great number have been withdrawn 
due to safety issues, being hepatotoxicity the most common. This hepatotoxicity also 
occurs in mice as observed with the SB203580 treatment in the LPS-induced acute 
hepatitis model. Almost all of p38α inhibitors are ATP competitors, generated by 
structural modifications of the first generation of pyrinidyl imidazoles. In this regard, 
new strategies for the inhibition of p38α should be designed with less likelihood to 
cross-react with other kinases or other cellular signaling molecules than ATP 
competitors.  
Recent results from our group and others indicate that p38γ and p38δ could be 
alternative targets for the treatment of inflammatory diseases and cardiovascular 
diseases. These kinases are also key regulators of cytokine production by macrophages 
and monocytes in inflammatory responses, as well as very important molecules in the 
regulation of neutrophil migration. Two myeloid populations involved in the 
pathogenesis of most of the chronic inflammatory diseases. Accordingly, it has been 
reported recently that Mapk12-/-Mapk13-/- double knockout mice are protected against 
rheumatoid arthritis, acute lung injury, skin inflammation and carcinogenesis [35, 45, 
81]. Besides, the blockage of neutrophil infiltration in the liver by p38γ and p38δ could 
protect against non-alcoholic fatty liver disease (NAFLD) a very frequent disease 
nowadays in developed countries, associated with obesity and insulin resistance. 
Moreover, our results show that p38γ and p38δ could be attractive pharmacological 
targets for the treatment of cardiac hypertrophy. However, selective small compound 
inhibitors for p38γ and p38δ isoforms are not currently available. There is one 
compound, BIRB796, which has a pan-isoform inhibitory activity. Although we do not 
observe hepatic toxicity with BIRB796 treatment in a mouse model of acute hepatitis, 
Boehringer Ingelheim completed phase II clinical studies in rheumatoid arthritis, 
Chron’s disease and psoriasis with this inhibitor, and stopped developing this drug due 
to liver enzyme elevations. The only p38γ inhibitor approved by the FDA and the 
European Drug Agency is Pirfenidone (Esbriet) for the treatment of pulmonary 
idiopathic fibrosis. The recent discoveries suggest that p38γ and p38δ are also involved 
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in the development and progression of different human diseases and that a greater focus 
should be put on the generation of selective and potent p38γ and p38δ inhibitors. 
As all the p38 isoforms, but p38β, have been involved in the regulation of inflammatory 
responses, one thing that we still don’t know is whether the inhibition of a single 
specific isoform will be more effective than to inhibit more than one at the same time. 
One alternative could be to use MKK3 and MKK6 inhibitors that disrupt the formation 
of the complex between p38 and the MKKs. It has been shown that cAMP, through 
dinein light chain (DLC) inhibits the p38 MAPK activation using this mechanism. Thus, 
small molecules that mimic this inhibition might serve as new inhibitors of the p38 
MAPK pathway. Nevertheless, p38 associated toxicities are more likely to occur with 
this strategy. To avoid them, an option would be to target only one upstream MKK, but 
more information about their functional differences and contributions in each tissue 
should be generated in order to be able to decide which MKK should be target in the 
different diseases. Likewise, it is important to study the expression pattern of the 
different p38 isoforms in a cell specific manner, as well as to define the particularities in 
the regulation of endogenous p38 MAPK isoforms in the different tissues. 
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CONCLUSIONS 
 
! p38γ y p38δ presentan un patrón de expresión muy característico en células 
mieloides. Los neutrófilos expresan altos niveles de p38δ, las células de kupffer 
altos niveles de p38γ. Sin embargo, los macrófagos y monocitos expresan 
niveles bajos de ambas isoformas. 
! La vía de señalización MKK3/6- p38γ/δ en células mieloides es esencial para la 
progresión del daño hepático y la hepatitis aguda en respuesta a LPS. 
Específicamente, p38γ y p38δ regulan la producción de TNFα en macrófagos y 
células de kuppfer a nivel de la elongación proteica, a través de la fosforilación 
inhibitoria de eEF2K y la subsecuente activación de eEF2. 
! En un modelo de ratón el silenciamiento de eEF2 reduce el daño hepático y 
retrasa significativamente la muerte por hepatitis aguda inducida por LPS, 
indicando que eEF2 es una potencial diana teraéutica para el tratamiento de esta 
enfermedad. 
! p38γ y p38δ juegan un papel clave en el desarrollo de esteatosis hepática. 
Ratones deficientes en p38γ y p38δ en células mieloides están protegidos frente 
al desarrollo de esteatosis inducida por 3 modelos diferentes de ratón, la 
inducida por las dietas MCD, HFD y HFF. Además, la expresión de p38γ y p38δ 
aumenta en el hígado de pacientes con esteatosis hepática. De esta forma la 
inhibición de p38γ y p38δ en células mieloides contituye un potencial 
tratamiento frente a la esteatosis hepática. 
! La infiltración neutrófilos en el hígado es un factor determinante en el inicio y 
desarrollo de la esteatosis hepática. Ratones deficientes en p38γ y p38δ en 
células mieloides están protegidos frente al desarrollo de esteatosis debido a una 
migración defectuosa de los neutrófilos hacia los hígados de dichos ratones. 
Además, modelos de ratones neutropénicos o la depleción de neutrófilos en 
ratones control, protegen frente a la esteatosis hepática inducida por la dieta 
MCD. Esto se debe a que los neutrófilos alteran el metabolismo hepático. 
! Ambas quinasas, p38γ y p38δ se expresan en el corazón. Tanto su expresión 
como activación incrementan durante las etapas tempranas del desarrollo 
postnatal cardiaco. 
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! p38γ y p38δ en cardiomiocitos regulan el crecimiento hipertrófico tanto 
fisiológico postnatal como el inducido por sobrecarga del corazón causada por el 
tratamiento con angiotensina-II. Esta regulación la realizan a través de la 
fosforilación de la proteína inhibidora de mTOR, DEPTOR, que resulta en su 
degradación y en la subsecuente activación de la vía de mTOR, inducción de la 
síntesis proteica y del crecimiento celular. 
! MKK3 y MKK6 son selectivas a la hora de activar las diferentes isoformas de 
p38MAPKs. En el corazón, MKK3 es esencial para la activación de p38γ y 
p38δ, mientras que MKK6 es necesaria para la activación de p38α. 
! La falta de activación de MKK6-p38α lleva a la hiperactivación de MKK3-
p38γ/δ y al desarrollo de hipertrofia cardiaca de tipo fisiológico. Mientras que el 
déficit en MKK3 lleva a un crecimiento cardiaco postnatal reducido. Ambos 
fenotipos son debido a alteraciones en la activación de p38γ y p38δ. 
! Corazones deficientes en MKK6 muestran una expresión alterada de varios 
canales iónicos cardiacos, sin embargo su función cardiaca es normal o incluso 
mejor que ratones control en condiciones basales. Sin embargo, el entrenamiento 
de resistencia en ratones Mkk6-/- lleva a una bradicardia más pronunciada y una 
prolongación del intervalo QT mayor que en los ratones control. Esto resulta en  
un índice incrementado de muerte súbita cardiaca.  
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! p38γ and p38δ expression pattern in myeloid cells is very characteristic. 
Neutrophils express high levels of p38δ, kupffer cells high levels of p38γ, while 
macrophages and monocytes express both isoforms at low levels.  
! MKK3/6-p38γ/δ signaling in myeloid cells is necessary for LPS-induced liver 
damage. Specifically, p38γ and p38δ in macrophages/kupffer cells regulate 
TNFα protein elongation through the inhibitory phosphorylation of EF2K, and 
the subsequent activation of eEF2. 
! eEF2 silencing in an in vivo model protects against LPS-induced hepatitis, 
indicating that eEF2 is a potencial therapeutic target for acute hepatitis 
treatment. 
! p38γ and p38δ play a key role in steatosis development. Mice lacking p38γ and 
p38δ in myeloid cells are protected against 3 different mouse models of diet 
induced steatosis and liver damage. Beides, p38γ and p38δ expression is up 
regulated in livers from patients with NAFLD. Therefore, p38γ and p38δ in 
myeloid cells are potencial therapeutic targets for the treatment of NAFLD.  
! Neutrophil liver infiltration is determinant in the pathogenesis of liver steatosis. 
Mice lacking p38γ and p38δ in myeloid cells are protected against steatosis due 
to a defective migration and infiltration of Mapk12-/-Mapk13-/- or Mapk13-/- 
neutrophils in the livers of these mice. Moreover, neutropenic mice or neutrophil 
depletion models protect against MCD-induced steatosis and liver damage. This 
is due to the fact that neutrophils alter liver metabolism. 
! Both isoforms p38γ and p38δ are expressed in the heart, and their expression 
and activation increases during the early postnatal cardiac development. 
! p38γ and p38δ in cardiomyocytes control cardiac physiological and pathological 
hypertrophic growth through the phosphorylation and subsequent degradation of 
DEPTOR, an inhibitory protein of mTOR pathway, which leads to mTOR 
activation, protein synthesis induction and promotion of cell growth. 
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! The up-stream MAP2Ks of the p38 pathway show selectivity in the activation of 
the different p38 isoforms in the heart. MKK3 is essential for p38γ and p38δ 
activation, whereas MKK6 is necessary for p38α activation. 
! The deficiency in MKK6-p38α activation leads to the hyperactivation of MKK3-
p38γ/δ in cardiac tissue and to the development of physiological cardiac 
hypertrophy. In contrast, the lack of MKK3 leads to a defective activation of the 
p38γ and p38δ isoforms associated with a decreased postnatal cardiac 
hypetrophic growth. 
! Although Mkk6-/- mice show altered expression levels of different cardiac ion 
channels, in basal condition their cardiac function is normal or even improved. 
However, upon endurance exercise chronic training, Mkk6-/- mice develop longer 
QT intervals and show increased susceptibility to sudden cardiac death. 
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